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ABSTRACT 
Group B streptococcus (GBS) is the leading cause of infectious neonatal morbidity and 
mortality in the United States. Maternal GBS colonization is the primary risk factor 
associated with neonatal infection. However, maternal risk factors for GBS colonization 
are ambiguous. A conceptual framework of gene-environment interactions guided the 
approach for this study analyzing DNA methylation, serum cytokines, and vitamin D 
levels. The purpose of this study was to identify potential maternal biomarkers associated 
with GBS colonization. Descriptive statistics were conducted to depict sample 
characteristics (n=42 pregnant women) and identify potential confounding variables 
including, but not limited to: medical history, race, weight, and infections. A series of 
repeated measures ANOVAs were performed to compare each of three serum cytokines 
(TNF-α, IL-6 and IL-10) and vitamin D levels between the two groups in each trimester 
of pregnancy. All statistical analysis was completed using a two-tailed alpha of < 0.05 or 
95% confidence interval. Mean differences of greater than 20% in DNA methylation of 
maternal white blood cells collected in the first trimester were analyzed using a false 
discovery rate of 0.05 to determine significance, as well as independent sample t-tests 
with a p-value of 0.05 using the Illumina Infinium platform and grouped by GBS status 
(n=9/group) identified in the third trimester. Function of differentially methylated genes 
was determined using DAVID Bioinformatics software to identify clinically relevant 
findings. No statistically significant differences in IL-6 F(2, 80) = 2.99, p = 0.056; IL-10 
F(2, 80) = 0.445, p = 0.642; TNF-α F(2, 80) = 2.187, p = 0.119; or vitamin D F(1.380, 
xv 
 
55.218) = 0.882, p = 0.384 were identified between GBS positive and negative women 
during pregnancy.  Analysis of DNA methylation indicates there are no statistically 
significant differences between GBS positive and GBS negative women using and FDR 
of 0.05. When a less stringent p-value of 0.05 was applied, 125 CpG sites differed by 
20% or more between GBS positive versus negative women and different results are 
yielded using multiple statistical approaches (GenomeStudio versus R). Functional 
analysis suggests genes with methylation differences in the cell morphogenesis cluster 
may be associated with GBS colonization, although the significance is questionable.  
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CHAPTER I 
INTRODUCTION 
Group B streptococcus (GBS) is the leading cause of neonatal morbidity and 
mortality due to infection in the United States (Phares et al., 2008). Maternal GBS 
colonization is the primary risk factor associated with the development of neonatal GBS 
sepsis (Verani, McGee, Schrag, & Division of Bacterial Diseases Centers for Disease 
Control and Prevention (CDC), 2010). While between 10 – 30 percent of pregnant 
women are colonized with GBS (Schrag et al., 2002), risk factors for maternal 
colonization are ambiguous and inconclusive in the literature. To prevent transmission of 
GBS, colonized women are normally given antibiotics during the intrapartum period 
which significantly reduces the incidence of early onset GBS infections in neonates 
(Verani et al., 2010). However, current screening techniques have a 10% false negative 
rate (Towers et al., 2010) and do not prevent preterm labor, miscarriages, and stillbirths 
caused by GBS colonization; nor do they reduce the incidence of late onset GBS sepsis in 
infants (Clifford, Garland, & Grimwood, 2011; Jordan et al., 2008; Verani et al., 2010). 
There is a compelling need to investigate genetic and environmental factors that may help 
identify biomarkers for colonization because GBS continues to cause poor pregnancy 
outcomes and is associated with the absence of definitive maternal risk factors for 
colonization. If genetic and environmental factors can be identified, early screening and 
effective interventions can be developed and implemented. Preliminary data from our 
laboratory indicated DNA methylation differences can be measured early in pregnancy 
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between women with and without late pregnancy GBS colonization. DNA methylation, 
an epigenetic modification that can result in altered gene expression and related protein 
production, has the potential to drastically impact health and alter disease susceptibility 
(Baccarelli, Rienstra, & Benjamin, 2010; Berger, Kouzarides, Shiekhattar, & Shilatifard, 
2009; Rodenhiser & Mann, 2006). Differential DNA methylation in genes regulating 
immunity and inflammation could lead to varied levels of pro-inflammatory tumor 
necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and anti-inflammatory interleukin-10 
(IL-10). TNF α, IL-6, and IL-10 are proteins that are produced in varying amounts in 
response to threats to the immune system and could be clinical laboratory indicators for 
GBS colonization (Berner, Welter, & Brandis, 2002; Fan et al., 2003; Madureira et al., 
2011; Maisey, Doran, & Nizet, 2008; Mikamo, Johri, Paoletti, Madoff, & Onderdonk, 
2004; Ng et al., 2003; Parameswaran & Patial, 2010; Puliti et al., 2002; Santhanam et al., 
1991; Vieira et al., 1991).  Additionally, serum markers associated with immune function 
and vitamin D (25[OH]D) status have previously been identified and utilized as 
prognostic indicators for infectious disease (Chesney, 2010; Fahey et al., 1990) and may 
be a cost effective clinical intervention if altered serum vitamin D (25[OH]D) levels are 
associated with GBS colonization status. The long term goal for investigating different 
exogenous and endogenous clinical indicators in women with and without GBS 
colonization is to identify factors that may help later identify a mechanistic explanation 
for maternal GBS colonization and to develop and implement targeted primary 
prevention strategies to reduce neonatal sepsis caused by GBS. The specific purpose of 
this study was to identify variants in maternal blood that are associated with maternal 
GBS colonization.  
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Significance 
Streptococcus agalactiae, or group B β-hemolytic streptococcus, is a gram 
positive bacterium that causes a wide spectrum of illness in multiple clinical populations. 
In 2005, GBS was attributed as the cause of 21,500 infections and 1,700 deaths in the 
United States (Phares et al., 2008). However, the rates of GBS colonization, independent 
of infection, were not reported or required to be reported. Primarily a bacterium that only 
causes invasive disease in patients with altered immune function (Johri et al., 2006), GBS 
was first associated with neonatal sepsis and maternal infection in the 1970s and 
continues to be the leading cause of neonatal sepsis (Verani et al., 2010). Maternal 
colonization with GBS is the strongest predictor for the development of GBS sepsis in the 
neonate. Currently, there are no effective strategies for preventing maternal GBS 
colonization because of the inconsistent results obtained from epidemiological studies 
(Clifford et al., 2011; Kovavisarach, Ying, & Kanjanahareutai, 2007; Zusman, Baltimore, 
& Fonseca, 2006). Studies investigating the number of pregnancies, maternal age, race, 
ethnicity, and other maternal characteristic have failed to identify common maternal risk 
factors. The variability in potential predisposing factors has resulted in research efforts 
focused on preventing transmission and subsequent development of GBS infection in 
neonates.  
Compounding the issue of GBS infection in neonates is the fact that their risk for 
infection continues into the first 3 months of life. GBS infections are categorized in 
neonates by time of disease onset after delivery as either early or late onset. Early onset 
neonatal GBS sepsis occurs within the first 7 days of life with onset usually occurring 
within the first 48 hours of life. The time period ascribed to late onset neonatal GBS 
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sepsis is an infection that develops after the first week of life up until the infant is 3 
months of age (Verani et al., 2010). In an attempt to circumvent GBS transmission to the 
neonate from colonized women, clinical guidelines recommend maternal screening for 
GBS colonization via cultures obtained from recto-vaginal swabs between 35-37 weeks 
gestation. If maternal screening tests are positive for GBS colonization, the CDC 
recommends intravenous antibiotics administration after the start of labor and at least 4 
hours prior to delivery to prevent transmission of GBS to the neonate (Verani et al., 
2010). Implementation of the CDC guidelines has resulted in a 80% decrease in the 
incidence of early onset neonatal GBS sepsis, although rates of late onset GBS sepsis 
have been unaffected (Schrag & Verani, 2013). The continued prevalence of early and 
late onset neonatal GBS sepsis since the guideline implementation could be a result of the 
10% false negative rate associated with maternal screening for GBS colonization (Towers 
et al., 2010). Of the infants who develop GBS infections, 61-82 percent of infants are 
born to mothers with negative GBS screening at 35-37 weeks gestation and 6.3%  of 
infants are colonized by GBS despite administration of maternal antibiotic treatment (Lin 
et al., 2011). This may be in part because colonization with GBS can be transient, 
intermittent, or persistent. Maternal GBS status could change between the time of 
screening and delivery. Additionally, the infant may become infected from environmental 
exposure after delivery (Verani et al., 2010). The transient nature of GBS colonization 
suggests that environmental factors or immune response may play a critical role in 
maternal colonization, warranting further investigation into maternal risk factors and 
more reliable screening. 
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In order to reach the Healthy People 2020 goal of a 10% reduction in neonatal 
GBS infections (U. S. Department of Health and Human Services (HHS), 2013), 
alternative interventions are required for two primary reasons. First, the 10% false 
negative rate during screening needs to be reduced. Women who screen negative for GBS 
colonization will not receive antibiotic prophylactic treatment and could contribute to the 
continued prevalence of GBS disease in neonates. Furthermore, it is unclear why some 
women initially screen negative and later convert to GBS positive status. The transient 
nature of some GBS colonization implies there may be environmental factors that 
contribute to colonization susceptibility. Second, increasing rates of antimicrobial 
resistance to intrapartum antibiotics are being reported. The antibiotic currently 
recommended for treatment of GBS colonization during pregnancy is intravenous 
penicillin (Verani et al., 2010). However, approximately 10% of the general population 
report having a penicillin allergy (Solensky, 2003). Patients with allergies are 
administered erythromycin with clindamycin or vancomycin instead. In the US, over 
54% of invasive strains of GBS are resistant to erythromycin and 33% are resistant to 
clindamycin (DiPersio & DiPersio, 2006) and similar rates of resistance are seen 
worldwide (Bergseng, Rygg, Bevanger, & Bergh, 2008; Janapatla, Ho, Yan, Wu, & Wu, 
2008; Uh et al., 2007). Dual resistance to both clindamycin and erythromycin is also 
increasing, with rates reported as high as 94% of clindamycin resistant isolates also being 
resistant to erythromycin (Back, O’Grady, & Back, 2011). Additionally, Stoll et al. 
(2011) found 53% of infants that developed early onset sepsis were born to mothers who 
had received intrapartum antibiotic treatment. The failure rates associated with current 
treatment methods are associated with continuing neonatal morbidity and moratlity. New 
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strategies which are robust at identifying women at risk for GBS colonization may 
increase the likelihood of developing successful intervention alternatives, further 
reducing the incidence of neonatal GBS sepsis. 
The significance of the problem surrounding maternal GBS colonization is 
compounded by the fact that current guidelines to prevent neonatal GBS do not prevent 
poor maternal and fetal outcomes associated with GBS colonization. Administering 
antibiotics during labor does not prevent stillbirths, miscarriages, chorioamnionitis, or 
other poor pregnancy outcomes associated with GBS prior to 35 weeks gestation. 
Furthermore, there has been a 32% increase in GBS infections in non-pregnant adults 
with no information on colonization rates available (Phares et al., 2008). It is unclear why 
there has been such a large increase in the incidence of GBS infections. 
Ambiguous risk factors for colonization, increasing rates of bacterial resistance to 
antibiotics, increasing GBS infections in non-pregnant populations, and failure rates 
associated with current treatment methods are compelling reasons to discover new 
approaches to identify individuals at risk for GBS colonization. Identification of factors 
associated with GBS colonization will provide new clinically relevant targets to prevent 
and treat GBS colonization. Identification of definitive environmental and/or genetic 
maternal risk factors associated with GBS colonization is a substantively different 
approach to preventing neonatal GBS sepsis. This contribution is significant and will 
improve scientific knowledge by identifying key differences in pregnant women with and 
without GBS colonization. If differences are identified between women with and without 
GBS colonization, knowledge gained from this study can be used to develop a more 
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accurate screening tool or prevent maternal GBS colonization thereby improving clinical 
practice and pregnancy outcome.
Purpose 
The purpose of this study was to identify variants in maternal blood that are 
associated with maternal GBS colonization by investigating the following specific aims:  
1. Differentiate serum levels of TNF-α, IL-6, and IL-10 as potential clinical 
laboratory indicators for GBS colonization longitudinally in pregnant women; and 
examine circulating 25-hydroxyvitamin D (25[OH]D) (vitamin D (25[OH]D) as a 
potential covariate of TNF-α, IL-6, and IL-10 serum levels. 
2. Determine if DNA methylation are different in pregnant women with and without 
GBS colonization.  
3. Examine the relationship of any differentially methylated genes for association 
with immune function and inflammatory serum markers in pregnant women 
colonized with GBS.  
Conceptual Framework 
Investigations of the interaction between genomic and environmental factors have 
been suggested as key research avenues in identifying the most effective methods to 
prevent disease. Cohesive investigations illuminate biochemical explanations for health 
problems and identify modifiable risk factors that can be controlled or altered to prevent 
disease (Willett, 2002). The relationship between genetic and environmental factors 
associated with the development of disease was first suggested in 1902 (Hunter, 2005). 
Examples of conditions known to be affected by genetic and environmental factors 
include: halitosis (Bretz et al., 2011), head and neck cancer after human papilloma virus 
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exposure (Jamaly et al., 2012), sun exposure and skin cancer (Rees, 2004), and an 
increased susceptibility to human immunodeficiency virus infection based on cytokine 
profiles (Smith et al., 1997). Hunter (2005) published a conceptual model (Figure 1)  
Figure 1. Gene-environment interaction. 
illustrating how gene-environment interactions can potentiate disease processes. In the  
model, either a genetic variant or environmental exposure may result in disease even in 
the absence of an interaction between the two. The gene-environment model described by 
Hunter shows relative risk for disease states can be the result of either 1) a genetic variant 
2) an environmental factor or 3) the interaction of the two. However, when there is an 
interaction between a predisposing genetic variant and environmental exposure, the risk 
for disease may be amplified. Hunter has used the inherited condition xeroderma 
pigmentosum to illustrate the model. Inheritance of the genetic mutation that causes the 
disorder greatly increases the risk for skin cancer and sun exposure further elevates risk 
(Cleaver, 2005; Kraemer, Lee, Andrews, & Lambert, 1994). When both elements are 
present, it results in a multiplicative effect drastically increasing disease risk (Figure 1). 
In other words the most basic interpretation of this relationship can be expressed as a 
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mathematical equation, genetic variants (G) x environmental exposure (E) = change in 
disease susceptibility (D): 
G x E = D 
Another example is that of emphysema. Individuals with the genetic mutation (G) 
causing an alpha 1-antitrypsin deficiency are likely to develop emphysema at a young age 
(DeMeo & Silverman, 2004). Smoking is an environmental exposure (E) linked to 
development of emphysema. An individual who has the mutation and smokes may 
develop more severe emphysema (ΔD) at an earlier age than a person with the mutation 
who does not smoke. 
Genetic Variants 
 The identification of the underlying genetic mechanism for an observable 
characteristic, referred to as a phenotype, is a common undertaking in the field of 
genetics. The genetic code contained within the nucleus of the cell is the genotype. The 
combination of dominant and recessive alleles, commonly called genes, and non-coding 
regions of the genome make up an individual’s genotype. The genotype serves as a 
blueprint, contributing to the development of the phenotype. Copy number variants, 
insertions, deletions, and single nucleotide polymorphisms are some examples of how 
changes in the genetic code can lead to phenotypic changes. Hunter (2005) does not 
define genetic variants when presenting his model. However, the most simplistic model 
compares the “genotype” of individuals with or without a given trait to illustrate how 
environment may impact the observed phenotype based on genotype. The complexity of 
the model increases when multiple genes contribute to the development of a single 
phenotype. Eye color is an example of a complex phenotype resulting from multiple 
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genes (Liu et al., 2009). Hunter (2005) did not include epigenetic modifications in his 
discussion of genetic variants, although he did acknowledge the plausibility of assessing 
factors altering gene expression in G x E interactions. Since the introduction of this 
simple model, the field has advanced to include methods for measuring epigenetic 
mechanisms that alter gene expression. Considering epigenetic alterations have the ability 
to augment phenotypic expression; inclusion in, or extension of, the model is logical. 
Environmental Variants 
 The environment has a profound impact on the health of individuals. While 
Hunter (2005) does not specifically define environmental variants in his model, he does 
consistently state that “environmental and lifestyle” factors must be assessed, implying a 
broad definition of environment. Ottman (1996) previously defined environmental 
exposures in gene-environment studies as: 
 The environmental risk factor can be an exposure, either physical (e.g., radiation, 
temperature), chemical (e.g., polycyclic aromatic hydrocarbons), or biological 
(e.g., a virus); a behavior pattern (e.g., late age at first pregnancy); or a “life 
event” (e.g., job loss, injury). This is not intended as an exhaustive taxonomy of 
risk factors, but indicates as broad a definition as possible of environmental 
exposures. (p. 764-765) 
Further, epidemiologists are experts at identifying associations between environmental 
exposure and disease processes. Unfortunately, many epidemiological studies fail to 
collect DNA samples making it impossible to assess the genetic variation in large 
samples of unrelated subjects. Decreasing the existing disconnect between epidemiologic 
and genetic analysis is possible when factors identified in epidemiologic studies are 
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assessed in genetic research involving human subjects. Most genetic studies involving 
human subjects collect some information about participants. Data may be limited to 
demographic information or include detailed laboratory values and other potentially 
relevant risk factors. When designing genetic studies with human subjects, improved 
assessment and collection of environmental exposure data could offer insight into disease 
processes (Hunter, 2005). 
Gene-environment Interactions 
 Hunter (2005) describes two possible approaches for interpreting gene-
environment interactions that contribute to disease in the model. The interpretation of the 
interaction is dependent on the statistical model selected, and must be appropriate for the 
type of clinical question being addressed. When scientists are interested in determining 
how factors contribute to the relative risk of a disease, they assume a multiplicative 
interaction where the risk is either increased or decreased when multiple factors 
contribute to disease development. Results from studies using a multiplicative approach 
usually report findings in terms of relative risk. Using the emphysema example from 
before, the probability of developing emphysema early is more likely to occur if a person 
with the genetic defect smokes. The probability of how likely it is for an outcome to 
occur is referred to as the relative risk.  
If the a priori assumption is the interaction is a joint effect, the relationship is 
additive. To illustrate this type of relationship a clinical example where diagnosis of a 
disease is usually based clinical presentation will be used as an exemplar. For example, a 
patient presents to their primary care provider with skin lesions, a fever, and headache 
and is subsequently diagnoses with varicella by the provider. Each symptom does not 
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does not cause varicella; it is caused by a virus that results in the presentation of a 
specific a set of symptoms. The collection of symptoms together results in the clinical 
presentation caused by the viral infection. Studies utilizing an additive approach 
methodology usually report findings as rate differences, such as 80% of patients with 
chicken pox have a headache. Hunter encourages explicitly stating if the relationship 
assumed for analysis is multiplicative (relative risk) or additive (percent affected) in order 
to appropriately replicate and compare research studies. Research investigating gene-
environment interactions has the potential to improve and individualize patient care by 
improving understanding of disease susceptibility allowing for development of alternate 
treatment and prevention strategies. 
 Modified Conceptual Framework 
 Epigenomic research has led to a greater understanding of how our genes and 
environment contribute to complex disease processes. Epigenome adds the Greek prefix 
“epi” to genome and literally translates to above the genome (epi, n.d). The epigenome is 
fundamental for normal human development and contributes to what makes individuals 
unique. Epigenomics is the study of heritable alterations in the chromosomes which do 
not change the DNA sequence itself, but result in a specific phenotype (Berger et al., 
2009). Structural and functional modifications of the epigenome modulate expression of 
the genes encoded by DNA. Nurses, as members of interdisciplinary teams, can use 
advances in epigenomic techniques to better assess levels of health and disease risk. 
Additionally, it is important when conceptualizing environment in the extended model 
that endogenous and exogenous environmental variants be considered. The environment 
should be considered anything outside of the DNA because any exposure to the DNA 
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could alter the epigenomic signature. Epigenomic alterations should be included in 
studies investigating gene-environment interactions due to the dynamic, and potentially 
reversible, nature of  the epigenome that can be modulated by endogenous and exogenous 
influences throughout the lifespan (Feinberg, 2008).  
 Moffitt, Caspi, & Rutter (2006) argue against incorporating epigenetic 
mechanisms into gene-environment interaction models because the alterations modulate 
the effects of environment on gene expression and do not represent actual alterations in 
the genes or the DNA sequence. This is true in some cases, but not all. For example, 
women with breast cancer type 2 susceptibility protein (BRCA2) mutations have a higher 
risk for developing ovarian cancer (Kanchi et al., 2014; King, 2003; Welcsh, 2001). 
Additionally, hypomethylation of BRCA2 in ovarian tumor DNA has been associated 
with advanced tumor staging (Chan, Ozcelik, Cheung, Ngan, & Khoo, 2002). In other 
words, there is an existing genetic variant that results in increased risk of a disease and 
the severity of disease is modulated by epigenetic variants. However, during embryonic 
development tissue specific DNA methylation patterns are established across the genome 
(Hajkova et al., 2002) and the epigenetic signature can be altered by environmental 
exposures. Since epigenetic (eG) modifications can occur as a direct result of 
environmental exposures (E) resulting in altered susceptibility to disease (∆D) without a 
genetic variant being present, the same conceptual model can be applied to disease states 
without mutations.   
Summary of Framework 
Since publication of Hunter’s (2005) model, methods for quantifying epigenomic 
modifications that alter gene expression have emerged. Assessing the impact of 
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environment on epigenetic signatures without gene mutations can be expressed as:  
eG x E = ∆ D 
Since DNA methylation patterns can contribute to the development of complex disease 
states, epigenetic modifications appear to be a good fit for Hunter’s model. The model is 
useful in guiding research studies analyzing DNA methylation patterns because the 
research can be initiated by identifying epigenetic and environmental components 
separately and then considering the interaction between them. When little is known about 
a disease process or risk factors for a disease are ambiguous, the investigator can initiate 
inquiry by looking for DNA methylation patterns that may be associated with the disease 
state. A limitation to this approach, as with any retrospective analysis, is that we cannot 
establish causation. However, effect size established from a small exploratory study can 
be used to estimate the sample size needed for a prospective study that incorporates 
environmental interactions. 
Application of multiplicative gene-environment interaction models is useful in 
designing studies to determine environmental factors that modify epigenomic variants. 
DNA methylation, an epigenetic process that predominates during development and can 
be modulated throughout postnatal life, is influenced by factors such as nutrition, body 
weight and smoking status that are amenable to nursing interventions (Davis & Uthus, 
2004; Kargul & Laurent, 2009). By modifying Hunter’s (2005) model incorporating 
epigenome, instead of genotype, it is possible to identify epigenomic signatures, 
environmental factors, and interaction between the two that result in complex disease 
states.  
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The purpose of this study was to identify variants in maternal blood that are 
associated with maternal GBS colonization. In chapter two, what is known about GBS 
colonization is reviewed to justify the need for using a substantially different approach to 
identifying host factors that may be associated with GBS colonization. To date, 
epidemiological studies have failed to identify consistent maternal risk factors. The 
approach for this study will be to analyze epigenomic variants of affected individuals, 
specifically DNA methylation, and evaluate several maternal endogenous environmental 
variants IL-10, IL-6, TNF-α, and serum vitamin D (25[OH]D) (25[OH]D). Lastly, 
alterations in DNA methylation patterns will be evaluated to determine if they are 
involved in functional pathways associated with immune function. Identification of 
specific alterations in DNA methylation that result in altered immune function would 
suggest a mechanistic explanation as to why a third of pregnant women are colonized 
with GBS. 
Research Questions 
1. Are serum levels of TNF-α, IL-6, IL-10, and vitamin D (25[OH]D) different in 
pregnant women with GBS colonization than pregnant women without GBS 
colonization?  
2. Are DNA methylation patterns different between pregnant women with GBS 
colonization and those without GBS colonization?  
3. Is there a relationship between differentially methylated genes and immune 
function in pregnant women colonized with GBS?  
Assumptions 
The study will be conducted based on the following pre-stated assumptions: 
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1. Pregnant women presenting with GBS colonization did not have clinical 
symptoms indicative of infection such as fever, chorioamnionitis, bacturia or 
preterm labor at the time recto-vaginal swabs for culture were collected. Medical 
records indicate no other active infections at the time of screenings. 
2. Altered levels of circulating TNF-α, IL-6, IL-10, and vitamin D (25[OH]D) are 
associated with infectious disease susceptibility (Berner et al., 2002; Fan et al., 
2003; P Madureira et al., 2011; Maisey et al., 2008; Mikamo et al., 2004; Ng et 
al., 2003; Parameswaran & Patial, 2010; Puliti et al., 2002; Santhanam et al., 
1991; Vieira et al., 1991). 
3. Serum vitamin D (25[OH]D) levels are variable related to cytokine production 
(Hopkins et al., 2011; Shab-Bidar et al., 2012). 
4. Environmental influences throughout life have the potential to induce variation in 
DNA methylation patterns, modulating gene expression that contributes to health 
and disease states (Baccarelli et al., 2010; Berger et al., 2009; Rodenhiser & 
Mann, 2006) 
5. Differences in maternal DNA methylation patterns during early pregnancy among 
women with and without GBS colonization represent a biomarker for early risk 
identification. 
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CHAPTER II 
REVIEW OF LITERATURE 
 Maternal group B streptococcus (GBS) colonization continues to be a global 
health burden among pregnant women and neonates despite current treatment and 
prevention strategies because neither adequately address the underlying cause of disease 
(Edmond et al., 2012; Verani et al., 2010). In this chapter, evidence supporting the 
modification of the gene-environment framework, described in chapter 1, to incorporate 
the inclusion of epigenomic-environment interactions will be described for GBS 
colonization as the intended research target. The characteristics of GBS and clinical 
significance of GBS colonization and infection will also be reviewed. GBS continues to 
be a pathogen of interest due to increasing resistance to antibiotics, continued neonatal 
infections despite antibiotic prophylaxis, and increasing incidence of invasive disease in 
non-pregnant adults. Current treatment and prevention protocols have been in place since 
the 1990s and the incidence of disease has plateaued in the neonatal population, but has 
risen in historically unaffected populations (Edmond et al., 2012; Phares et al., 2008; 
Schrag & Verani, 2013). Most recently, multiple scientific teams have begun to develop 
vaccines against GBS in attempts to mitigate the disease burden caused by GBS (Johri et 
al., 2006; Schrag & Verani, 2013). However, characteristics of the bacterium and ethical 
issues have hindered successful vaccine development. The intent of this study was to 
identify variants in maternal blood that are associated with maternal GBS colonization 
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that could help identify  new intervention targets to prevent GBS colonization and 
subsequent infection. 
Group B Streptococcus 
 GBS is a gram positive bacterium that causes invasive diseases, such as 
pneumonia, meningitis, chorioamnionitis, and sepsis, primarily affecting pregnant 
women, the elderly, and infants. GBS continues to cause significant morbidity and 
mortality, particularly in neonatal populations, despite current clinical practice designed 
to prevent the transmission of GBS from mother to neonate during delivery (Phares et al., 
2008). Clinical recommendations described in Chapter 1 to circumvent GBS transmission 
to the neonate, have significantly decreased the incidence of early neonatal sepsis. 
However, there have been no further decrease in the amount of late or early onset sepsis 
and new approaches for prevention infection are need to further reduce poor outcomes 
associated with GBS infection. What is known about GBS infection and colonization will 
be reviewed, as well as novel new approaches to identify endogenous maternal factors 
that may be associated with risk for GBS colonization. 
Characteristics of GBS bacterium 
GBS are facultative anaerobic gram positive cocci that grow in pairs or chains. 
Initially, GBS was only associated with cattle as the cause of bovine mastitis. Lancefield 
(1933), first categorized streptococci into five groups based on cell wall carbohydrate 
antigens, and the groups also differ in laboratory identification techniques, colony 
morphology, and disease association. The groups are labeled A-E, GBS belongs to 
Lancefield group B, producing 1-3 mm diameter grayish-white flat mucoid colonies 
when grown in the laboratory. The colonies have a narrow zone of hemolysis with a 
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positive CAMP test. CAMP is an acronym for the scientist who developed the test 
(Christie, Atkinson, Munch, Peterson) for selectively identifying GBS. The additive they 
developed results in a larger area of clearance around the colonies because the additive 
increases the hemolytic activity of GBS (CDC, 2010). Group B specific antigen must also 
be detected when identifying GBS, usually done by latex agglutination. However, 
molecular identification via rapid polymerase chain reaction (PCR) and other methods is 
becoming more common (Bergseng et al., 2008; Kong, Gowan, Martin, James, & Gilbert, 
2002).  
GBS Pathogenesis 
The key feature of GBS that allows it to evade the host immune response is the 
thick capsular polysaccharide layer that surrounds the bacterium. Antigenic differences in 
the layer allows for differentiation into one of 10 distinct serotypes (Ia, Ib, II-IX) 
(Lancefield & Freimer, 1966; Slotved, Kong, Lambertsen, Sauer, & Gilbert, 2007). 
However, some GBS isolates are of indeterminate serotype which is likely because the 
antigens for the serotype have not yet been identified (Ferrieri, Baker, Hillier, & Flores, 
2004). Prevalence of serotypes varies by geographic location (Ippolito et al., 2010), 
although serotype III causes most cases of disease in infants (48.9%) with serotype Ia 
(22.9%), serotype  Ib (7.0%), serotype II (6.2%), and serotype V (9.1%) accounting for 
the majority of other cases (K M Edmond et al., 2012). The capsular polysaccharide layer 
prevents the binding of compliment factor C3 to the surface of GBS, allowing evasion of 
the immune recognition (Doran & Nizet, 2004; Spellerberg, 2000). 
GBS beta-hemolysin/cytolysin (β-h/c) is the second virulence factor that is 
involved in GBS pathogenicity. GBS β-h/c is a non-immunogenic pore-forming 
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membrane associated toxin capable of damaging multiple tissues and impacts disease 
severity (Nizet et al., 1996; Puliti et al., 2000; Ring et al., 2002). In animal models GBS 
β-h/c resulted in increased bacterial load, pro-inflammatory cytokines IL-6 and IL-1α, 
and mortality compared to non-hemolytic mutants (Puliti et al., 2000). However, when 
GBS β-h/c damages host cells it results in the release of IL-8 causing local inflammation 
and recruitment of neutrophils seen in GBS infections (Doran, Chang, Benoit, Eckmann, 
& Nizet, 2002). Additionally, macrophages exposed to GBS β-h/c have higher expression 
of nitric oxide synthase which generates 4 fold more nitric oxide than strains without β-
h/c. High levels of nitric oxide are exhibited in septic shock caused by GBS β-h/c (Ring 
et al., 2002). 
 The surface protein C5a peptidase plays a key role in adhesion to host cells and is 
present on all strains and serotypes of GBS (Cheng et al., 2001; G. Y.-H. Liu & Nizet, 
2004). C5a peptidase is encoded by the ScpB gene and enables binding to epithelial cells 
(Brown et al., 2005). However, if the ScpB gene is deleted it does not completely inhibit 
GBS from adhering to host cells, suggesting that other factors play a role in GBS 
adherence to host cells (Cheng, Stafslien, Purushothaman, & Cleary, 2002; Lindahl, 
Stalhammer-Carlemalm, & Areschoug, 2005; Tamura, Hull, Oberg, & Castner, 2006). 
The following additional surface proteins also contribute to GBS adherence to host cells 
to varying degrees: pili, α-C protein, Lmb, FbsA, and Rib. The surface proteins interact 
with fibronectin, fibrinogen, laninin, and integrins that attach to host cells (Doran & 
Nizet, 2004; Lindahl et al., 2005). 
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Maternal GBS Colonization 
Rates of maternal GBS colonization vary extensively worldwide (Table 1). Rates 
of GBS colonization have been reported as low as 1.8% in Maputo, Mozambique (de 
Steenwinkel et al., 2008), up to 65% in non-pregnant women in the United States (Meyn, 
Krohn, & Hillier, 2009). The gastrointestinal tract is thought to be the primary reservoir 
associated with maternal GBS colonization; sexual activity and abnormal vaginal 
microbiota presumably contribute to the development of vaginal GBS colonization 
(Meyn et al., 2009).  GBS also is likely sexually transmitted because sexual partners are 
frequently colonized with the same strain (Foxman et al., 2006; Manning et al., 2004; 
Meyn et al., 2009; Meyn, Moore, Hillier, & Krohn, 2002). Maternal factors that have 
previously been associated with colonization are: young maternal age, black race, and 
having low levels of GBS-specific anticapsular antibodies (Verani et al., 2010). However, 
a study by Kovavisarach et al. (2007) identified older maternal age as a risk factor and 
Zusman et al. (2006) found no association with race or maternal age. Therefore, risk 
factors associated with maternal colonization based on epidemiological studies appear to 
differ by geographic location and are ambiguous (Kovavisarach et al., 2007; Phares et al., 
2008; Verani et al., 2010; Zusman et al., 2006). Further research is necessary to identify 
factors associated with maternal GBS colonization so targeted prevention methods can be 
developed. 
GBS Disease in Pregnant Women 
The incidence of invasive GBS disease in pregnant women is twofold higher than 
non-pregnant women (Deutscher et al., 2011). GBS can result in stillbirth, preterm birth, 
premature rupture of membranes, abortion, bacteremia, endometritis, chorioamnionitis, 
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Table 1. Global Maternal GBS Colonization Rates 
Country Colonization 
Rate (%) 
Reference 
   
Brazil 17.9 (Zusman et al., 2006) 
Central African Republic 17.5 (Brochet, Couvé, Bercion, Sire, & Glaser, 
2009) 
Germany 16.0 (Brimil et al., 2006) 
Korea 
 
Lebanon 
 
8.3 
17.7 
(Kim et al., 2011) 
(Seoud et al., 2010) 
Mozambique 1.8 (de Steenwinkel et al., 2008) 
Netherlands 21.0 (Valkenburg-van den Berg et al., 2006) 
New Zealand 
 
Norway 
 
 
Senegal 
 
Switzerland 
 
22.0 
34.8 
                        
20.0 
21.0 
(Grimwood et al., 2002) 
(Hakon Bergseng, Bevanger, Rygg, & 
Bergh, 2007) 
(Brochet et al., 2009) 
(Rausch, Gross, Droz, Bodmer, & Surbek, 
2009) 
 Taiwan 
 
Thailand 
6.2 
18.1 
(Yang et al., 2012) 
(Kovavisarach et al., 2007) 
United Kingdom 21.3 (N. Jones, Oliver, Jones, Haines, & Crook, 
2006) 
United States 24.2 (Verani et al., 2010) 
Uruguay 
 
Zimbabwe 
17.3 
31.6 
(Laufer et al., 2009) 
(Moyo, Mudzori, Tswana, & Maeland,2000) 
 
pneumonia, puerperal sepsis, endocarditis, and infections of the genital tract, placenta, 
and amniotic sac. There is currently no known way to prevent GBS colonization and 
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GBS screening is not conducted until late in pregnancy. Identification of maternal factors 
associated with risk for colonization may allow for the development of prevention and 
treatment strategies to prevent poor early pregnancy outcomes associated with GBS 
colonization. New prevention and treatment strategies are necessary because 70% of 
women who have poor pregnancy outcomes due to GBS will also endure poor fetal 
outcomes for their offspring (Phares et al., 2008; Verani et al., 2010).  
Maternal GBS Screening and Treatment 
 The CDC currently recommends screening for GBS colonization 35-37 weeks 
into the pregnancy for all pregnant women. Women positive for GBS are treated with 
antibiotics after they go into labor, preferably at least 4 hours prior to delivering the 
infant. Penicillin G (5 million units) and ampicillin (2 grams) are first line antibiotics 
used to prevent neonatal sepsis in infants born to mothers with GBS colonization because 
they both reach minimum bacteriocidal concentrations in the amniotic fluid, maternal, 
and fetal circulations (Pacifici, 2006; Verani et al., 2010).  The following medications are 
recommended for GBS prevention for women with severe penicillin allergy: cefazolin, 
clindamycin, erthyromycin, and vancomycin. However, drug levels of these antibiotics 
are lower in fetal serum than maternal serum or have variable transfer rates across the 
placenta (Pacifici, 2006; Philipson, Sabath, & Charles, 1973). Ampicillin administered 
intravenously exceeds the minimum bactericidal concentration to kill 99.9% of GBS 
within five minutes of intravenous administration in the maternal and fetal circulation 
(Bloom, Cox, Bawdon, & Gilstrap, 1996). Penicillin levels 179 times above the minimum 
concentration required to eliminate GBS have been collected in fetal serum (Barber, 
Zhao, Buhimschi, & Illuzzi, 2008), indicating intrapartum antibiotics result in significant 
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maternal and fetal exposure from the intrapartum antibiotics administered. Neonatal 
serum levels of ampicillin are higher than maternal concentrations after delivery and 
persist for at least 5.6 hours (Colombo, Lew, Pedersen, Johnson, & Fan-Havard, 2006). 
Further studies evaluating the persistence of antibiotics in the fetal circulation after 
delivery are sparse, but likely contribute to the decreased incidence in early onset 
neonatal GBS sepsis.  
 Maternal Vaccination: Currently, there are a number of clinical trials underway 
examining proposed GBS vaccines for immunization of women prior to, or during, 
pregnancy. The vaccines currently being tested target either GBS capsular carbohydrates 
or proteins (Heath, 2011; Johri et al., 2006). Immunization with the capsular carbohydrate 
alone proved not to be sufficiently immunogenic. However, when capsular carbohydrate 
is combined with tetanus toxoid conjugate vaccine sufficient antibodies are produced 
against GBS (Baker, Rench, & McInnes, 2003). Baker at al.’s (2003) study only added 
conjugated type III capsular carbohydrate to the tetanus toxoid and did not result in 
immunity to other GBS serotypes. Ongoing studies are investigating potential capsular 
carbohydrate vaccines that are multivalent to ensure broader coverage to prevent 
infection. Despite the success of generating some immunity to GBS, a number of 
concerns related to GBS vaccine development remain. For example, vaccines may not be 
effective globally since there is variation in risk factors in the literature. There are also 
significant ethical concerns related to testing vaccines on pregnant women that could 
harm to the fetus (Johri et al., 2006; Paradiso, 2001). Vaccine manufacturing companies 
directly contribute to a lag in vaccine development for pregnant women because of fears 
of liability if the exposed child develops health issues later in life (Kaposy & Lafferty, 
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2012). Liability fears related to administering vaccines during pregnancy may worsen in 
light of growing evidence illustrating altered epigenomic patterns resulting from chemical 
exposures occurring in utero. For example, permanent alteration in methylation patterns 
can occur in fetal DNA in response to chemical exposures in utero, such as DES 
described previously. Litigation has also resulted from residual DES effects on the 
grandchildren of women given the medication during pregnancy (Rothstein, Cai, & 
Marchant, 2009). In light of this, vaccines and systemic antibiotic treatment to prevent 
GBS transmission may not be the least harmful approach. Further research is needed to 
determine the long term impact of vaccine and antibiotic administration in utero and early 
in development.  
GBS Disease in Neonates 
 GBS remains the leading cause of neonatal infectious morbidity and mortality, 
despite the administration of antibiotics colonized women to prevent vertical transmission 
(Clifford et al., 2011; Verani et al., 2010). The incidence of GBS disease in neonates is 
lower in developed countries, 0.4 - 0.81 per 100 live births, than in developing countries 
0.91 - 1.81 per 100 live births (Table 2). Neonatal fatality rates are also 
disproportionately higher in some developing nations (Table 2), which could be due to 
variable prevalence of serotypes by geographic location (Johri et al., 2006) and different 
standards of medical care (Edmond et al., 2012; Heath, 2011). 
 Meningitis, bacteremia, and pneumonia are the neonatal clinical diagnoses most 
commonly caused by invasive GBS. In the US, the incidence of invasive neonatal GBS 
infection is higher in African American infants  (Phares et al., 2008). A meta-analysis 
completed by Edmond et al. (2012) indicated that infants weighing less than 1.5 kg at 
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Table 2. Global Neonatal GBS Morbidity and Mortality 
Country Incidence/1000 Fatality Rate 
(%) 
Reference 
  
Denmark 0.4 8.0 (Ekelund & Konradsen, 
2004) 
Jamaica 0.91 3.6 (Trotman & Bell, 2006) 
Malawi 1.81 33.0 (Gray, Bennett, French, 
Phiri, & Graham, 2007) 
Netherlands 0.56 12.3 (Trijbels-Smeulders et 
al., 2007) 
Norway 0.66 6.5 (1996-2005) 
20.0 (2006) 
(Bergseng et al., 2008) 
United Kingdom and 
Ireland 
 
0.72 9.7 (Heath et al., 2004) 
United States 0.81-0.68 5.0-9.0 (Phares et al., 2008) 
 
birth are 8 times more likely to develop invasive illness caused by GBS than normal 
weight infants. Additionally infants between 1.4 - 2.5 kg at birth are three times more 
likely to develop GBS infection. Neonatal GBS disease is classified by time of invasive 
disease onset after birth. Early onset GBS disease occurs during the first 7 days of life. 
Late onset GBS disease occur after the first week of life through the first 90 days after 
birth (Verani et al., 2010). In the US, the number of cases of early onset (1232) and late 
onset disease (1036) are nearly equal since the CDC guidelines for intrapartum antibiotics 
were implemented in the 1990s. However, mortality is higher for infants with early onset 
GBS disease (83 versus 48 deaths) (Phares et al., 2008). 
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Early Onset Neonatal GBS Disease 
 The incidence of early onset GBS disease in neonates has decreased from 1.7 
cases per 1,000 live births in 1990 to 0.37 cases per 1,000 live births in 2008 in the US; 
as a result of widespread implementation of intrapartum antibiotic administration for 
mothers colonized with GBS. Maternal GBS colonization is the strongest predictor of 
early onset disease. Other risk factors for early onset neonatal disease are GBS in 
maternal urine at any point in pregnancy, rupture of membranes greater than 12 hours, 
delivery before 37 weeks gestation, young maternal age, African American race, 
infection, low maternal anticapsular antibodies to GBS, prior delivery with GBS, and 
maternal fever greater than 37.5˚C during labor (Verani et al., 2010).  Women with heavy 
GBS colonization are more likely to infect their infants versus women who have a lower 
bacterial load (Regan et al., 1996; Yancey, Duff, Kubilis, Clark, & Frentzen, 1996). In 
other words, women with more GBS present have a higher likelihood of infecting their 
infants with GBS.  A majority of infants that develop early onset disease are full term 
(77%) and 90% of infants become ill within 12 hours of birth (Phares et al., 2008). The 
most common presentation of early onset disease are pneumonia and sepsis, and less 
commonly meningitis (Verani et al., 2010). 
Late Onset Neonatal GBS Disease 
 The incidence of late onset GBS disease in neonates is currently 0.35 cases per 
1,000 live births (Jordan et al., 2008). Intrapartum antibiotic administration for GBS 
colonization has not had any significant effect on the incidence of late onset disease 
(Berardi et al., 2013; Phares et al., 2008). Late onset disease commonly presents as 
bacteremia and meningitis, and less commonly pneumonia or local site infections such as 
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cellulitis (Berardi et al., 2013; Jordan et al., 2008). African American infants are 
disproportionately affected (Jordan et al., 2008). Unlike the presentation and time of 
onset of early onset disease, late onset disease is different between term and preterm 
infants; suggesting that there may be different mechanisms involved. For example, 
Berardi et al (2013) identified term infants present with late onset disease earlier than 
preterm infants. Additionally, the etiology may be different from early onset disease 
because less than 30% of infants who develop late onset disease had mothers with 
positive GBS screenings. It is been speculated the source may be breast milk, persistent 
maternal colonization (for the 30% where maternal GBS colonization was present), or 
healthcare workers but additional studies are needed for validation. Further, Jordan et al. 
(2013) identified that 47% of infants that developed late onset disease had been exposed 
to intrapartum antibiotics for either GBS colonization, Cesarean section, or other 
complications. Late onset disease has not been studied with the same intensity as early 
onset disease. Now that the incidence of early and late onset neonatal disease is 
equivalent, the depth of research investigating factors associated with late onset neonatal 
GBS may improve.  
GBS Infection in Non-pregnant Populations 
The incidence of GBS infections in non-pregnant adults doubled from 3.6 per 
100,000 people in 1990 to 7.3 per 100,000 people in 2007 (Skoff et al., 2009). 
Traditionally, GBS disease was seen in individuals with compromised immune systems 
due to advanced age or other underlying conditions. Similar to neonatal GBS disease, 
bacteremia is a common outcome of invasive GBS in adults followed by skin and/or soft 
tissue infections, and pneumonia. Since the implementation of intrapartum antibiotics for 
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GBS colonized mothers, half of case fatalities are adults older than 65 years old (13.2% 
of those infected perish) and are approaching pneumonia fatality rates (20.6%) for the 
elderly population (Edwards, Rench, Palazzi, & Baker, 2005; Schrag et al., 2000). 
Colonization rates are similar to those seen in pregnant women (21.7%) and almost half 
of the elderly (47.3%) affected are colonized with serotype V (Edwards et al., 2005), 
whereas over 60% of disease in neonates is caused by serotype III and Ia (K M Edmond 
et al., 2012). Since this incidence is rising in this population, identification of factors 
contributing to maternal GBS colonization may also be informative for reducing the 
incidence in the elderly population as well.  
GBS Resistance to Antibiotics 
As previously described, infants born to mothers adequately treated with 
intrapartum antibiotics still develop GBS disease and a large proportion of infants are 
born to mother with negative GBS screening. Additionally, GBS positive women treated 
with intrapartum antibiotics are more than 4 times likely to be positive for GBS 6 weeks 
after delivery than women not given intrapartum antibiotics (Manning et al., 2008). 
Interestingly, 65% of women in Manning et al.’s (2008) study continue to have GBS 
colonization despite antibiotic treatment and 18.3% of women that retained GBS positive 
status were colonized with a different strain of GBS. Perhaps the persistence of GBS 
colonization in mothers despite antibiotic treatment is a contributing factor in the 
unchanged incidence in late onset neonatal GBS disease since the implementation of 
intrapartum antibiotic protocols. Conversely, GBS bacteria may just be resistant to the 
antibiotic treatment. In recent years, there has been a push in implementing antibiotic 
stewardship programs in hospital settings to decrease the rates of antibiotic resistance. 
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The programs should also incorporate GBS prophylaxis recommendations and providers 
should be aware of the resistance rates in their area. Many studies evaluating antibiotic 
resistance of GBS assert the strains remain susceptible to penicillin and amoxicillin 
(Castor et al., 2008; Chohan, Hollier, Bishop, & Kilpatrick, 2006; Garland et al., 2011). 
However, reduced susceptibility to penicillin by GBS has been identified in Hong Kong 
and warrants further monitoring for increasing resistance (Chu et al., 2007). Antibiotic 
sensitivity testing is particularly warranted for women with penicillin allergies, since 
clindamycin and erythromycin resistance is high (Table 3). Notably in the US, strains that 
are clindamycin or erythromycin resistance are likely to have dual resistance to both 
erythromycin (94.3%) and clindamycin (71.5%), respectively. In light of increasing  
Table 3. Global GBS Resistance to Antibiotics 
Country E C EC Reference 
Percent (%) Resistant 
Australia 17 22 38 (Garland et al., 2011) 
Korea  9.7 6.8 - (Uh et al., 2007) 
Malawi 21 - - (Gray et al., 2007) 
New Zealand - 15.4 7.7 (Grimwood et al., 2002) 
Norway* 11.9 10.9 25.4 (Bergseng et al., 2008) 
Taiwan  44.0 39.0 - (Janapatla et al., 2008) 
United States 54.0 33.0 - (DiPersio & DiPersio, 2006) 
United States 
(New York) 
50.7 38.4 94.3/71.5 (Back et al., 2011) 
E = Erythromycin 
C = Clindamycin 
EC = Both Clindamycin and Erythromycin 
*= E & C reported for adult cases EC reported for neonatal disease 
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antibiotic resistance, identification of definitive environmental and/or genetic maternal 
risk factors associated with GBS colonization could result in alternate clinical approaches 
for preventing neonatal GBS sepsis.  
Epigenome-Environment Interaction and GBS Colonization 
Epidemiologic findings suggest an association between environmental factors and 
epigenetic alterations, serving as the basis for many complex diseases including obesity, 
type 2 diabetes, asthma, autism spectrum disorder, and attention deficit hyperactivity 
disorder (Latham, Sapienza, & Engel, 2012). Environmental influences that range from 
behavioral conditions, dietary factors, and toxic exposures can be modulated to achieve 
optimal health outcomes for the populations. Additionally, infections and events 
occurring within a person can alter epigenetic signatures (Tolg et al., 2011). Because of 
this, measuring endogenous factors that may contribute to disease development are also 
valuable in epigenomic-environment interactions studies. Further, if modifiable 
exogenous environmental factors can be linked to an altered endogenous environment or 
epigenome, implications for treatment and prevention are ascertained. 
Epidemiologists have identified associations between environmental exposures 
and disease for decades linking poor hand hygiene of healthcare workers with patient 
sepsis in the 19th century (Gould, 2010), poor nutrition during pregnancy to 
cardiovascular disease later in life in offspring (Barker & Osmond, 1986; Barker, 1995), 
and smoking to lung cancer (Doll & Hill, 1950).  However, epidemiological studies 
traditionally do not identify biologic mechanisms that cause disease and are limited to 
identifying the association between population-level risk factors and disease. 
Determining the role of DNA methylation in the origin of disease could help identify 
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epigenetic linkages, not explained by a change in sequence or genetic alteration, that have 
been elusive for most complex diseases. Factors identified in epidemiologic studies 
combined with DNA methylation analyses have the potential to identify epigenomic-
environment interactions at critical time points across the lifespan that contribute to 
disease phenotype and inheritance. Analysis of DNA methylation patterns alone will not 
explain why or how phenotypes are altered; nor will they identify effective primary, 
secondary or tertiary intervention strategies. Environmental factors (e.g., diet, lifestyle, 
stress) must be measured to identify interactions that may cause alterations in DNA 
methylation. Clinical assessments completed by nurses, particularly of lifestyle factors 
that alleviate or exacerbate symptoms, can help identify modifiable factors that are 
related to altered DNA methylation patterns. Each person’s DNA and environmental 
exposures are unique and assessing both simultaneously will result in more personalized 
healthcare. For example, clinical assessments first recognized the association between 
diethylstilbestrol (DES) administration to prevent miscarriage and development of 
reproductive tract anomalies in offspring. In vitro and in adults, DES did not cause 
alteration in methylation patterns. However, DES causes hypermethylation of a gene 
responsible for reproductive tract development to organisms exposed in utero that 
persisted into adulthood (Bromer, Wu, Zhou, & Taylor, 2009). Therefore, it is necessary 
to perform detailed assessments of patient, and family, medical history to identify how 
exposures may alter gene expression because the associations are not always obvious.  
To illustrate the utility of evaluating epigenomic changes in the context of gene-
environment interaction models as described in Chapter 1, the concept of DNA 
methylation and how perturbations in DNA methylation patterns can alter gene 
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expression and disease susceptibility will be reviewed. DNA methylation is the best 
understood epigenetic mechanism that modulates gene expression (Baccarelli, Rienstra, 
& Benjamin, 2010). Differential methylation induced by endogenous or exogenous 
influences can lead to both genome instability and inappropriate gene transcription, 
contributing to pathology.  DNA methylation patterns are often specific to lineage, organ, 
and cell-type (Cedar & Bergman, 2012). For example, all the human cells in an 
individual contain the exact same DNA. The epigenomic signature of a cell will program 
it to differentiate into a heart, eye, or skin cell. Abnormal loss or gain of methylation at 
key DNA sites may result in inappropriate expression of a gene. When specific patterns 
of methylation are associated with a phenotype, such as risk for disease, the patterns can 
be used to identify those at risk for poor health outcomes and provide the basis for new 
treatments. The investigation of epigenetic markers to identify biological mechanisms of 
complex disease processes, such as atherosclerosis(Guay et al., 2013; Lund et al., 2004; 
Zaina, Lindholm, & Lund, 2005), schizophrenia(Auta et al., 2013; Costa et al., 2002; 
Sharma, 2005), and lupus(Absher et al., 2013; Li, Gorelik, Strickland, & Richardson, 
2014; Sekigawa et al., 2003), have been increasing in recent years (Bergman & Cedar, 
2013; Petronis, 2010; Rakyan, Down, Balding, & Beck, 2011; Rodenhiser & Mann, 
2006).  Furthermore, DNA methylation is heritable during cellular reproduction, and 
likely from one generation to another. This means methylation signature can pass from 
both cell to cell and transfer from parent to offspring (Guerrero-Bosagna & Skinner, 
2012; Rodenhiser & Mann, 2006).  Therefore, DNA methylation patterns passed across 
generations may provide an explanation for the transmission of complex disease 
susceptibility among families that is modulated by environmental exposures (Figure 2). 
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Figure 2 illustrates how alterations in DNA methylation by exogenous and endogenous 
factors can contribute to level of susceptibility to complex disease in individuals, with 
transmission of the pattern throughout future generations (Wright, Ralph, Ohm, & 
Anderson, 2013). 
 
 
Figure 2.  Influence of DNA Methylation in Complex Disease States.  
 DNA methylation patterns associated with GBS colonization could not be 
identified in the literature. However, altered DNA methylation patterns are known 
modulators of immune function and alterations have been associated with other infectious 
disease processes (Table 4). Notably, T-lymphocyte cell function and cytokine expression 
are altered by methylation patterns present on T cells (Fitzpatrick, Shirley, & Kelso, 
1999). Additionally, DNA methylation patterns are altered by bacterial infection 
(Mikovits et al., 1998; Tolg et al., 2011) and different methylation patterns associated 
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with the development of disease have been identified in animal models when they are 
colonized with altered bacterial populations after birth (Olszak et al., 2012). Since DNA 
methylation vitally contributes to cell differentiation in the immune system and 
programming memory in immune cells, it is an excellent candidate for identifying 
unknown mechanisms that may be associated with infectious diseases susceptibilities.  
Table 4. DNA Methylation and Immune Function 
Immune Function or Alteration Reference 
  
Bacterial infection induces hypermethylation (Tolg et al., 2011) 
Discriminates between regulatory and conventional T cells (Baron et al., 2007) 
Downregulation of IFN-γ in fetus, helps prevent fetal loss (White, Watt, Holt, & 
Holt, 2002) 
IgE production (Liu, Ballaney, Al-
alem, & Quan, 2008) 
Maintenance of T cell memory and cytokine expression pattern (Fitzpatrick et al., 1999) 
Maternal bacterial infection promotes fetal hypermethylation (Bobetsis et al., 2007) 
Number and function of regulatory T cells (Schaub et al., 2009) 
Viral infection increases DNA methylation (Mikovits et al., 1998) 
 
DNA Methylation 
 DNA methylation is an epigenetic modification that may result in gene silencing, 
gene activation resulting in chromosome instability, inappropriate gene expression, and 
inability to carry the epigenomic signature to future cell lines (Bergman & Cedar, 2013; 
Cedar & Bergman, 2012; Jones, 2012; Rodenhiser & Mann, 2006). Epigenetic changes 
are heritable alterations in the chromosome that do not change the DNA sequence that 
result in a specific phenotype, which are observable characteristics (Berger et al., 2009; 
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He, Chen, & Zhu, 2011; Tost, 2010). DNA methylation is a specific epigenetic alteration 
in which a methyl group attaches to a cytosine (C) residue in DNA that is followed by a 
guanine (G) residue connected by a phosphate bond, commonly referred to as a CpG 
dinucleotide, and is currently the most well understood epigenetic mechanism (Baccarelli 
et al., 2010; Cedar & Bergman, 2012; Chen & Riggs, 2011; P. A. Jones, 2012). Areas 
with dense concentrations of CpG dinucleotides are located in promoter regions of genes, 
which is where transcription factors bind to initiate the reading of a DNA sequence so a 
gene will be expressed. Methylation of cytosines located in the promoter region can alter 
gene expression by blocking transcription of the DNA, resulting in gene silencing. 
Conversely, a loss of methylation at these sites may result in inappropriate expression of 
a gene.  
Between 60-90 percent of cytosines are methylated in human DNA (Ehrlich et al., 
1982) and the establishment of “normal” DNA methylation patterns are necessary for 
embryonic development. Normal patterns of methylation are required for the 
differentiation of cell types. For example, every cell in an individual’s body has the same 
DNA sequence and methylation patterns present on the DNA sequence is specific to 
tissue type(Cedar & Bergman, 2012; Jones, 2012; Laird, 2010). In other words, the 
methylation pattern for a cell in the heart will be different from the methylation pattern 
on a cell in the eye, even though the DNA sequence is exactly the same. Alterations in 
methylation patterns also explain some of the processes that occur in complex disease 
states, such as delayed onset disease or situations where only one identical twin develops 
cancer (Boks et al., 2009; Fraga et al., 2005; Kaminsky et al., 2009; Petronis, 2001). 
Furthermore, there is evidence that DNA methylation patterns are altered by 
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environmental exposures (Table 5), implying that we have the ability to intervene to 
prevent disease or promote desired health outcomes. Patterns of methylation associated  
Table 5. Environmental Exposures that Alter DNA Methylation 
Environmental factor Reference 
  
Alcohol (Choi et al., 1999) 
  
Bisphenol-A (BPA) (Bromer, Zhou, Taylor, Doherty, & Taylor, 2010) 
  
Diethylstilbestrol (DES) (Bromer, Wu, Zhou, & Taylor, 2009) 
Exercise (Barrès et al., 2012) 
Fear (Miller & Sweatt, 2007) 
Hydralazine (Cornacchia et al., 1988) 
Maternal Care  (Weaver et al., 2004) 
Maternal Diet (Wolff, Kodell, Moore, & Cooney, 1998) 
Microbiome (Olszak et al., 2012) 
Procainamide (Cornacchia et al., 1988b) 
Smoking (Toyooka et al., 2003) 
Traffic pollution  (Baccarelli et al., 2009) 
 
with a specific phenotype, such as susceptibility to infection, have potential for use in 
identifying people at risk for developing conditions and as treatment targets. Leukemia 
treatments based on epigenetic markers have been approved and used successfully in the 
clinical setting (Rodriguez-Paredes & Esteller, 2011). Identifying differences in DNA 
methylation patterns during early pregnancy in women with GBS colonization could 
represent a biomarker for early risk identification or develop methods to prevent 
colonization. Furthermore, because there is a strong relationship between DNA 
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methylation patterns and the function of cells in the immune system (Table 4); 
differential DNA methylation in genes associated with immune function could offer 
mechanistic insight as to why certain bacteria, like GBS, colonize some individuals and 
not others.  
Environmentally Induced Modification 
 Environmental influences throughout life have the potential to induce variation in 
DNA methylation patterns, modulating gene expression that contributes to health and 
disease states (Baccarelli et al., 2010; Berger et al., 2009; Rodenhiser & Mann, 2006). 
For example, permanent alteration in methylation patterns can occur in fetal DNA in 
response to chemical exposures in utero. Diethylstilbestrol (DES) is a synthetic estrogen 
that was administered to pregnant women to prevent spontaneous abortions prior to the 
mid 1970’s. DES causes hypermethylation of homeobox protein Hox-A10 (HOXA10), a 
gene that controls uterine organ development, resulting in reproductive tract anomalies 
that persist into adulthood (Bromer et al., 2009). Furthermore Bromer et al.,  determined 
the hypermethylation of HOXA10 was specific to the fetus and did not occur laboratory 
experiments using cell line or the pregnant women who received DES.  
Assessment of DNA methylation patterns in disease states where the mechanism 
that alters gene expression are unknown can help identify etiology of disease. For 
example, in 1915, Kendall determined the microbes that colonize the gastrointestinal tract 
at birth are involved in normal development of the immune system. However, the 
biological mechanism of how this occurred remained unknown for years. Olszak et al. 
(2012) recently published a study suggesting that the type of bacteria that colonize the 
gastrointestinal tract in the neonatal period has an effect on the function of cells in the 
39 
 
immune system. This study was performed on germ-free and specific-pathogen free mice. 
Further, Olszak’s study suggests that microbial exposure alters gene expression in 
specific tissues. The authors of the study noted hypermethylation of CpG sites in 
colonand lung tissues of the chemokine (C-X-C motif) ligand 16 (CXCL16) gene 
occurred when specific pathogens were not present during development. The CXCL16 
gene encodes a chemokine receptor on invariant natural killer T cells (iNKT), resulting in 
higher accumulations of iNKT cells that are involved with inflammatory processes. 
Additionally, the higher accumulation of the iNKTs only occurred in the colon and lung 
when specific bacteria were not present. The authors hypothesize an environmental 
exposure later in life triggers various inflammatory disease processes programmed by the 
methylation changes in the bowel and lungs, like asthma and irritable bowel syndrome. 
Therefore, exposure to bacteria early in development affects the programming of the 
immune system, in mice, by causing perturbation in DNA methylation patterns. They 
concluded the findings could be extrapolated to humans because the mouse model used is 
similar to human cells. Further studies investigating alterations of methylation patterns in 
humans may be needed to demonstrate the effects of environmental exposures on 
immune function. This study aims to identify differential DNA methylation patterns in 
pregnant women colonized with GBS. If differential patterns are identified, future 
investigations will be focused on identifying causes of the altered methylation patterns.  
Endogenous Maternal Environment 
Other clinical indicators could potentially be used to identify pregnant women at 
increased risk for GBS colonization and have not been discussed in published literature. 
Clinical indicators, such as serum cytokine levels that reflect immune system functioning, 
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could also be associated with altered DNA methylation patterns. Variability in serum 
markers associated with immune function and vitamin D (25[OH]D) status have 
previously been identified and utilized as prognostic indicators of disease states, such as 
respiratory infections (Chesney, 2010), human immunodeficiency virus infections (Fahey 
et al., 1990), pancreatitis (Pezzilli et al., 1995), and depression (Kiecolt-Glaser & Glaser, 
2002). There has been a plethora of research investigating the role of vitamin D 
(25[OH]D) as an immune function modulator in recent years (Figure 3) and could offer a 
cost effective intervention target if low serum vitamin D (25[OH]D) levels are associated 
with GBS colonization . In this section, a brief review of immune function during 
pregnancy, relevant cytokines, and vitamin D (25[OH]D) will be discussed. 
 
Figure 3. PubMed results for “Vitamin D” and “Immune Function”. 
Immune System During Pregnancy 
Multiple alterations in immune function are necessary during pregnancy to 
prevent the mother’s body from recognizing the developing fetus as a foreign pathogen. 
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Serum markers of immune function are increasingly being evaluated in pregnancy 
because alterations occur throughout normal pregnancy and inappropriate levels 
contribute to the development of pathology during pregnancy (Ponsonby, Lucas, Lewis, 
& Halliday, 2010). Alterations in the maternal immune system vary during pregnancy 
and can be effected by the overall health of the mother. For example, if a woman has a 
preexisting autoimmune disorder, like rheumatoid arthritis, she may experience remission 
from symptoms during the pregnancy as a result of altered immune functioning that 
protects the fetus. However, pregnancy does not result in the same altered state 
throughout the entire pregnancy because there are three distinct phases. First, in the early 
stages of pregnancy the environment is that of an invasion (Ashkar, Di Santo, & Croy, 
2000; Dekel, Gnainsky, Granot, & Mor, 2010; Shimada et al., 2006). Implantation 
occurs, the placenta develops and an inflammatory environment allows the establishment 
of these entities in the maternal system. The initial pro-inflammatory stage enables 
vasculature to develop, removes the cellular byproducts of implantation and results in the 
clinical manifestation of “morning sickness” that is seen in the early stages of 
pregnancy(Mor & Cardenas, 2010). In the second phase, the initial inflammatory state 
resolves and an anti-inflammatory state begins to predominate; creating a safe 
environment for fetal growth. In the final phase, a pro-inflammatory environment is 
induced in order to deliver the fetus (Romero et al., 2006). Increased inflammatory 
markers contribute to the promotion of the rupture of membranes, uterine contractions, 
and delivery (Mor & Cardenas, 2010). 
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Cytokines 
Cytokines are proteins produced by cells that are generally classified as pro-
inflammatory or anti-inflammatory (Denney et al., 2011). There is redundancy of 
function between cytokines. Multiple cytokines illicit the same action, and have multiple 
target cells, so it can be difficult to attribute an action to a specific cytokine (Miyajima, 
Hara, & Kitamura, 1992). Cytokines are secreted by, and activate, various cells involved 
in the host immune response including activated phagocytes, epithelial cells, and T cells 
(Abbas, Lichtman, & Pillai, 2012). In general, cytokines produced by T-helper 1 (Th1) 
cells are pro-inflammatory and cytokines produced by T-helper 2 (Th2) cells are anti-
inflammatory and some cytokines exhibit properties of both (Brogin Moreli, Cirino 
Ruocco, Vernini, Rudge, & Calderon, 2012). An imbalance of pro versus anti-
inflammatory cytokines produces inflammation or muted immune responses. This can be 
attributed to the magnification of the normal synergistic or antagonistic effects that 
cytokines exhibit (Abbas, Lichtman, & Pillai, 2012). During normal pregnancy there is a 
shift to upregulate expression of Th2 cells and suppression of Th1 cells to prevent 
abortion of the fetus during development (Thellin & Heinen, 2003). Disruption of this 
altered balance of the immune system during pregnancy has been associated with 
gestational diabetes, preeclampsia, preterm labor, abortion and infection (Brogin Moreli 
et al., 2012; Fichorova et al., 2011). However, studies investigating levels of cytokines 
throughout pregnancy have presented dissimilar cytokine values during normal 
pregnancy (Curry et al., 2008; Makhseed et al., 2000; Vassiliadis, Ranella, Papadimitriou, 
Makrygiannakis, & Athanassakis, 1998). Variations in results could be explained by 
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different methodologies used to measure the cytokines and disparate sample sizes (30 
versus 1200).  
In a recent study, Fichorova et al. (2011) identified patterns in immune function 
markers that were specific to the type of bacteria present in the vaginal mucosa and 
placenta of pregnant women. They found that TNF-α, IL-8 and ICAM-1 were elevated in 
the presence of Gardnerella, which is the most common causative pathogen of bacterial 
vaginosis. When multiple organisms associated with bacterial vaginosis were present, 
pro-inflammatory cytokine (TNF-α, IL-1β, IL-6), chemokine (IL-8), and acute phase 
marker (CRP and serum amyloid A) levels were elevated. Furthermore, Lactobacillus, 
which colonize the vaginal mucosa and are not pathogenic, suppress pathogenic strains 
and downregulate pro-inflammatory cytokines (Donato, Gareau, Wang, & Sherman, 
2010; Othman, Neilson, & Alfirevic, 2007; Zeuthen et al., 2010). However, patterns of 
immune function serum markers were not analyzed related to GBS colonization or 
infection in any identified studies. For this study, TNF-α, IL-6, IL-10 and vitamin D 
(25[OH]D) status were selected specifically for analysis because of their identified 
association with infectious diseases and action during pregnancy and because serum 
levels for these specific cytokines were available to for secondary analysis for this study. 
TNF-α: TNF-α is a serum immune function marker of interest because it is 
involved with coordination of the cytokine cascade and regulation of macrophage 
biology, which are both needed to fight infection. Alteration in TNF-α serum levels 
contribute to the development of various disease states, including sepsis and autoimmune 
conditions (Parameswaran & Patial, 2010). Macrophages are the primary producers of 
TNF-α in non-pregnant populations. However, in pregnant women the placenta 
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contributes to increased TNF-α levels throughout pregnancy (Brogin Moreli et al., 2012). 
The elevated TNF-α levels increase insulin resistance, which could contribute to the 
development of hyperglycemia or gestational diabetes during pregnancy (Kirwan et al., 
2002). There have been no human studies analyzing TNF-α in pregnant women related to 
GBS infection or colonization. However, in vitro experiments show an increase in TNF-α 
production in cells exposed to GBS (Berner et al., 2002; Mikamo et al., 2004). 
Additionally, TNF-α and IL-6 levels in mice increase systemically when inoculated with 
GBS when IL-10 production is decreased resulting in 60% mortality (Puliti et al., 2000). 
Because TNF-α levels increase in laboratory and animal studies as a result from GBS 
exposure, serum TNF-α levels may be increased in pregnant women colonized with GBS. 
Furthermore, due to the inverse relationship TNF-α and IL-6 have with IL-10 in response 
to GBS exposure in animal models, IL-6 and IL-10 will also be evaluated in this study.  
IL-6: IL-6 is a serum immune function marker that is a pro-inflammatory cytokine 
involved in the acute phase in the immune response. IL-6 is elevated in amniotic fluid of 
pregnant women with premature rupture of membranes due to intrauterine infections and 
also increases during active labor (Santhanam et al., 1991). Elevated serum IL-6 levels 
have also been identified in other inflammatory conditions experienced during 
pregnancy, like preeclampsia (A. Sharma, Satyam, & Sharma, 2007).  It is unclear if a 
similar elevation in IL-6 occurs in women with GBS colonization. However, IL-6 
production does increases in vitro and in animal studies with exposure to GBS (Berner et 
al., 2002; Mikamo et al., 2004; Puliti et al., 2002). The increase in IL-6 in response to 
GBS exposure has not been verified or validated in human studies. Therefore, in this 
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study we will evaluate the level of serum IL-6 to determine if a similar increase in IL-6 
production occurs in pregnant women in response to GBS colonization. 
IL-10: IL-10 is a serum immune function marker that inhibits the synthesis of pro-
inflammatory cytokines, such as IL-6 and TNF-α, and stimulates the production of B 
cells and their differentiation into antibodies (Vieira et al., 1991). Additionally, IL-10 
levels vary during pregnancy and may be involved in the maintenance of a viable 
pregnancy (Denney et al., 2011; Hashii et al., 1998). Early in pregnancy IL-10 is 
protective because it inhibits secretion of inflammatory IL-6, TNFα, and INF-γ allowing 
the fetus and placenta to develop without being rejected by the maternal system. As the 
pregnancy progresses, the level of IL-10 decreases and the resulting increase in 
inflammatory cytokines allows the initiation of labor (Brogin Moreli et al., 2012).  
Reduced IL-10 levels are associated with fetal loss in the first trimester, 
preeclamsia, gestational diabetes, and preterm birth (Brogin Moreli et al., 2012). Serum 
levels of IL-10, as related to GBS colonization in pregnant women, have not been 
evaluated. Although, Madureira et al. (2011) conducted a study using a murine model and 
found reduced levels of IL-10 in animals that carry GBS antibodies, which conferred  
immunity to the bacteria in offspring. Conversely, Bebien et al. (2012) found that the 
βh/c component of GBS induced IL-10 production. The higher production of IL-10 
inhibited IL-12 production, which is involved in inducing immune responses, resulting in 
GBS being able to escape host cell detection and survive. When Bebien administered 
recombinant IL-10 to the GBS infected mice to test the effect of IL-10, the number of 
GBS in the mice increased significantly. If results from the animal studies described can 
be translated to humans, it is expected that there will be some elevation in serum IL-10 
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levels later in pregnancy in women colonized with GBS. Elevated IL-10 levels could be 
the result of GBS presence, like Madureira’s study, or because the normal IL-10 
elevation in early pregnancy enables GBS colonization in exposed women, like Bebien’s 
study. Regardless of the mechanism, elevated IL-10 could be a clinical laboratory 
indicator for GBS colonization in pregnant women during the third trimester.  
Vitamin D (25[OH]D) Status 
Circulating vitamin D (25[OH]D) deficiencies have been associated with 
susceptibility to infectious diseases such as influenza, tuberculosis, and pneumonia 
(Chesney, 2010).  Vitamin D3 is the form of vitamin D that is produced by the skin in 
response to sunlight and primarily the form of vitamin D consumed from foods 
containing vitamin D. Vitamin D3 is then converted to Vitamin D (25[OH]D) in the liver. 
Vitamin D (25[OH]D) is the circulating form of the vitamin that is traditionally measured 
to identify vitamin D status in clinical populations (Hollis, 2005, 2008, 2012). It is 
generally accepted that serum vitamin D (25[OH]D) levels must be above 20 ng/ml to 
maintain normal physiologic processes and fetal development during pregnancy. 
Recently, vitamin D (25[OH]D) experts suggest that levels greater than 32 ng/ml are 
necessary to support all physiologic processes that require vitamin D (25[OH]D) for 
optimal functioning, like preventing infections (ACOG, 2011; Holick, 2011; Hollis, 
2012). Therefore, the normal increase in serum vitamin D (25[OH]D) levels during 
pregnancy may be involved in preventing infection and colonization with pathogenic 
bacteria during normal pregnancy. There is a possibility that colonized women may have 
lower serum vitamin D (25[OH]D) levels, predisposing them to group B streptococcus 
colonization. To date, no randomized control trials evaluating the effects of vitamin D 
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(25[OH]D) supplementation during pregnancy related to maternal colonization or 
infection have been completed (De-Regil Luz, Palacios, Ansary, Kulier, & Peña-Rosas 
Juan, 2012). However, a meta- analysis conducted by Thorne-Lyman and Fawzi (2012) 
suggests that it is unknown how vitamin D (25[OH]D) relates to maternal infections since 
the relationship between vitamin D (25[OH]D) and immunity has only recently been 
established. There is currently no documented relationship between serum vitamin D 
(25[OH]D) levels and maternal GBS colonization. 
Implications for the Nursing Discipline 
Person, health, environment, and nursing are the metaparadigm concepts that 
remain the pillars of the nursing discipline. Perception of these concepts constantly 
evolves to incorporate new knowledge gained through practice, research, education, and 
exposure to other disciplines. Since most human disease processes are multifactorial in 
nature and nurses interact with individuals throughout the illness-wellness continuum, it 
is imperative nurses understand how gene-environment interactions impact health. 
Research investigating exogenous and endogenous, like DNA methylation and serum 
cytokines and how they respond to environmental exposures, continues to generate data 
that improves our understanding of factors associated with complex disease processes. As 
the state of the science continues to evolve, nurses must begin to incorporate new data 
into their own research to deliver the best possible care to patients.  
Investigations designed to identify biologic mechanisms explaining how 
epidemiologically defined risk factors result in complex disease processes lag behind data 
generated by epidemiologic studies (Dempfle et al., 2008; Hunter, 2005; Khoury, Davis, 
Gwinn, Lindegren, & Yoon, 2005; Martino & Prescott, 2011). Nurses, as members of 
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interdisciplinary teams, can utilize advances in epigenomic techniques to better assess 
levels of health and disease risk that may help explain findings identified in 
epidemiological studies.  Nurses are well suited to investigate factors that may contribute 
to epigenomic variation because by nature of the profession, nurses continuously bridge 
science and technology to patient populations (Clark, Adamian, & Taylor, 2013; 
Loescher & Merkle, 2005).  This study aimed to identify DNA methylation patterns and 
serum immune system markers associated with maternal GBS colonization. If vitamin D 
(25[OH]D) plays a role in the modulation of serum immune system markers, it would be 
a cost effective clinical intervention that could be introduced into practice to reduce GBS 
colonization rates and an alternative to antibiotic treatment. This study exemplifies how 
translational research can be initiated by hypotheses from the bedside, examined at the 
bench and brought back to the bedside to improve health outcomes.  
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CHAPTER III 
METHODS 
Design 
 An exploratory secondary data analysis was completed using acquired 
quantitative data and maternal peripheral blood samples that were previously collected in 
a prospective longitudinal cohort study of nulliparous pregnant women. The data was 
initially collected to evaluate differences in women with and without preeclampsia. All 
women who had preeclampsia were excluded from this analysis because women with 
preeclampsia have different methylation patterns than women without preeclampsia 
(Anderson, Ralph, Wright, Linggi, & Ohm, 2013). The participants were enrolled in the 
primary study during the first trimester of their pregnancy and were followed through the 
time of childbirth. Eligibility criteria for the primary study included; English speaking, no 
previous births after 20 weeks gestation, age >18 years, and singleton pregnancy. At 
enrollment between 10-14 weeks gestation, baseline demographic information and 
venipuncture to collect blood for genome-wide DNA methylation analysis and other 
serum blood tests including TNF-α, IL-6, IL-10 and circulating vitamin D (25[OH]D 
were completed. In subsequent trimesters (second trimester 22-26 weeks gestation and 
third trimester 32-36 weeks gestation), venipuncture to collect blood for serum blood 
tests including TNF-α, IL-6, IL-10, and circulating vitamin D (25[OH]D) was completed. 
A subgroup of 6 women (n=2 GBS positive; n=4 GBS negative) were selected as control 
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samples for genome-wide DNA methylation analysis in the primary study. The 
methylation analysis was completed on peripheral blood samples obtained in the first 
trimester using the Infinium bead-based array platform (Illumina, Inc., San Diego, CA). 
For this study, only women (n=42) with documented uncomplicated (no preeclampsia, 
gestational diabetes, chorioaminoitis, etc) pregnancies in the primary study were included 
in the cytokine and vitamin D analysis.  A subset of 18 women (n=9/group) were 
evaluated for differential genome wide methylation differences.  
Procedures 
Collection of Physiologic Data 
 Prior to commencement of data collection, this study was approved by the 
University of North Dakota Institutional Review Board (Appendix A). The primary study 
was approved by the University of North Dakota Institutional Review Board (Appendix 
B) and Altru Health System (Appendix C) prior to enrollment of participants into the 
study. Informed consent was completed by participants after verbal and written 
descriptions of the parent study were given. Participants were informed that blood 
samples would be taken and laboratory studies would be conducted on DNA extracted 
from these samples. Serum collected for cytokine and vitamin D analysis was collected 
via venipuncture. Whole blood was collected in a red top vacutainer (B-D) blood tube, 
retained at room temperature and allowed to clot for 1 hour followed by centrifugation at 
1,000 x g at 4 degrees centigrade for 10minutes. Serum (500 µl) was placed in separate 
vials and frozen at -80 degrees centigrade until they were analyzed for the parent study. 
Cytokine laboratory analysis were completed at the United States Department of 
Agriculture, Agricultural Research Service (USDA ARS) Grand Forks Human Nutrition 
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Center and vitamin D laboratory analysis was completed in the Brown-Borg laboratory at 
the University of North Dakota, School of Medicine and Health Sciences for the parent 
study. Only de-identified data was utilized in the current study. Medical history, GBS 
colonization status, and information about the participants had previously been extracted 
from the medical record for the purpose of the primary study using a standard data 
abstraction form (Appendix D). Descriptive statistics were used to elicit information 
about the study population including: age, race/ethnicity, ethnicity, weight, sex of the 
infant, gestational age at birth, and co-morbidities. 
Cytokine Laboratory Analysis 
Cytokine analysis that was previously completed on serum samples for TNF-α, 
IL-6, and IL-10 (Bio-Plex, Millipore, Fountain Hills, AZ) at each of the three pregnancy 
trimesters. In brief, the target protein antibody was coupled to dual beads and incubated 
with sample. The protein of interest was captured, combined with a biotinylated antibody 
for a different epitope, and detected using a dual-laser flow based reader. For the cytokine 
analyses, the serum was diluted one volume of sample to three volumes of Bio-Plex 
human serum sample diluent. Next, 50 µl of assay diluent was added to each well in the 
96 well plate. Then, 200 µl of cytokine standard, control, or sample was added to each 
plate and allowed to incubate at room temperature for two hours.  All fluid from the wells 
was aspirated and each well washed a total of four times.  200 µl of conjugate was then 
added to each well and allowed to incubate a room temperature for two hours. After 
aspirating all fluid from the wells and washing the wells four times, 200 µl of substrate 
solution was added to all the wells, covered with foil and incubated at room temperature 
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for 20 minutes. Lastly, 50 µl of stop solution was added to each well and read the plate at 
450nm within 30 minutes with the wavelength correction set at 540 or 570nm. 
Vitamin D (25[OH]D) Laboratory Analysis 
Circulating vitamin D (25[OH]D) levels were previously analyzed from serum as 
follows using the Immunodiagnostic Systems Ltd (IDS) 25-Hydroxyvitamin D 
enzymeimmunoassay (EIA) kit. Per the manufacturers assay protocol, the assay allows 
for 39 samples to be run in duplicate with 2 built in controls. The assay has good 
correlation with other methods for determining vitamin D (25[OH]D) in both serum or 
plasma with excellent sensitivity and specificity (5.3 - 7.4% variability within assay, and 
5.3 - 11.7% between assays (Hyppönen, Turner, Cumberland, Power, & Gibb, 2007). 
Briefly, the procedure for vitamin D (25[OH]D) EIA analysis was completed by adding 
25 µl of serum to 1 ml of a propriety buffer reagent that dissociates vitamin D from 
protein. The diluted samples were then incubated at room temperature in a vitamin D 
antibody coated plate for 2 hours.  Enzymes that bind selectively to the vitamin D biotin 
complex was then added and the samples were then washed. Next, a chromogenic 
substrate was added to the samples. The reaction was then stopped by adding a 
hydrochloric acid solution so the intensity can be measure of the treated vitamin D biotin 
labeled complex using a microtitre plate reader. 
DNA Methylation Laboratory Analysis 
 To complete the DNA methylation analysis portion of this study, the following 
steps were completed to examine the hypothesis that “differences in maternal DNA 
methylation patterns during early pregnancy are present in women with and without GBS 
colonization.” DNA methylation was previously quantified in peripheral white blood 
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cells, collected in the first trimester, in a subset of six participants in the primary study 
using the Infinium bead-based array platform at the University of Minnesota’s 
Biomedical Genomics Center and Illumina Core laboratory. Of those participants, four 
screened negative for GBS and two screened GBS positive in the third trimester.   
In order to identify trends and potential differences in methylation between GBS 
positive and negative women, 12 additional samples were analyzed for this study (n=5 
GBS negative; n=7 GBS positive). Samples were randomly selected from the remaining 
samples from the primary study. Genome-wide DNA methylation was determined using 
the Infinium platform (Illumina, Inc., San Diego, CA) at the University of Minnesota’s 
Biomedical Genomics Center and Illumina Core Laboratory. Results from these samples 
were pooled with the results previously obtained to evaluate changes in DNA methylation 
between groups using the GenomeStudio Data Analysis Software that is compatible with 
output from Illumina.  DNA methylation analysis was also completed using R 3.0.2 
Statistical Environment for Windows. 
DNA methylation at over 485,000 individual CpG dinucleotides in peripheral 
blood collected from women with and without GBS colonization (n=9 GBS negative; n= 
9 GBS positive) was quantified. Samples underwent bisulfite conversion, which turns 
unmethylated cytosines to uracil and leaves methylated cytosines unaffected. The change 
allowed two query probes to detect differences in methylation between samples for 
predefined segments of DNA based on binding of specific nucleotides. This process is 
known to have greater than 99% conversation efficiency, yielding highly sensitive single-
nucleotide resolution of methylation status. The quantitative amount of methylation at 
each CpG loci was reported as a beta value (β = methylated sites / (unmethylated gene + 
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methylated sites + 100)) (Bibikova et al., 2011). Beta values range from 0-1 and 
represents the percentage of DNA methylation (0-100) present at a given site. The 
Infinium platform processes 12 samples per plate.  
Individual CpG dinucleotides that differed in DNA methylation between women 
with and without GBS colonization by +/- 20% as a percentage of total methylation, were 
designated as differentially methylated. Statistical significance of these changes between 
groups was then determined by t-tests (using a two-tailed, alpha of 0.05) (see Data 
Analysis section). In order to determine the potential for clinical relevance of 
differentially methylated CpG sites, functional analysis of genes with differentially 
methylated CpGs was also completed (see Functional Analysis section).  
The specific function of individual genes was verified utilizing GeneCards and 
Pubmed. In order to validate the array, six genes were selected for validation of 
methylation patterns via bisulfite sequencing by Genwiz, Inc. (South Plainfield, NJ), 
based on greatest mean methylation differences. Two of the six gene sites also underwent 
a cloning step to assist in identifying methylation on specific CpG sites since the quality 
of DNA may not have been sufficient to obtain accurate reading without magnification 
because it is a clinical blood sample with multiple cell types present. After the samples 
were bisulfite treated, sequencing was used to determine the DNA sequence and validate 
the results from the Illumina Infinium array. The next sections describe the process in 
greater detail. 
Extraction of White Blood Cells from Blood 
For the initial study, whole blood was obtained via venipuncture and collected in 
a purple top vacutainer (B-D) blood tube containing ethylenediaminetetraacetic acid 
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(EDTA).  Collection tubes were immediately placed on ice during transport to the 
GFHNRC, followed by centrifugation at 1,000 x g at 4˚C for 10 minutes.  Plasma was 
removed and buffy coat collected and aliquoted into 1ml vials and frozen at -80 degrees 
centigrade until they were analyzed. The WBCs separate from the rest of the sample into 
a “buffy coat” layer as a result of being mixed with the EDTA. All other cell types are 
lysed from the EDTA solution and the WBCs form a pellet in the bottom of the tube 
when centrifuged. After centrifuging, the liquid components above the pellet were 
pipetted off leaving the WBC pellet. The remaining debris was washed from the WBC 
pellet by resuspending the pellet in EDTA solution, centrifuging, and discarding the fluid.   
DNA Extraction from WBCs 
Pelleted cells from the previous step were resuspended and homogenized by 
adding 270 µl of lysis buffer to the sample in preparation for DNA extraction. Next, 30µl 
of proteinase K (10 mg/ml from Invitrogen) was added to each sample tube and the tubes 
were vortexed to thoroughly mix the samples. The samples were then incubated 
overnight at 60˚ C. The next day, the samples were incubated at 100˚C to deactivate the 
enzyme. The samples were then transferred into 2ml phase lock microcentrifuge tubes 
and 300 µl phenol:choloroform:isoamyl alcohol (25:24:1) was added to each sample. The 
tubes were then centrifuged and the upper aqueous phase was transferred into a fresh 
microcentrifuge tube. Next 600 µl of 100% ethanol and 30 µl of 7.5 M ammonium 
acetate were added to each tube containing the aqueous phase and samples were 
incubated for 3 hours at -20˚C. The samples were then centrifuged, the fluid was 
discarded and the remaining pellet was washed with 300 µl of 75% ethanol. The samples 
were centrifuged again and the remaining DNA pellets were allowed to air dry.  
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DNA Quantification 
All of the DNA sample pellets from the previous procedure were then 
individually re-hydrated in 100 µl of nuclease free water and the DNA concentrations of 
each sample were determined using the Epoch micro-volume spectrophotometer system. 
After each well of the spectrophotometer was calibrated by running all 16 plate wells 
with 2 µl DNAse and RNase free water, 2 µl of a DNA sample was added to each well to 
determine the amount of DNA in the sample.  For this study, 30µl of each of the 12 
samples were plated and sent to the University of Minnesota for genome wide 
methylation analysis. The remaining samples volumes were used to validate DNA 
methylation patterns identified by the Illumina platform. 
Bisulfite Conversion of DNA 
To verify the DNA methylation patterns identified by the Illumina Infinium array, 
remaining DNA from six participants (3 GBS positive and 3 GBS negative) were treated 
for bisulfite conversion using the EZ DNA Methylation Kit (Zymo Research). Per the kit 
specifications, the protocol has greater than 99% conversion efficiency converting 
unmethylated cytosine residues to uracil and greater than 99% protection of methylated 
cytosines.  Samples were prepared, based on the concentration of DNA in each sample 
after being quantified using the Epoch micro-volume spectrophotometer system, for an 
input DNA amount of 500ng/sample. For example, if the amount of DNA in a sample 
was 59.9 ng, 
500 ng (1µl/59.5ng) = 8 µl of the sample with DNA was used for next step 
The appropriate volume of DNA from each sample for 500ng/sample along with 5 
µl of M-dilution buffer and nuclease free water was added to a microcentrifuge tube to 
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yield a total volume of 50 µl for each sample. For example, 8µl of DNA sample + 5 µl 
M-dilution buffer + 37 µl water = 50 µl. Samples were then incubated for 15 minutes at 
37˚ C. Next, 100 µl of CT conversion reagent was mixed with each sample and the 
samples were then incubated in the dark for 14 hours at 50˚ C. 
 The samples were then incubated at 0-4˚C (on ice) for 10 minutes. While the 
incubation was ongoing, 400 µl of M-binding buffer was added to a Zymo-spin IC 
column tube for each of the six samples, then the samples were added to the Zymo-spin 
IC column tubes and mixed by inversion after incubation was complete. The tubes were 
then centrifuged at full speed (≥ 10,000 x g) for 30 seconds. The flow-through was 
discarded and 100 µl of M-wash buffer was added and the tubes were again centrifuged 
at full speed for 30 seconds. Next, 200 µl of M-desulphonation buffer was added to each 
sample tube and the samples were incubated at room temperature for 15-20 minutes. The 
samples were then centrifuged at full speed for 30 seconds and then washed with 200 µl 
of M-wash buffer. The samples were then centrifuged at full speed for 30 seconds and 
washed again with 200 µl of M-wash buffer and centrifuged at full speed for 30 seconds. 
The Zymo-spin IC columns for each sample were then placed into a fresh 1.5 ml 
microcentrifuge tube and 10 µl of M-elution buffer was added directly to the column 
matrix and centrifuged for 30 seconds. The samples were then stored at -20˚C until the 
primers were designed to complete polymerase chain reaction (PCR) and validation 
sequencing.  
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Primer Design 
 Primers were designed to cut the DNA and validate methylation patterns in six 
sites identified as differentially methylated between women with and without GBS 
colonization. The sites were selected based on greatest difference in methylation between 
groups that were known genes (3 sites with loss of methylation, 3 with methylation gain). 
Two of the six sites were also be amplified using TOPO cloning reactions in anticipation 
that the amplification of the DNA samples via PCR alone may not yield adequate quality 
samples for sequencing. The DNA sequences for the six sites were determined utilizing 
University of California, Santa Cruz (UCSC) Genome Browser (Kent et al., 2002). The 
chromosome number and map information for the genes, from the Illumina Infinium 
output, were entered into the search box. After selecting “DNA” from the “view” 
dropdown a new window opens allowing selection of how many nucleotides away from 
the CpG of interest you would like the software to search for a suitable region to cut the 
DNA for sequencing. Segments 250 bases upstream and 250 bases downstream were 
entered as criteria to ensure the region of interest would be in the resultant product after 
PCR was complete. The actual DNA sequence was then copied and pasted into The Li 
Lab Department of Urology, University of California, San Francisco MethPrimer design 
tool (Li & Dahiya, 2002). The identified primer sequence was then used to order the 
primers from Integrated DNA Technologies (IDT) (http://www.IDTDNA.com) and 
utilized in the PCR step. DNA site sequences, primer sequences and properties of the 
primers supplied by IDT are located in Appendix E. When the primers arrived from IDT, 
all were rehydrated into a stock solution of 1µg/µl. For example, one vial was 0.27 
mg/vial, therefore 270 µl of DNAse/RNAse free water was added to rehydrate the 
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sample. From the stock solutions, a working concentration of 200 ng/µl for each primer 
was created by adding 20 µl of stock and 80 µl of DNAse/RNAse free water to a 1.5 ml 
microcentrifuge tube. Stock and working concentrations for each primer were then stored 
at -20˚C. 
Polymerase Chain Reaction 
To complete the PCR step for each primer, the ZymoTaqTM PreMix protocol was 
completed using the bisulfite treated DNA (described previously) from each of the six 
participants (3 GBS positive, 3 GBS negative) for all six primers. The following reaction 
set up was used for each primer for each sample of DNA: 25 µl Zymo TaqTM PreMix, 1 
µl forward primer, 1 µl reverse primer, 1 µl bisulfite treated DNA, 22 µl DNase/RNase 
free water. The following conditions were used for the PCR reaction using a hot start: 
initial denaturation at 95˚C for 10 minutes, followed by 35 cycles of denaturing at 95˚C 
for 30 seconds, annealing at 54ºC for 35 seconds, and extension at 72˚C for 45 seconds. 
After the 35 cycles were completed, final extension at 72˚C for seven minutes was done 
followed by a hold at 4˚C for 30 minutes.  The PCR products were visualized by 
electrophoresis in agarose gel (0.5 gm agarose, 50ml TAEx1 buffer, with 5µl DNA star) 
at 100V with a 100bp ladder. 13.5 µl of each sample was loaded into the gel with 1.5 µl 
x10 loading dye. Products were produced for all primers (Appendix F). 
Methylation Validation 
 In order to validate the methylation patterns identify by the Illumina Infinium 
array, the PCR products that were produced in the previous step were sent to Genewiz, 
Inc. (South Plainfield, NJ) for sequencing. A portion of the PCR products from ANXA2 
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and RHPN1 were cloned using the Topo TA-cloning kit; all remaining products were 
purified using the QIAquick® PCR purification kit described in the following sections.  
 PCR Clean-up: First, five volumes of PB buffer were added for every volume of 
PCR product for each sample. The samples were then transferred to QIAquick spin 
column tubes and centrifuged for 60 second. After discarding the flow through, the 
samples were washed with 0.75ml of PE buffer, then centrifuged 60 seconds. After 
removing the flow through, samples were centrifuged again for 60 seconds and the 
columns were then placed in a clean 1.5 ml microcentrifuge tube. Then, 50 µl of EB 
buffer was added to the center of the column and centrifuged for one minute to elute the 
DNA. All samples were then sent to Genewiz, Inc. (South Plainfield, NJ) for sequencing 
(Appendix G). Since the samples were not of adequate quality for sequencing, cloned 
samples were also sent to validate the array.  
 TOPO TA-cloning: PCR products from ANXA2 and RHPN1 were used in the 
cloning protocol to optimize segments for sequencing using the TOPO TA Cloning Kit 
for Sequencing (Invitrogen, Life Technologies). Briefly, 4 µl of fresh PCR product was 
incubated at room temperature for 30 minutes with 1 µl salt solution (1.2M NaCl, 0.06 M 
MgCl2), and 1 µl TOPO vector, then placed on ice. Next, 2 µl from the completed 
reactions were added to a vial of One Shot® Chemically Competent E. coli, which were 
then incubated on ice for 30 minutes. The samples were then heat shocked at 42 degrees 
C for 30 seconds, then placed back on ice. Next, 25 µl of room temperature Super 
Optimal broth with Catabolite repression (S.O.C. medium) was added to each sample and 
the samples were shaken horizontally at 200 rpm for one hour at 37 degrees C. 
Kanamycin selective agar plates were prepared and two different concentrations (20 µl 
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and 50 µl) were plated for each sample to ensure adequately spaced colonies. The plates 
were then incubated at 37 degrees C overnight. Then, 10 white colonies were selected 
and suspended in individual test tubes with 3ml Luria Broth (LB broth) containing 50 
µg/mL kanamycin and incubated overnight.  
The plasmid DNA was then extracted using the QIAprep® Spin Miniprep Kit 
High-Yield Protocol. First, sample tubes were centrifuged at 8,000 rpm for three minutes 
at room temperature to pellet the bacteria with plasmid products. The pellets were then 
resuspended in 250 µl P1 buffer and placed into a microcentrifuge tube. Next P2 buffer 
was added to the samples and mixed by inverting the tube 10 times. Then 350 µl of N3 
buffer was added to each tube, mixed by inverting 10 times and then centrifuged at full 
speed for 10 minutes. The supernatant was then pipetted into QIAprep spin columns and 
centrifuged at full speed for 60 seconds and the flow through was discarded. Next, the 
samples were washed with 500 µl PB buffer and centrifuged again at full speed for 60 
seconds. Then 750 µl of PE buffer was added to each sample and centrifuged for 60 
seconds. Samples were centrifuged for an additional minute to ensure all wash buffers 
had been removed. The spin columns were then placed into a clean microcentrifuge tube 
and 60 µl of EB buffer was added to each tube. Samples were incubated at room 
temperature for 60 seconds and were then centrifuged for one minute to elute the DNA. 
Samples were then sent to Genewiz, Inc. for validation; and sequencing was successfully 
matched (Appendix G). 
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Data Analyses 
Statistical Analysis 
 All cytokine and vitamin D (25[OH]D) data analysis procedures were performed 
using Statistical Package for Social Sciences (SPSS) version 22. All variables were 
examined for violations of statistical assumptions, including missing values and outliers, 
with SPSS Frequencies, and Explore.  Upon completion of data screening to ensure all 
univariate and multivariate assumptions were met, descriptive statistics were completed 
to describe the sample characteristics and compare the groups (GBS positive and 
negative). The normality of the distribution of cytokines was determined by evaluating 
the skewness, kurtosis, and Kolmogorov-Smirnov statistics for each variable. Pearson 
correlation tests were completed to determine if cytokines and vitamin D (25[OH]D) 
levels co-varied throughout pregnancy. Since there was no significant correlation among 
these variables, a series of repeated measures ANOVAs were performed to compare each 
of the three cytokines (TNF-α, IL-6 and IL-10) and vitamin D (25[OH]D) between the 
two groups (n=16 GBS positive and n=26 GBS negative) from each of the three 
trimesters of pregnancy. Mauchly’s test was used to identify violations in sphericity and 
bonferroni corrections were applied for multiple comparisons.  The Greenhouse-Geisser 
correction for a violation in sphericity was used for vitamin D (25[OH]D) analysis. Given 
the restrictions of performing a secondary analysis, it was not feasible to change the 
sample size. However, performing a compromised post-hoc power analysis using 
“G*power” software indicated that the current sample size allowed 69% power and a 
medium effect size of 0.3. This particular type of power analysis was developed for 
studies where the sample size cannot be altered and equates the risk of committing a 
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Type I and Type II error (Faul, Erdfelder, Buchner, & Lang, 2009; Faul, Erdfelder, Lang, 
& Buchner, 2007). This approach to analysis helps in identifying trends and effect size so 
sample size can be determined in future investigations that have adequate power.   
Mean values for serum cytokine and vitamin D (25[OH]D) levels were utilized to 
conduct a one-way multivariate analysis of variance (MANOVA) to correct for 
confounding resulting from data being collected over time, determine observed effect size 
and observed power. The results obtained were then used in G*power to determine the 
number of participants that would be required to see an effect with the power and effect 
size calculated from the study sample. All data analyses procedures in the study were 
performed using a two-tailed alpha of 0.05. 
For DNA methylation analysis, fluorescent background intensities were 
normalized using the Genome Studio software. A series of negative controls are 
embedded into the assay that the software utilized to generate the detection p values for 
each probe. The specific normalization process applied when using GenomeStudio 
software is propriety information, and a limitation of using this software for methylation 
analysis (Gentleman et al., 2004; Hansen et al., 2013, Smyth, 2005). Probes that had 
detection p values greater than 0.05 were considered not to have reliable signal intensities 
and eliminated from analysis. Independent sample t-test comparisons were conducted to 
examine differences in mean DNA methylation at individual CpG sites between GBS 
positive and negative groups. The selection of independent sample t-test was driven by 
the fact the methylation testing was limited to 18 participants and DNA methylation was 
reported as a percentage of methylation at each CpG site. Findings from this analysis will 
inform the researcher of the effect size so that proper sampling can be determined for 
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future research. All statistical techniques were performed using a 2-tailed alpha of < 0.05 
or 95% confidence interval. Statistical analysis of raw data provided by Illumina was also 
completed using the minfi package (Hansen, Ayree, & Irizarry, 2013) in the R 
programming environment (R Core Team, 2013) to first normalize the data and identify 
differentially methylated regions by using the limma package (Smyth, 2005). 
Significance testing was also completed using Benjamini and Hochberg’s false discovery 
rate to correct for multiple comparisons (Benjamini & Hochberg, 1995) because it is the 
recommended standard and used for a majority of studies investigating specific clinical 
outcomes in human samples (Allison, Cui, Page, & Sabripour, 2006; Benjamini & 
Hochberg, 1995; Michels et al., 2013; Storey, 2003; Tusher, Tibshirani, & Chu, 2001; 
Wilhelm-Benartzi et al., 2013; York, 2003). R code used for analysis with normalization 
figures are located in Appendix I. Established work flows with detailed explanations of 
computations and code are available in open source, published workflows and user 
manuals for minfi (Hansen, Ayree & Irizarry, 2013) and limma (Smyth, 2005) packages.  
Briefly, raw data were preprocessed using a series of minfi commands (Appendix 
I) to normalize the intensity for methylated and unmethylated channels (G. K. Smyth, 
Yang, & Speed, 2003). For the statistical analysis of DNA methylation, M-values were 
used because they are logit transformed β values and result in data that more closely 
follows a normal distribution and preferred for statistical methods such as a t-test. Beta 
values exhibit severe heteroscedasticity for extremes of methylation (highly methylated 
or unmethylated). Because the logit transformation corrects for this, M-values outperform 
beta values in terms of detection rate and true positives for detecting differences of CpG 
sites on the extremes of percent methylated. Dedeurwaerder et al.’s (2011) conversion 
65 
 
method for beta to M-values was utilized for analysis because a peak correction can be 
performed on the M-values to adjust the Infinium II probes. Infinium claims there are no 
differences between type I and II detection probes that affect detection of differential 
methylation (Bibikova et al., 2011). However, design I type probes have been shown to 
be more stable and have a more extensive detection range than type II probe, therefore 
require correction for statistical analysis (Dedeurwaerder et al., 2011). Using M-values 
results in more accurate analysis of the data, although are difficult to clinically interpret. 
Therefore, after using the logit transformed values (M-values) for statistical analysis, the 
data were back transformed to yield peak-corrected beta values for reporting and to allow 
for easier clinical interpretation of findings because beta values are biologically 
meaningful (Du et al., 2010).  Sites with known single nucleotide polymorphisms (SNPs) 
were excluded from the analysis as these sites can disturb the accuracy of the Infiniuim 
probes (Bibikova et al., 2011b; Dedeurwaerder et al., 2011). Additionally, SNP sites were 
excluded to remove confounding effects that could result from having two different 
modifications at the same site. Furthermore, SNP analysis is beyond the scope of this 
project and the original consent form was not written to include this type of analysis. 
After all the raw files were normalized to ensure the peaks of the Infinium II 
design bead type probes were comparable to the peak locations of the Infinium I bead 
bead type probes and converted to M-values, differential methylation analysis was 
conducted using the limma package. This package was selected because it performs 
additional normalization and offers commands that are ideal for use with small data sets. 
Essentially, Symth (2005) designed the program to strengthen analysis for small data sets 
by “borrowing information across genes” (p. 4) using empirical Bayesian methods to help 
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control for variance; which results in less false discoveries for small data sets than other 
programs. All normalization and analytics commands were designed for two color 
channel arrays, including the Infinium platform used for this study (Gentleman et al., 
2004; Smyth, Yang, & Speed, 2003; Smyth, 2004; Smyth, 2005). The series of R 
commands fit each CpG site into a linear model using least squares fitting, then a contrast 
matrix was created to compare values between GBS positive and GBS negative women 
and in the final normalization command, the empirical Bayesian command incorporates 
the use of array weights to improve identification of CpG sites that are most likely to be 
different (Ritchie et al., 2006; G. Smyth, 2005). This correction for multiple comparisons 
increases the likelihood of identifying clinically meaningful results and reduces the 
chance of identifying false positives. 
Functional Analysis 
In order to evaluate the last research question, that differential DNA methylation 
in genes associated with immune function and inflammation, a functional analysis of 
genes associated with differential DNA methylation was completed using Database for 
Annotation, Visualization, and Integrated Discovery (DAVID) Bioinformatics Resource 
version v6.7 (Huang, Sherman, & Lempicki, 2009a; Huang, Sherman, & Lempicki, 
2009b). Functional analysis reveals potential mechanistic underpinnings of GBS 
colonization or other clinically relevant information. Gene lists with significant 
differentially methylated CpG sites were uploaded into the DAVID v6.7 database. Sites 
with a gain of methylation in women with GBS colonization were uploaded as one group 
and those with a loss of methylation were entered as a separate group, to investigate 
changes in function based on differences in methylation at those sites. DAVID 
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determines functional categories of genes and classifies them with “high” stringency 
selected by the investigator for analysis (Huang, Sherman, & Lempicki, 2009a; Jiao et al., 
2012). Using a classification stringency of “high” to determine functional annotation 
clusters identifies a “tight, clean, and smaller numbers of clusters” (Huang et al., 2009a, 
p. 47) that are more likely to be associated with biologically meaningful results. Output 
generated by the DAVID software also includes enrichment scores for each cluster, with 
higher numbers indicating there may greater involvement in the disease state being 
studied. Pathways with enrichment scores greater than 1.3 are likely most important in 
the functional or disease process, although lower scoring clusters could also offer insight 
into biological mechanisms associated with the disease process. Statistical calculations 
presented related to the function of the genes are determined utilizing conservative 
correction methodologies for multiple comparisons (Bonferroni; Benjamini, and 
Hochberg) (Huang et al., 2009). The specific function of individual genes was verified 
utilizing GeneCards® and Pubmed and reviewed in the discussion chapter. 
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CHAPTER IV 
RESULTS 
 This chapter presents the results by first providing general descriptive statistics of 
the sample characteristics, followed by presentation of the statistical analyses that were 
completed to answer the research questions as presented in chapter one.  
Description of Sample 
A total of 42 women had an outcome of uncomplicated pregnancy in the parent 
study and were included in the analysis for this study. Among those women, 38% were 
GBS positive (n = 16) and 62% were GBS negative (n = 26), 9 participants from each 
group had DNA methylation analyzed. The sample population was primarily comprised 
of Caucasian women (84%), reflecting the demographics of the area from which the 
subjects were recruited. Race was self-identified by participants upon entry to the parent 
study.  Other demographic data of the participants are presented in Table 6, which shows 
that no statistically significant differences were found (age, weight, gestational age at 
delivery, or infant gender) between GBS positive and negative women. Notably, there are 
no significant differences in co-morbidities, infections, or antimicrobial usage.  Infection 
data and antimicrobial data were extracted from the medical record for usage at any point 
during the pregnancy because it may alter the vaginal microbial composition. Currently, 
there is no information in the literature describing how long and when vaginal microbiota 
returns to a woman’s baseline composition or how it may contribute to GBS status.  
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Table 6. Maternal Characteristics Compared between GBS Positives and Negatives 
Variable Total Sample 
(N=42) 
GBS + 
(n=16) 
GBS – 
(n=26) 
t /χ2 p 
  
Maternal Age 
(years) [M(SD)] 
26.6 (4.10) 25.1 (3.05) 27.5 (4.46) -1.806 0.194 
      
Maternal Prenatal 
Weight (pounds) 
[M(SD)] 
168.7 (35.5) 161.2 (31.6) 173.3 (37.5) -1.074 0.573 
      
Gestational Age at 
Birth (weeks) 
[M(SD)] 
 39.1 (1.25) 38.7 (1.45) 39.2 (1.08) -1.488 0.763 
  
Race [n(%)]      
     Caucasian   38 (90.5) 14 (87.5) 24 (92.3) 1.679 0.432 
     Multi-racial 3 (7.1) 1 (6.25) 2 (7.7)   
     Native Hawaiian/ 
     Pacific Islander 
1 (2.4) 1 (6.25) 0 (0)   
      
Infant Gender [n(%)]      
     Female 
     Male 
     Missing 
 
Maternal Asthma 
[n(%)] 
 
22 (52.4) 12 (75) 
4 (25) 
0 (0) 
 
2 (12.5) 
10 (38.5) 
15 (57.7) 
1 (3.8) 
 
5 (19.2) 
5.480 0.065 
 
 
 
0.570 
19 (45.2)  
1 (2.4)  
 
7 (16.7) 
 
0.323 
Infection [n(%)] 
     None 
     Respiratory               
 
28 (66.7) 
3 (7.1) 
3 (7.1) 
1 (2.4) 
1 (2.4) 
1 (2.4) 
5 (11.9) 
 
 
13 (31) 
29 (69) 
 
10 (62.5) 
1 (6.2) 
1 (6.2) 
0 
1 (6.2) 
0 
3 (18.8) 
 
 
5 (31.2) 
11 (68.8) 
 
18 (69.2) 
2 (7.7) 
2 (7.7) 
1 (3.8) 
0 
1 (3.8) 
2 (7.7) 
 
 
8 (30.8) 
18 (69.2) 
 
3.998 
 
 
 
 
 
 
 
 
0.001 
 
0.677 
 
 
 
 
 
 
 
 
0.974 
 
 
     Urinary Tract 
     Chlamydia  
     Herpes 
     Tuberculosis 
     Unknown 
 
Antimicrobial [n(%)] 
     Yes 
      No 
P indicates significance level based on a two-tailed alpha of 0.05  
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Serum Cytokine and Vitamin D (25[OH]D) Analysis 
Research Question 1: Are serum levels of TNF-α, IL-6, IL-10, and vitamin D (25[OH]D) 
different in pregnant women with GBS colonization than pregnant women without GBS 
colonization? 
Cytokines and vitamin D (25[OH]D) levels were not normally distributed for the 
42 participants (Table 7). However, ANOVA is considered robust to departures in 
normality. Kepple and Wickens (2004) argue when sample size is greater than 
approximately 12 ANOVA analyses can be successfully completed if normality has been 
violated. Further, the laboratory values analyzed in this study were highly variable and 
were not normally distributed in similar studies that evaluated cytokine levels (Curry et 
al., 2008; Makhseed et al., 2000). Because cytokine levels are variable between 
individuals (not normally distributed, making it impossible to identify outliers) all 
participant data were included in the analysis in order to assess if evaluation of serum 
cytokine levels and vitamin D (25[OH]D) would be a useful clinically relevant measure 
Table 7. Tests of Normality for Serum Cytokines and Vitamin D (25[OH]D) 
Variable* Skewness Kurtosis Kolmogorov-
Smirnov 
Shapiro-Wilk 
   Stat df P Stat df P 
TNF-α 1.484 3.989 0.141 42 <0.001 0.851 42 <0.001 
IL-6  4.999 26.755 0.478 42 0.036 0.898 42 0.001 
IL-10 0.462 -0.059 0.107 42 <0.001 0.273 42 <0.001 
(25[OH]D) 1.918 5.797 0.196 42 0.200 0.947 42 0.052 
Stat = statistic 
df = degrees of freedom 
P = significance 2-tailed 0.05 
*mean laboratory values across all trimesters 
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for predicting GBS colonization susceptibility. Serum cytokine and vitamin D (25[OH]D) 
levels were described by time during pregnancy with the following notations: T1 = first 
trimester (10- 14 weeks); T2 = second trimester (22-26 weeks); and T3 = third trimester 
(32-36 weeks). Correlation tests indicate vitamin D (25[OH]D) levels were not correlated 
with serum TNF-α, IL-6, or IL-10 levels during pregnancy, except T1vitamin D 
(25[OH]D) and T3 IL-10 (Table 8). Therefore, vitamin D (25[OH]D) was not used as a 
covariate and repeated measures ANOVA was completed on serum vitamin D 
(25[OH]D), TNF-α, IL-6 and IL-10 independently.  
Table 8. Serum Vitamin D (25[OH]D) and Cytokine Correlations 
 
Variable T1 Vitamin D 
(25[OH]D) 
T2 Vitamin D 
(25[OH]D) 
T3 Vitamin D 
(25[OH]D) 
 r P R P r P 
T1 TNF-α -0.111 0.483 -0.265 0.090 -0.277 0.076 
T2 TNF-α -0.001 0.994 -0.005 0.975 -0.101 0.523 
T3 TNF-α -0.018 0.091 -0.031 0.846 -0.067 0.674 
T1 IL-6 -0.192 0.224 -0.140 0.375 -0.162 0.305 
T2 IL-6 -0.224 0.154 -0.147 0.352 -0.186 0.238 
T3 IL-6 -0.215 0.172 -0.162 0.306 -0.183 0.245 
T1 IL-10  0.142 0.368 0.074 0.642 0.063 0.693 
T2 IL-10  0.007 0.963 0.093 0.557 0.018 0.911 
T3 IL-10   0.310*  0.046* 0.214 0.173 0.129 0.415 
r = Pearson correlation 
P=significance 2-tailed 0.05 
 
TNF-α 
 TNF-α levels were compared between GBS positive (n=16) and negative (n=26) 
women across three trimesters of pregnancy. Mean TNF-α levels were calculated for each 
group in each trimester (Table 9, Figure 4a). A repeated measures ANOVA revealed no 
significant difference in TNF-α between GBS positive and negative women, F(2, 80) = 
2.187, p = 0.119, η2 = 0.052 with an observed power of 0.453.   
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IL-6 
 IL-6 levels were compared between GBS positive (n=16) and negative (n=26) 
women across three trimesters of pregnancy. Mean IL-6 levels were calculated for each 
group in each trimester (Table 10, Figure 4b). A repeated measures ANOVA revealed no 
significant difference in IL-6 between GBS positive and negative women, F(2, 80) = 
2.991, p = 0.056, η2 = 0.070 with an observed power of 0.566. 
Table 9. Serum TNF-α Levels                          Table 10. Serum IL-6 Levels 
 
 Mean (SD) 
 GBS + GBS - 
T1 IL-6 1.06 (2.98) 1.28 (5.71) 
T2 IL-6 1.67 (4.21) 1.04 (5.31) 
T3 IL-6 1.25 (3.58) 1.31 (6.70) 
 
IL-10 
 IL-10 levels were compared between GBS positive (n=16) and negative (n=26) 
women across three trimesters of pregnancy. Mean IL-10 levels were calculated for each 
group in each trimester (Table 11, Figure 4c). A repeated measures ANOVA revealed no 
significant difference in IL-10 between GBS positive and negative women, F(2, 80) = 
0.445, p = 0.642, η2 = 0.011 with an observed power of 0.120. 
Vitamin D (25[OH]D) 
 Vitamin D (25[OH]D) levels were compared between GBS positive (n=16) and 
negative (n=26) women across three trimesters of pregnancy. Mean vitamin D(25[OH]D) 
levels were calculated for each group in each trimester (Table 12, Figure 4d). Mauchly’s 
test indicated a violation in the assumption of sphericity, W(2) = 0.551, p < 0.05. Based 
 Mean (SD) 
 GBS + GBS - 
T1 TNF-α 6.20 (2.77) 6.44 (1.92) 
T2 TNF-α 6.21 (2.74) 7.41 (4.75) 
T3 TNF-α 8.71 (6.19) 7.46 (2.54) 
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on a Greenhouse-Geisser correction for the sphericity violation, a repeated measures 
ANOVA revealed no significant difference in vitamin D (25[OH]D) between GBS 
positive and negative women, F(1.380, 55.218) = 0.882, p = 0.384, η2 = 0.022 with an 
observed power of 0.169. 
Table 11. Serum IL-10 Levels                  Table 12. Vitamin D (25[OH]D) Levels 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Cytokines and Vitamin D (25[OH]D) Across Pregnancy. 
 Mean (SD) 
 GBS + GBS - 
T1 IL-10 4.23 (3.27) 4.23 (3.06) 
T2 IL-10 5.29 (3.48) 4.35 (4.55) 
T3 IL-10 4.64 (4.56) 4.08 (2.85) 
 Mean (SD) 
 
 GBS + GBS - 
T1 Vit. D 27.22 (9.36) 23.76(6.21) 
T2 Vit. D 30.18(10.94) 25.14(6.42) 
T3 Vit. D 30.08(14.09) 24.89(7.06) 
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Multivariate Analysis 
Mean values for serum cytokine and vitamin D levels were utilized to conduct a 
one-way multivariate analysis of variance (MANOVA) to correct for the confounding 
resulting from data being collected over time, determine effect size and observed power 
(Table 13).  MANOVA revealed that serum cytokines and vitamin D levels do not 
significantly combine to affect GBS colonization status Wilks’ Ʌ = 0.927, F(4, 37) = 
0.725, p = 0.581, partial η2 = 0.073.  Further analysis comparing the sample based power 
and power needed to see a significant effect of cytokines and vitamin D on GBS status, 
indicates large sample sizes are required to see significant difference (Table 14)  
Table 13.  Multivariate Results 
 
 Mean ± SD Partial η2 Observed 
Power 
 GBS + GBS -   
TNF-α (pg/ml) 7.04 ± 3.34 7.11 ± 2.75 <0.001 0.051 
IL-6 (pg/ml) 1.33 ± 3.57   1.21 ± 5.89  <0.001  0.051 
IL-10 (pg/ml) 4.72 ± 3.19   4.22 ± 3.16  0.006  0.077 
(25[OH]D)(ng/ml) 29.16 ± 11.13   24.59 ± 6.24 0.068 0.384 
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Table 14. Comparison of Sample Based Power to 80% Power with Required N 
Effect Size Observed Power Required Power 
    
IL-10 0.006 
  
  0.077 0.8 
  GBS + = 2,228 : GBS - = 
3,342 
Total N = 5,570 
 
GBS + = 286,230 : GBS - = 
429,346 
Total N = 715,576 
 
    
Vit. D 
(25[OH]D) 
0.068 
  
  0.384 0.8 
  GBS + = 658 : GBS - = 986 
Total N = 1,644 
GBS + = 2,230 : GBS - = 3,344 
Total N = 5,574 
    
 
DNA Methylation Analysis 
Research Question 2: Are DNA methylation patterns different between pregnant 
women with GBS colonization and those without GBS colonization? 
GenomeStudio Statistical Analysis  
Analyses comparing the pooled mean methylation of GBS positive and negative 
women (n = 9/group) identified a total of 141 CpG dinucleotides that were differentially  
methylated in maternal peripheral white blood cells between women who had a positive 
screening for GBS and those who had a negative screening. Figure 5, depicts the average 
beta scores of the 141 CpG dinucleotides that were identified as differentially methylated 
by greater than 20% betweem GBS positive and GBS negative women and statistically 
significant with a p value of less than 0.05. Of the 141 CpG sites, 62 sites had a gain of 
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methylation and 79 sites had a loss in methylation in women with positive GBS screening 
compared to GBS negative women. CpG sites with differential methylation were 
distributed across the chromosomes (Figures 6a and 7a), associated with known genes 
(62%) and located predominantly in the body (66%) of genes (Figures 6b and 7b). 
Approximately half of the CpG sites (49%) were not associated with CpG islands 
(Figures 6c and 7c). 
 
  GBS Negative          GBS Positive 
Figure 5. Differential Methylation with GBS Colonization (GenomeStudio). 
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a) Chromosomal Distribution 
 
b) Proximity to Gene
 
c) Proximity to CpG Island 
 
Figure 6. DNA Methylation Gain Distributions with GBS (GenomeStudio).  
0
2
4
6
8
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y
N
u
m
b
er
 o
f 
S
it
es
Chromosome
Total CpGs Known Genes
0
5
10
15
20
25
30
5'UTR TSS1500 TSS200 1st Exon 3'UTR Body None
N
u
m
b
er
 o
f 
C
p
G
s
Relation to Known Genes
0
10
20
30
40
N Shelf N Shore Island S Shore S Shelf None
N
u
m
b
er
 o
f 
C
p
G
s
Relation to CpG Island
78 
 
a) Chromosome Distribution 
 
b) Proximity to Genes 
 
c) Proximity to CpG Island 
 
Figure 7. DNA Methylation Loss Distributions with GBS Colonization (GenomeStudio).  
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R Statistical Environment Analysis 
Analyses conducted in R comparing the pooled mean methylation of GBS 
positive and negative women (n = 9/group) identified no statistically significant 
differences in methylation at any CpG site when a 20% change in beta value when FDR 
was used to determine significance at any level is used for analysis ( adjusted p= 0.001, 
0.05, 0.01). Figure 8 is a volcano plot presenting all CpG sites with parameters set to 
highlight blue any sites with greater than a 20% difference in methylation between GBS 
positive and GBS negative women that met significance using an FDR of 0.05. No blue 
CpG sites are present on the graph, indicating there is no statistically significantly 
different methylation at any CpG site by GBS status for this sample (R code and 
mathematical code returning zero results available in Appendix I). The plot is designed 
using the log values for more concentrated clear visualization of the data. In order to 
compare the results using the R programming environment to the results produced using 
the GenomeStudio software, the analysis was also conducted using the same unadjusted p 
value to determine significance at 0.05. A total of 125 CpG dinucleotides that were 
identified as having greater than 20% difference in methylation in maternal peripheral 
white blood cells between GBS positive and negative women.  Of the 125 CpG sites, 54 
sites had a gain in methylation and 71 sites had a loss in methylation for women with 
positive GBS screening at 37 weeks compared to GBS negative women when alpha is 
0.05. CpG sites with differential methylation were distributed across the chromosomes 
(Figures 9a and 10a), associated with known genes (62%) and located predominantly in 
the body (59%) of genes (Figures 9b and 10b). Approximately half of the CpG sites 
(51%) were not associated with CpG islands (Figures 9c and 10c).   
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Figure 8. Volcano Plot of CpG Methylation Differences by GBS Status (R) 
 
 
 
 
 
 
 FDR < 0.05 CpG site 
 FDR > 0.05 CpG site 
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a) Chromosomal Distribution 
 
b) Proximity to Gene 
 
c) Proximity to CpG Island 
Figure 9. DNA Methylation Gain Distributions with GBS (R).  
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a) Chromosomal Distribution 
 
a) Proximity to Gene 
 
b) Proximity to CpG Island 
 
Figure 10. DNA Methylation Loss with GBS (R).  
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Gene Comparison 
Using two different statistical software applications to identify significant 
differentially methylated CpG sites yielded a discordant number of CpG sites, 141 using 
GenomeStudio software and 125 using R programming environment. Of the known genes 
associated with the CpG sites, 52% of the genes identified were common in the results 
using both packages, 29% were specific to analysis with the GenomeStudio platform and 
19% were unique to analysis conducted using the R platform (Table 15). Highlighted  
Table 15. Differentially Methylated Genes by Statistical Approach 
Statistical 
Approach 
                               Genes      
Methylation Gain 
 
GenomeStudio CASD1, HLA-DRB6, LGALS8, SPTBN4, TUBAL3, ANAPC2, 
NAT14, OCA2, SYT8, TNNT3, ZNF628 
 
R AHRR, BAZ2B, C1orf192, CLECL1, HRNBP3, RASA3, 
RBMY1F, RBMY2FP, SPINK5, TIAL1, TTC22, TUBB8 
 
Both Approaches ATP8B3, BTNL9, C21orf29, C3orf50, CCS, CNST, COPB1, 
DCAF11, INSC, KRTAP12-3, KRTAP12-4, LMX1B, MAGI2, 
MIB2, MRI1, NFIC, PIWIL2, RELN, RHPN1, SNX26, 
STAG3L4, TAGLN3, TAS2R60, TP73, UST 
 
Methylation Loss 
 
GenomeStudio CLPTM1, FAM120B, FAM69B, KIAA1199, MTUS2, TIMP2, 
VIPR2, ZNF137, BMP8B, FLJ37201, FLJ43860, FOXK2, JRK, 
KCNH6, MRGPRX2, PPIE, SND1, SULF2, ZNF490, ZNF665 
 
R ADORA3, BRMS1, CCDC50, MYO10, NCRNA00052, OPRM1, 
RIN1, TTTY12, TTTY18 
 
Both Approaches ACTN3, AKR1C2, ANXA2, ARID1B, B4GALNT3, C2orf69, 
CAMK1D, COL11A2, CUL3, DEFB128, DMBX1, 
FAM124B,FRMD4A, GAP43,GCK, JPH3, KCNK7, KRTAP27-
1, LAMB1, MAPK10, MGMT, MORN1, PRKCA, PTPRN2, 
RAB11B, SAMD4A, SERPINF2, SLC39A14, TOP1MT, 
WDR36, ZMAT2 
84 
 
genes in the table are associated with SNPs and had been excluded from analysis in the R 
environment because SNPs disturb the accuracy of the Infiniuim probes as described in 
the methods section (Bibikova et al., 2011b; Dedeurwaerder et al., 2011).  
Validation of Methylation 
 In order to validate the methylation identified by the Illuminia Infinium 450K 
array, 6 CpG sites (3 = gain of methylation; 3 = loss of methylation) identified as 
differentially methylated by GenomeStudio analysis were selected. Sites that were at the 
extremes of differential methylation, associated with known genes and that primers could 
be developed were used (Table 16). Six participants were selected at random (3 GBS 
positive; 3 GBS negative) to validate the array. Participant samples that were sent 
immediately for sequencing after bisulfite treatment were too poor of quality  
Table 16. Primer Sequences 
UCSCREFGENE Sequence 
 
RHPN1fwd GGATGTATTTTTTTTAGTGGTTGG 
RHPN1rev CCTCACCCAAATAAACCCTACT 
  
HLA-DRB6fwd TATTTTAGGATGGATTAGGAGAAAAA 
HLA-DRB6rev CAAAAATTTATAAACACTTCAACAATAC 
  
MRI1fwd AATTTTTGATTTTAAGTGATTTGTT 
MRI1rev AAACTATTTCTAAACCATTTTCTACTC 
  
ANXA2fwd TTGAGGAAAAATAATAAAGAGTTATTAGAT 
ANXA2rev AACCTAAACAATACCATTCAAAACAA 
  
GAP43fwd TTTAGGTGTGTGTTTATTTTTAGGA 
GAP43rev TAACCTTATCTAATTTATCATTTTAACAAC 
  
CUL3fwd TAGGGGAAAATTGAGGTTATAAGAAG 
CUL3rev TCCTCCTACAATACTAAAATTACAAAC 
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for sequencing as anticipated (Appendix G). The CpG sites associated with ANXA2 (loss 
of methylation in GBS positive women) and RHPN1 (gain of methylation in GBS 
positive women) were successfully cloned and were of sufficient quality for sequencing.  
The DNA used for primers designed with ANXA2 and RHPN1 CpG sites are in Figure 9 
below, as the product for these sites were successfully cloned and sequenced Figure 10. 
In Figure 9, CpG sites within the primer products are blue text and the CpGs identified as 
differentially methylated by GBS status are highlighted yellow. The gray area the DNA 
added to identify primers, as described in the methods chapter, and the primer sequence.  
ANXA2>hg19_dna range=chr15:60643907-60644407 5'pad=250 3'pad=250 strand=+ 
repeatMasking=none 
GGCCACATTCACTTACCCAGGTTCAGGAAAGCATTTTCCAGGTCTCCTTT 
AACCTCTTTCCTGATGCTTTCCAACATGTCATAAGGGCTGTAACTCTTGT 
ACCTATCAAATACTGAGGAAAAACAACAAAGAGTTATCAGATCCGAGCCA 
CTAGTCAAAGCTGTCAACGATCACCCACCTAGTTTTATGCACCATAATTT 
TTTTAAAAATTGAGGATGATCACAGCATCCTAGGAGCTTAGAGGTTACCA 
CGGTGACCAGAGCCAACATTGGCCAAGTTTGTCGTGGAACAGCCATACCA 
CCTGTCCTGAATGGCACTGCCCAGGCCACATATTTGGACCATCTCTATCT 
CCCCTGAGTGGAACCCATTCCATCCGAAAACCATAGGAAACAGTACAGAG 
CATGCACCAAAGTCCACTACTTCAACAAATAATGGCAAGACCAAATGATC 
ATCAAACAAGAAGGAGCTGCAGAATAAAGCACCAAATGCAGAAACTATTT 
G 
 
RHPN1>hg19_dna range=chr8:144457427-144457927 5'pad=250 3'pad=250 strand=+ 
repeatMasking=none 
TCAGTCTGGCTTCTGGTGTCCTTGGCAGGTGCCAGCCTCCCCCGCTGACCCCC
ATCACGAGTCAGCAGCTTACCCCACCGACCACGTCCTTCTGCATTGACTGCC 
TCCTGTCCTGCTCTGGCCAGGCCTGTGTTCACACTAGTTCTGTCCAGCCC 
CTCCCTGTGAGGCCAGCTCCAGCCCCAGCGCATGGTGACCATCCCGTTAC 
CCATGGGCAGGATGCACTCCTCGGCTGGCGAGGCGCAGCCTGGTG 
CGGGCGCCACGGGGTCGGGCTGTGATCGCCTGTGGCCTCCCTGCAGGGCT 
GTGACTCCCTGACGCAGATCCAGTGCGGCCAGCTGCAGAGCCGCAGGGCC 
CAGATTCACCAGCAGATTGACAAGGAGCTGCAGATGCGGACGGGCGCTGA 
GAACCTCTACAGGTCAGTGCTTGAGACTGCCCGGCCCCGGGAGCAGGGCC 
CACCTGGGTGAGGGGGGCAGGACAGCCACGCAGGCAGATGTCTGCCCCAT 
G 
 
Figure 9. ANXA2 and RHPN1 DNA, Primer, and Product Sequences 
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ANXA2 Participant 10 GBS+ beta value Raw = 0.5709; GS = 0.5638; R= 0.5969  
 
ANXA2 Participant 2 GBS- beta value Raw = 0.8634; GS = 0.8490; R = 0.9388  
 
ANXA2 Participant 14 GBS+ beta value Raw = 0.5409; GS = 0.5344; R = 0.5589  
 
ANXA2 Participant 6 GBS – beta value Raw = 0.8833; GS = 0.8723; R = 9471  
 
Figure 10. Methylation at ANXA2 and RHPN1 CpG Sites of Cloned Sequences 
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ANXA2 Participant 8 GBS- beta value Raw = 0.8901; GS = 0.8768; R = 0.9539  
 
ANXA2 Participant 16 GBS + beta value Raw = 0.4998; GS = 0.4939; R = 0.4997  
 
RHPN1 Participant 10 GBS+ beta value Raw = 0.8229; GS = 0.8186; R = 0.8920 
 
RHPN1 Participant 2 GBS- beta value Raw = 0.4076; GS = 0.4058; R = 0.3845 
 
RHPN1 Participant 14 GBS+ beta value Raw = 0.8049; GS = 0.8005; R = 0.8855 
 
 
Figure 10. Cont. 
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RHPN1 Participant 8 GBS- beta value Raw = 0.3858; GS = 0.3842; R = 0.3629 
 
RHPN1 Participant 6 GBS – beta value Raw = 0.3915; GS = 0.4073; R = 0.3684 
 
RHPN1 Participant 16 GBS + beta value Raw = 0.7804; GS = 0.7764; R = 0.8620 
 
Figure 10. Cont. 
In Figure 10, the CpC sites that were identified as having significantly different 
methylation have a red box around the CpG site in the DNA product sequence. Each 
figure are cloned sequences for one participant. The notation above the each participant 
figure indicates the primer by name, participant, GBS status, raw Infinum beta value, and 
normalized betas calculated by GenomeStudio software and the R programming 
environment.  Black squares indicate the CpG site was methylated, gray squares indicated 
an unmethylated CpG and white squares indicate it could not be determined. The percent 
of cloned CpG site methylation was manually calculated by dividing the number of 
methylated CpGs for the specific site by total number of CpGs that methylation could be 
determined for the site for each of the participant clones (Table 16). Methylation percent  
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in the cloned sequences was congruent with percent methylation determined by the 
Illumia Infinium array (Table 16). Participants that had CpG sites where methylation 
status could not be determined (RHPN1 participant 6, 2 undetermined; RHPN1 
Patrticpant 8, 5 undetermined; RHPN1 particpant 14, 4 undetermined) did not correlated 
as strongly as other sites. CpG sites that were identified as significantly different by only 
one of the software packages had similar beta values, and greater delta beta values did not 
correlate with significance. Table 17 presents beta results for all participants for one site  
Table 17. Beta Value Similarity of Significant Results  
 
GS= GenomeStudio; R = R statistical environment 
Participant Raw beta GS beta R beta Raw beta GS beta R beta
1 0.4466 0.4435 0.4343 0.3979 0.3958 0.3750
2 0.0689 0.0683 0.0365 0.8440 0.8376 0.9241
3 0.8832 0.8766 0.9710 0.4294 0.4273 0.4045
4 0.8767 0.8711 0.9312 0.4414 0.4397 0.4251
5 0.4216 0.4193 0.4058 0.8268 0.8219 0.9052
6 0.8424 0.8372 0.9160 0.4147 0.4130 0.3963
7 0.8430 0.8358 0.9268 0.4256 0.4233 0.4131
8 0.8263 0.8196 0.9055 0.8222 0.8165 0.9019
9 0.8606 0.8548 0.9252 0.8553 0.8501 0.9209
Average Negaive 0.6744 0.6696 0.7169 0.6064 0.6028 0.6296
10 0.4428 0.4405 0.4270 0.8536 0.8485 0.9186
11 0.0519 0.0516 0.0320 0.8801 0.8735 0.9480
12 0.8383 0.8312 0.9263 0.8177 0.8119 0.9097
13 0.0532 0.0529 0.0293 0.8271 0.8216 0.9060
14 0.4477 0.4453 0.4365 0.8244 0.8197 0.9031
15 0.8578 0.8527 0.9235 0.8430 0.8388 0.9113
16 0.0532 0.0529 0.0293 0.8362 0.8315 0.9134
17 0.8666 0.8608 0.9362 0.8343 0.8299 0.9106
18 0.0688 0.0685 0.0373 0.4285 0.4269 0.4111
Average Positive 0.4089 0.4063 0.4197 0.7939 0.7891 0.8591
Delta beta -0.2655 -0.2633 -0.2972 0.1878 0.1863 0.2295
SND1 RASA3
Genome Studio R environment
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Identified as significant using GenomeStudio software (SND1) or the R environment 
(RASA3). The delta beta for both sites is higher after the R normalization, however only 
the RASA3 site was identified using the R analysis pipeline as significantly different and 
SND1 was not. The SND1 site was identified as being significantly different by Genome 
studio, and RASA3 was not. This type of incongruence is similar at all discordant 
significant results. 
Functional Analysis of Methylation 
Research Question 3: Is there a relationship between differentially methylated genes and 
immune function in pregnant women colonized with GBS? 
 Since no CpG sites were identified as differentially methylated when FDR is 
applied to determine significance, results produced using the less stringent alpha of 0.05 
for significance were used for functional analysis. Cluster analysis using DAVID 
revealed differential methylation in women with GBS is primarily related to basic cellular 
processes. DAVID analysis was performed as described in the methods section 
independently for DNA methylation results from GenomeStudio (Table 16), R (Table 
17), and genes common to both analytical approaches (Table 18).  However, none of the 
functional clusters were significant using FDR of 0.05 and the cell morphogenesis cluster 
was the only functional cluster that was significant at an alpha level of 0.05 for data 
output from GenomeStudio, R and for common genes identified by both approaches. The 
results of the functional analysis using the data generated with this sample yielded 
different functional clusters from the preliminary data analysis used when designing and 
conceptualizing this study that clustered more specifically to immune function such as 
major histocompatibility complex and antigen presentation (Appendix H).  
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Table 16. Biological Pathways Associated with GBS (GenomeStudio data) 
 
 
Functional 
Cluster
Enrichment 
Score Genes
p-
value FDR
Keratin 1.26 KRTAP12-3, KRTAP12-4, ZNF628 0.04 0.98
Cellular metabolic 
and biosynthetic 
processes
1.15 LMX1B, ANAPC2, PIWIL2, NFIC, TP73 0.04 0.97
Protein kinase and 
phosphorylation
0.87 ANAPC2, RELN, TP73 0.10 0.99
Regulation of 
transcription
0.67 LMX1B, NFIC, TP73 0.17 1.00
Cell cycle 0.64 ANAPC2, PIWIL2, TP73 0.17 1.00
Cytoplasmic 
membrane-
bounded vesicle
0.53 ATP8B3, COPB1, SYT8 0.26 1.00
Transcription 
factor activity
0.42 LMX1B, NAT14, NFIC, TP73, ZNF628 0.22 1.00
Ion binding 0.31 ATP8B3, LMX1B, CCS, MIB2, RELN, 
TP73, ZNF628
0.40 1.00
Membrane 0.25 ATP8B3, CASD1, NAT14, BTNL9, 
CNST, COPB1, PIWIL2, MAGI2, OCA2, 
0.53 1.00
Extracellular 
matrix
1.58 TIMP2, ANXA2, COL11A2, LAMB1 0.02 0.96
Cell 
morphogenesis
0.84 CUL3, GAP43, LAMB1, PRKCA 0.03 1.00
Regulation of 
apoptosis
0.75 MGMT, ACTN3, CAMK1D, CUL3, 
PRKCA
0.18 1.00
Methylation Gain
Methylation loss
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Table 16. Cont. 
 
 
Functional 
Cluster
Enrichment 
Score Genes
p-
value FDR
Cytoplasmic 
membrane-
bounded vesicle
0.57 RAB11B, ANXA2, SERPINF2, SND1 0.22 0.98
Phosphorus 
metabolic process
0.56 CAMK1D, GCK, MAPK10, PRKCA, 
PTPRN2
0.27 1.00
Protein 
dimerization 
activity
0.56 MTUS2, ACTN3, COL11A2, DMBX1 0.18 1.00
Ion transport 0.53 JPH3, KCNK7, KCNH6, SLC39A14 0.13 1.00
Cellular 
homeostasis
0.46 COL11A2, GCK, JPH3, PRKCA 0.28 1.00
Transcription 
regulation
0.39 ARID1B, DMBX1, FAM120B, FOXK2, 
SND1,  ZNF490, ZNF665
0.36 0.98
Ion binding 0.34 MGMT, ACTN3, ANXA2, CAMK1D, 
FOXK2, KCNK7, KCNH6, PRKCA, 
SLC39A14, SULF2, ZNF490, ZNF665, 
ZMAT2
0.44 1.00
Nucleotide 
binding
0.33 RAB11B, CAMK1D, GCK, MAPK10, 
PPIE, PRKCA, TOP1MT
0.58 1.00
Regulation 
metabolic and 
biosynthetic 
processes
0.28 ARID1B, GCK, PRKCA, SAMD4A 0.42 1.00
Biological 
adhesion
0.25 ACTN3, COL11A2, LAMB1 0.52 1.00
Zinc ion binding 0.18 MGMT, TIMP2, PRKCA, SLC39A14, 
ZNF490, ZNF665, ZMAT2
0.43 0.97
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Table 16. Cont. 
 
Table 17. Biological Pathways Associated with GBS (R data) 
 
Functional 
Cluster
Enrichment 
Score Genes
p-
value FDR
Membrane-
enclosed lumen
0.16 ARID1B, MGMT, DMBX1, GCK, 
SERPINF2, TOP1MT
0.65 1.00
Zinc finger, C2H2-
like
0.14 ZNF490, ZNF665, ZMAT2 0.62 1.00
Transmembrane 0.07 MRGPRX2, B4GALNT3, CLPTM1, 
FAM69B, JPH3, KCNK7, KCNH6, 
PTPRN2, SLC39A14, VIPR2
0.87 1.00
Functional 
Cluster
Enrichment 
Score Genes
p-
value FDR
RNA recognition 
motif, RNP-1
1.19 RBMY1F, TIAL1, HRNBP3 0.06 1.00
Cellular metabolic 
and biosynthetic 
processes
0.97 LMX1B, PIWIL2, NFIC, TP73 0.08 1.00
Induction of 
apoptosis
0.71 TIAL1, AHRR, TP73 0.09 1.00
Metal-binding 0.65 ATP8B3, LMX1B, RASA3, BAZ2B, 
CCS, MIB2, RELN, TP73
0.17 1.00
Regulation of 
transcription
0.64 LMX1B, TIAL1, AHRR, BAZ2B, NFIC, 
TP73
0.11 1.00
Cytoplasmic 
membrane-
bounded vesicle
0.61 ATP8B3, COPB1, SPINK5 0.21 1.00
Transcription 
factor activity
0.60 LMX1B, NFIC, TP73 0.18 0.99
Ion binding 0.44 ATP8B3, LMX1B, RASA3, AHRR, 
BAZ2B, CCS, MIB2, RELN, TP73
0.43 1.00
Methylation Gain
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Table 17. Cont. 
 
Functional 
Cluster
Enrichment 
Score Genes
p-
value FDR
Transcription 
regulation
0.29 LMX1B, TIAL1, AHRR, BAZ2B, NFIC, 
TP73
0.42 1.00
Intrinsic to 
membrane
0.06 ATP8B3, CLECL1, RASA3, BTNL9, 
CNST, PIWIL2, TAS2R60, UST
0.83 1.00
Cell 
morphogenesis
1.63 CUL3, GAP43, LAMB1, PRKCA 0.01 1.00
Neuron 
development
0.85 GAP43, LAMB1, PRKCA 0.07 1.00
Phosphorus 
metabolic process
0.84 CAMK1D, GCK, MAPK10, PRKCA, 
PTPRN2
0.11 1.00
Nucleotide binding 0.73 RAB11B, CAMK1D, GCK, MAPK10, 
MYO10, PRKCA, TOP1MT
0.10 0.79
Serine/threonine 
protein kinase
0.68 CAMK1D, MAPK10,PRKCA 0.09 1.00
Cellular 
homeostasis
0.67 GCK, JPH3, PRKCA 0.16 1.00
G-protein coupled 
receptor protein 
signaling pathway
0.64 ADORA3, GAP43, OPRM1 0.65 1.00
Ion transport 0.52 JPH3, KCNK7, SLC39A14 0.22 1.00
Regulation 
biosynthetic 
processes
0.42 ARID1B, GCK, SAMD4A 0.36 1.00
Biological adhesion 0.41 ACTN3, COL11A2, LAMB1 0.39 1.00
Cytoplasmic 
membrane-
bounded vesicle
0.36 RAB11B, ANXA2, SERPINF2 0.39 0.99
Methylation loss
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Table 17. Cont. 
 
Table 18. Biological Pathways Common between R and GenomeStudio 
 
Functional 
Cluster
Enrichment 
Score Genes
p-
value FDR
Membrane-
enclosed lumen
0.28 ARID1B, MGMT, DMBX1, GCK, 
SERPINF2, TOP1MT
0.46 0.98
Receptor 0.18 ADORA3, OPRM1, PTPRN2 0.82 1.00
Ion binding 0.09 MGMT, ACTN3, ANXA2, CAMK1D, 
KCNK7, PRKCA, SLC39A14, ZMAT2
0.81 1.00
Zinc ion binding 0.06 MGMT, PRKCA, SLC39A14, ZMAT2 0.81 1.00
Integral to 
membrane
0.06 ADORA3, B4GALNT3, JPH3, 
NCRNA00052, OPRM1, KCNK7, 
PTPRN2, SLC39A14
0.99 1.00
Functional 
Cluster
Enrichment 
Score Genes
p-
value FDR
Cellular metabolic 
and biosynthetic 
processes
1.46 LMX1B, PIWIL2, NFIC, TP73 0.03 1.00
Metal-binding 0.51 ATP8B3, LMX1B, CCS, MIB2, RELN, 
TP73
0.28 0.99
Regulation of 
transcription
0.50 LMX1B, NFIC, TP73 0.08 0.99
Intrinsic to 
membrane
0.06 ATP8B3, BTNL9, CNST, PIWIL2, 
TAS2R60, UST
0.74 1.00
Cell 
morphogenesis
1.77 CUL3, GAP43, LAMB1, PRKCA 0.01 0.97
Regulation of 
apoptosis
1.34 MGMT, ACTN3, CAMK1D, CUL3, 
PRKCA
0.05 0.98
Extracellular matrix 1.14 ANXA2, COL11A2, LAMB1 0.05 0.98
Methylation Gain
Methylation loss
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Table 18. Cont. 
 
Summary of Results 
 In summary, the results from this study indicate that there are no significant 
differences in DNA methylation between women with and without GBS colonization 
when FDR is used to determine significance of DNA methylation differences that are 
Functional 
Cluster
Enrichment 
Score Genes
p-
value FDR
Neuron 
development
0.94 GAP43, LAMB1, PRKCA 0.07 1.00
Serine/threonine 
protein kinase
0.79 CAMK1D, MAPK10,PRKCA 0.07 1.00
Cellular 
homeostasis
0.75 GCK, JPH3, PRKCA 0.14 0.99
Phosphorus 
metabolic process
0.74 RAB11B, CAMK1D, GCK, MAPK10, 
PRKCA, PTPRN2
0.12 0.83
Metal ion transport 0.59 JPH3, KCNK7, SLC39A14 0.19 0.99
Cellular 
biosynthetic 
processes
0.49 ARID1B, GCK, SAMD4A 0.31 1.00
Biological adhesion 0.49 ACTN3, COL11A2, LAMB1 0.31 0.98
Cytoplasmic 
membrane-
bounded vesicle
0.46 RAB11B, ANXA2, SERPINF2 0.31 0.98
Membrane-
enclosed lumen
0.43 ARID1B, MGMT, DMBX1, GCK, 
SERPINF2, TOP1MT
0.31 0.99
Ion binding 0.19 MGMT, ACTN3, ANXA2, CAMK1D, 
KCNK7, PRKCA, SLC39A14, ZMAT2
0.64 1.00
Zinc ion binding 0.10 MGMT, PRKCA, SLC39A14, ZMAT2 0.68 1.00
Integral to 
membrane
0.02 B4GALNT3, JPH3, KCNK7, PTPRN2, 
SLC39A14
0.80 1.00
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greater than 20% between groups. However, if a less stringent p-value of 0.05 is used 
there are a small number of CpG sites that have significant differences with greater than a 
20% difference in methylation. The number of significantly different CpG sites identified 
using different software for analysis varies (141 versus 125). No significant association 
was found between serum TNF-α, IL-6, IL-10 or vitamin D (25[OH]D) levels and 
maternal GBS colonization status. Lastly, analysis of functional pathways did not find a 
correlation between differentially methylated genes and genes directly related to cytokine 
production or specific immune pathways. No functional clusters were significant when 
applying FDR for significance; and only the cell morphology functional cluster was 
significant for output from both GenomeStudio and R data when an alpha of 0.05 was 
applied. 
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CHAPTER V 
DISCUSSION 
 GBS sepsis continues to be the leading cause of infectious neonatal morbidity and 
mortality despite current practice guidelines to prevent the transmission of GBS from 
mothers to their infants (Phares et al., 2008). The primary purpose of this exploratory 
study was to identify variants in maternal blood that are associated with maternal GBS 
colonization  in order to assist with the development of more accurate screening tools 
and/or assist in identifying to targets to prevent maternal GBS colonization. It is unknown 
why GBS selectively colonizes one third of pregnant women, placing the health of 
women and their offspring at risk. Currently in the US, all pregnant women are screened 
for GBS colonization between 35-37 weeks gestation (Verani et al., 2010). However, 
significant false negative screening results and infant illness despite maternal antibiotic 
treatment during labor requires further investigation to identify a biological reasons as to 
why certain women are preferentially colonized with GBS (Lin et al., 2011; Towers et al., 
2010). For this study, variants that can be measure in the serum that are increasingly used 
for monitoring and diagnosing other clinical conditions, were investigated to determine if 
there was any association between serum levels and maternal GBS colonization status. 
This contribution to science is significant because the relationship between DNA 
methylation patterns, TNF-α, IL-6, IL-10, and vitamin D (25[OH]D) with maternal GBS 
colonization status have not previously been reported.  
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Maternal Serum Cytokines and Vitamin D (25[OH]D) 
Research Question 1: Are serum levels of TNF-α, IL-6, IL-10, and vitamin D (25[OH]D) 
different in pregnant women with GBS colonization than pregnant women without GBS 
colonization? 
 This study was designed to capitalize on data that was collected for a previous 
study. Other clinical indicators could potentially be used to identify pregnant women at 
increased risk for GBS colonization that have not previously been considered. Clinical 
indicators, such as serum cytokine levels that reflect immune system functioning, could 
also be associated with altered DNA methylation patterns. Variability in serum markers 
associated with immune function and vitamin D (25[OH]D) have been previously 
reported and utilized as a prognostic indicator of disease states, such as respiratory 
infections (Chesney, 2010), human immunodeficiency virus infections (Fahey et al., 
1990), pancreatitis (Pezzilli et al., 1995), and depression (Kiecolt-Glaser & Glaser, 2002). 
Research investigating the role of vitamin D (25[OH]D) as an immune function 
modulator has increased dramatically in recent years (Figure 3) and could offer a cost 
effective intervention target if low serum vitamin D (25[OH]D) levels are associated with 
GBS colonization.  
 Multiple alterations in immune function are necessary during pregnancy to 
prevent the mother’s body from perceiving the developing fetus as a foreign pathogen. 
Serum markers of immune function are being increasingly evaluated in pregnancy 
because alterations occur throughout normal pregnancy and inappropriate levels 
contribute to the development of pathology during pregnancy (Ponsonby et al., 2010). In 
a recent study, Fichorova et al. (2011) identified patterns in immune function markers 
101 
 
that were specific to the type of bacteria present in the vaginal mucosa and placenta of 
pregnant women. Notably, they found TNF-α, IL-1β, IL-6, IL-8 and ICAM-1 were 
elevated when pathogenic organisms associated with bacterial vaginosis were present. 
Furthermore, Lactobacillus, which colonize the vaginal mucosa and are not pathogenic, 
suppress pathogenic strains and downregulate pro-inflammatory cytokines (Donato et al., 
2010; Othman et al., 2007; Zeuthen et al., 2010). However, no evidence could be found 
in the literature to suggest that patterns of immune function serum markers have been 
explored with regards to GBS colonization or infection. Additionally vitamin D 
(25[OH]D), a known modulator of immune function and deficiencies, has been 
associated with susceptibility to infectious diseases (Chesney, 2010). It is generally 
accepted that serum vitamin D (25[OH]D) levels must be above 20 ng/ml during 
pregnancy to maintain normal physiologic processes and fetal development. Recently, 
experts have noted vitamin D (25[OH]D) levels greater than 32 ng/ml are necessary to 
support all physiologic processes (e.g. infection prevention) that require vitamin D 
(25[OH]D) for optimal functioning (ACOG, 2011; Holick et. al., 2011).  For this study, 
TNF-α, IL-6, IL-10 and vitamin D (25[OH]D) were selected specifically for analysis 
because of the reported association with infectious diseases and action during pregnancy. 
The serum cytokine and vitamin D (25[OH]D) levels were evaluated throughout the 
pregnancy in order to identify any difference in how the levels change throughout 
pregnancy, as well as independently during each trimester. Laboratory results were also 
evaluated to identify any direct correlation between serum cytokine and vitamin D 
(25[OH]D) levels. 
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First, correlation tests indicated that vitamin D (25[OH]D) levels were not 
correlated with serum TNF-α, IL-6, or IL-10 levels during pregnancy. The initial 
hypothesis of the study was that vitamin D (25[OH]D) would be correlated with TNF-α, 
IL-6, or IL-10 levels because vitamin D (25[OH]D) modulates immune function. Because 
there was no correlation between the cytokines and vitamin D (25[OH]D); vitamin D 
(25[OH]D) was not used as a covariate and repeated measures ANOVA was completed 
using serum vitamin D (25[OH]D), TNF-α, IL-6 and IL-10 independently instead of the 
originally planned repeated measures ANCOVA (with vitamin D (25[OH]D) as the 
covariate). In addition to there being no correlation between serum vitamin D (25[OH]D) 
levels and the serum cytokines, no significant association between serum TNF-α or IL-6 
levels and maternal GBS colonization status was identified. In vitro experiments have 
indicated there is an increase in TNF-α production in neonatal and adult peripheral 
mononuclear cells (Berner et al., 2002) and human epithelial cells (Mikamo et al., 2004) 
exposed to GBS. Additionally, TNF-α and IL-6 levels increase systemically in murine 
models when the mice are inoculated with GBS resulting in high mortality rates (Puliti et 
al., 2000). Because TNF-α levels increase in laboratory and animal studies as a result of 
GBS exposure, this investigator hypothesized that TNF-α levels may be elevated in 
pregnant women who are GBS positive. In this study, TNF-α levels were only elevated in 
pregnant women with GBS during the third trimester and the difference was not 
statistically significant. Furthermore, results from the one-way MANOVA indicated 
TNF-α has no effect (partial η2 < 0.001) on GBS colonization status in pregnant women. 
Given this very low η2, it is unlikely that any significant difference would be identified in 
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TNF-α values in pregnant women with and without GBS colonization; even with a larger 
sample size. 
There is an increased IL-6 production in vitro, and in animal models, with 
exposure to GBS (Berner et al., 2002; Mikamo et al., 2004; Puliti et al., 2002). The 
increase in IL-6 in response to GBS exposure has not been verified or validated in human 
studies. This study evaluated the level of serum IL-6 to determine if a similar increase in 
IL-6 production occurs in pregnant women in response to GBS colonization and found no 
statically significant effect. Results from the one-way MANOVA indicated IL-6 has no 
effect (partial η2 < 0.001) on GBS colonization status in pregnant women. It is unlikely 
that even with a larger sample size any significant difference would be identified in IL-6 
values in pregnant women with and without GBS colonization.  
Two previous studies in murine models identified an increase in IL-10 levels 
related to GBS exposure or infection (Bebien et al., 2012; Madureira et al., 2011). No 
statistically significant elevation in IL-10 levels in pregnant women who were GBS 
positive were observed at any point during pregnancy. Because of the small sample size, 
we calculated the mean serum level values and conduct a one-way MANOVA to correct 
for confounding resulting from data being collected over time, determine effect size and 
observed power. Because we found a negligible effect (partial η2 = 0.006) of IL-10 on 
GBS colonization status, it may be warranted to repeat the study with a larger sample 
size.  
Serum vitamin D (25[OH]D) levels had a small effect on GBS colonization status. 
The normal increase in serum vitamin D (25[OH]D) levels during pregnancy that may be 
involved in preventing infection and colonization with pathogenic bacteria during normal 
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pregnancy was not evident in this study (De-Regil Luz et al., 2012). Surprisingly, 
multivariate analysis revealed that GBS positive women are more likely to have higher 
serum vitamin D (25[OH]D) levels. However, both GBS positive (29.16 ng/ml) and GBS 
negative women (24.59 ng/ml) had serum vitamin D (25[OH]D) levels below the 32 
ng/ml recommended for optimal physiologic functioning during pregnancy. Both groups 
of women likely had low vitamin D (25[OH]D) levels because of the fact that the primary 
study was undertaken in the high northern latitude. Unfortunately, previous studies 
evaluating vitamin D (25[OH]D) levels related to GBS colonization status could not be 
found in the literature. Therefore, it is unclear how these results should be interpreted. A 
meta-analysis conducted by Thorne-Lyman and Fawzi (2012) revealed it is unknown 
how vitamin D (25[OH]D) relates to maternal infections since the relationship between 
vitamin D (25[OH]D) and immunity has only recently been established. Vitamin D 
(25[OH]D) levels across pregnancy will be evaluated in a larger cohort of women in an 
upcoming follow-up study to determine if the same results persist. Repeating the analysis 
with a larger cohort may result in better understanding of the significance of these study 
results and how vitamin D (25[OH]D) is related to GBS status during pregnancy. Post-
hoc power analysis indicated that replicating the study with a larger sample size may 
yield significant differences in vitamin D (25[OH]D) levels associated with GBS 
colonization status because serum vitamin D (25[OH]D) levels appear to have some 
effect on GBS colonization status (partial η2 = 0.068).  
Maternal DNA Methylation 
Research Question 2: Are DNA methylation patterns different between pregnant women 
with GBS colonization and those without GBS colonization? 
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DNA methylation is currently the most well understood epigenetic modification 
and is increasingly being integrated into clinical nursing research. In this study, the 
investigator used previously collected peripheral blood samples in order to complete the 
study in a timely and cost effective manner. The exploratory nature of this genome wide 
DNA methylation analysis allowed the investigator to quantify methylation of individual 
CpG sites. Specifically, DNA methylation in peripheral white blood cells that were 
collected during the first trimester of pregnancy in women colonized with GBS in late 
pregnancy were compared to women who screened negative for GBS in the third 
trimester of pregnancy. Preliminary analysis of a subset of individuals by the investigator 
(n=6), initially indicated that over 1,000 potential early pregnancy DNA methylation 
differences existed between women with and without late pregnancy GBS colonization. 
Since DNA methylation is an epigenetic modification that can result in altered gene 
expression, with the potential to impact health and disease susceptibility, this study was 
designed to see if the preliminary differences identified in a very small sample (2 GBS 
positive, 4 GBS negative) would persist in a larger sample. Previous studies have 
identified potentially useful, clinically relevant DNA methylation biomarkers for 
preeclampsia using a sample size of n=6/group (Anderson et al., 2013). For this study, 
the sample size was increased to n=9/group, which reduced the number of statistically 
significant differentially methylated sites from over 1,000 genes between women with 
and without GBS colonization to 141 CpG sites using the GenomeStudio software. Due 
to the small number of significant genes and the drastic decrease in potentially different 
CpG sites, it is premature to assume these sites may be an early biomarker for GBS 
colonization. Support for this assessment will be evident in the discussion of the variation 
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in the number and actual genes associated with differentially methylated CpG sites using 
different software for statistical analysis. Prior to this study, no other papers could be 
identified in the literature investigating host DNA methylation patterns related to 
colonization with a certain microbe. As discussed in chapter 2, this is an area of inquiry 
that will likely increase over time because of the role that methylation plays with cell 
differentiation and memory in immune cells (Bobetsis et al., 2007; Torsten Olszak et al., 
2012; Schaub et al., 2009; Tolg et al., 2011). 
 Of the 18 women included in the methylation analysis for this study, data 
extracted from the medical record indicated no difference in baseline characteristics 
between GBS positive and GBS negative women. Further, no significant differences in 
maternal co-morbidities that may indicate, or cause, altered immune function; such as 
asthma, infections or antimicrobial usage were found. Because some of the 
normalizations features incorporated into the analytic component of GenomeStudio 
software are proprietary, it has limited functionality in assessing and presenting 
differentially methylated data and may limit reproducibility (Gentleman et al., 2004; 
Smyth, 2005). Data analysis pipelines for biology and bioinformatics were design 
because “the primary motivations for an open-source computing environment for 
statistical genomics are transparency, pursuit of reproducibility and efficiency of 
development” (Gentleman et al., 2004, p. R80.2). Therefore, statistical analyses were also 
completed using the R statistical environment to ensure accurate normalization and 
interpretation and reproducibility of analysis of the raw data. Additionally, Hansen et al. 
(2013) noted that it was unclear as to what process is used for normalization by 
GenomeStudio because it is not explicitly publicized. Due to the lack of transparency of 
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normalization methods used in GenomeStudio analytic software that limits 
reproducibility of analysis, biostatisticians and R developers recommend not using 
GenomeStudio to conduct statistical analysis. However, R and GenomeStudio are both 
used extensively to conduct methylation analysis. Because both programs are frequently 
used, the results produced using GenomeStudio and R to conduct statistical analysis were 
included in the results section. Some of the differences in the results are likely a direct 
result of different normalization methods of the raw data in each platform. Each result 
can be reproduced using the specified statistical software, although results differ between 
software packages.  
For the actual statistical analysis of DNA methylation using the R statistical 
environment, M- values were used, instead of beta values because M-values are 
homoscedastic across different levels of methylation. Given that beta values exhibit 
severe heteroscedasticity at the methylation extremes, M-values are the superior choice 
for conducting valid differential and statistical analysis (Du, Kibbe, & Lin, 2008). 
However, M-values are difficult to interpret clinically for relevance because the 
transformed negative values are not biologically interpretable. Therefore, after using the 
logit transformed values (M values) for statistical analysis, the data were reported using 
the original untransformed beta values to allow for clinical interpretation of the findings. 
In fact, beta values are most frequently reported because beta values represent a 
percentage of methylation, and therefore are more biologically meaningful (Du et al., 
2010).    
 Regardless of the statistical platform used for the data analysis, we did find over 
100 CpG sites with significantly different methylation between women who were GBS 
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positive or GBS negative when applying an alpha of 0.05. Of the sites identified by both 
GenomeStudio and R statistical environment, there were 56 common genes. However, it 
is expected that statistically by chance 24,250 CpG sites would be identified as 
differentially methylated when using an alpha of 0.05 (485,000 sites in the array * 0.05 = 
24,250). In other words, basic statistics indicate an arbitrary investigator is more likely to 
find a significantly different methylated CpG site between GBS positive and negative 
women, than the sites identified using an alpha of 0.05 actually being significant. Similar 
analytic approaches for identifying biomarkers, such as the NIMBL package for Matlab, 
likely also lack the power to identify sub-sample heterogeneity or reasonably identify 
biomarkers in a sample of this size when not using FDR to determine significance. 
Therefore, conducting additional testing assessing for significant in this sample would not 
yield valuable biomarker information because no sites are significantly different when 
FDR is applied to determine significance. It is imperative to generate empirical estimates 
of test statistics (and p-values) via bootstrapping methods for small sample sizes, coupled 
with FDR to appropriately safeguard against over-interpretation of microarray data 
(Benjamini & Hochberg, 1995; Tusher, Tibshirani, & Chu, 2001; York, 2003). 
Furthermore, recommendations for design and analysis of epigenome-wide association 
studies, such as this one, include using multiple-testing adjustments and validating the 
methylation in a similar but different cohort using a different laboratory methodology 
(Michels et al., 2013).   Analysis of methylation on this study cohort using FDR indicate 
no CpG sites have significantly different methylation using any FDR cutoff value 
(adjusted p value= 0.99992 for all values, Appendix I). The lack of significance maybe 
attributed to small sample size and the use of peripheral blood instead of vaginal 
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epithelial cells. Michels et al. (2013) stated “As natural variation affects DNA 
methylation, larger sample sizes will typically be required for EWAS than for GWAS for 
any given phenotype, even when the most technically sophisticated assays are used” (p. 
952), therefore it is premature to assume that any of the CpG sites identified in this study 
with 18 participants will yield reliable biomarker results regardless of approach. In future 
studies, the same analysis will be completed using a larger sample size of GBS positive 
and GBS negative women who have already had genome-wide methylation analysis 
completed. This investigator suspects that repeating the analysis on a larger cohort of 
women may further decrease the number of statistically significant differentially 
methylated sites identified, or result in completely different findings between the two 
groups of women. Such replication will also enable the investigator to determine if genes 
identified by only one of the approaches (GenomeStudio or R) are no longer significant. 
Further analysis with a larger sample or statistical simulations, such as bootstrapping that 
are beyond the scope of this dissertation, may be able to better identify why the results 
differ when using different software to perform statistical analysis.  
Additional studies will also be needed to determine the significance of DNA 
methylation on gene expression. RNA was not collected in the parent study, and therefore 
gene expression studies using RNA could not be completed for this study. However, 
based on the location of differential DNA methylation, it is possible that the differentially 
methylated CpG sites associated with genes may have an effect on gene expression. CpG 
islands, dense regions of cytosine and guanine dinucleotides, contribute to the regulation 
of gene transcription and subsequent gene expression (Deaton & Bird, 2011). 
Approximately 72% of known gene promoter regions are associated with CpG islands 
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(Saxonov, Berg, & Brutlag, 2006). Results from the analysis conducted in the R 
environment identified 15 CpG sites that were within CpG islands and 44 CpG sites were 
located in the regions flanking the islands that may also result in altered gene expression 
patterns (Doi et al., 2009). Upon follow-up studies methylation at these sites will be 
assessed, since they are most likely related to gene expression.  Appropriate samples will 
also be collected to perform RNA and protein analysis in the next study.  
 If a selective and specific biomarker panel for GBS colonization based on 
differential methylation patterns can be developed after repeating the analysis with a 
larger cohort, it could be useful for identifying women at risk for poor pregnancy 
outcomes (e.g. miscarriage, preterm birth, premature rupture of membranes and maternal 
infections) that occur as a result of GBS prior to 35-37 weeks of pregnancy. Since DNA 
methylation vitally contributes to programming memory in immune cells, altered 
methylation patterns in women with GBS could represent a novel target for designing 
novel treatment and prevention modalities.  
Biologic Functions Associated with Altered Methylation 
Research Question 3: Is there a relationship between differentially methylated genes and 
immune function in pregnant women colonized with GBS? 
Although no CpG sites were differentially methylated when applying FDR for 
significance, functional analysis was conducted using DAVID bioinformatics data base to 
determine if the differentially methylated genes identified using an alpha of 0.05 may be 
related to immune function or inflammation. A recently published manuscript by 
Laayouni et al. (2014), identified alterations in 20 genes associated with immune function 
in populations exposed to Yersinia pestis that have persisted over time and resulted in 
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altered predisposition for autoimmune disorders in individual of European descent. 
Laayouni’s team found variant SNPs in genes that alter how the immune system responds 
to Y. pestis. They found that the production of pro-inflammatory cytokines is increased in 
response to Y. pestis. The increased inflammatory response allowed for some of the 
population to be resistant to, or heal from, the Black Plague. These SNP variations are not 
seen in populations that were out of the endemic area during the Black Plague. 
Laayouni’s group suggested that the SNP variations, driven by pathogenic exposure, 
contribute to the increased prevalence of autoimmune disorders in populations of 
European descent where Black Plague was endemic. The SNP variants are not present in 
populations not exposed to Y. pestis and the populations also exhibit lower prevalence of 
autoimmune disorders. Lauyouni’s study further supports that genetic variation can be 
driven by, and contribute to, pathogen specific immune response that persists for 
generations. Multiple studies have identified altered DNA methylation patterns that have 
occurred in response to, or as a result of, exposure to specific pathogens (Bobetsis et al., 
2007; Mikovits et al., 1998; Tolg et al., 2011). This study was the first to evaluate DNA 
methylation patterns in women with GBS colonization and functional analysis reveals 
these changes may play contribute to colonization susceptibility. 
Genes incorporated into significant functional clusters using the DAVID 
bioinformatics software were independently searched within the GeneCards® database, 
The Human Gene Compendium Encyclopedia (http://www.genecards.org/). Functional 
cluster analysis was completed using DAVID bioinformatics software. None of the 
functional categories were significant when FDR is applied to determine significance of 
the clusters identified. However, for genes identified by using both GenomeStudio and R 
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software as being differentially methylated, the cell morphogenesis functional cluster has 
potential to offer mechanistic insight into GBS colonization and was significant using and 
alpha of 0.05 (p=0.01). The functional cluster was associated with methylation loss in 
GBS positive women. The cell morphogenesis cluster includes four differentially 
methylated genes and has an enrichment score of 1.77, which is above the suggested 1.3 
cutoff value indicating likely involvement in biological process (Huang et al., 2009a).  
What makes this particular cluster interesting is that the genes within the cluster are 
associated with various immune functions and pathways. Gómez et al., (2010) 
determined that there is an association with PRKCA and bacterial vaginosis. This gene is 
associated with abnormal bacteria in the vagina and a similar association may exist with 
GBS susceptibility. The CUL3 gene is in a SuperPaths specifically related to antigen 
processing and the adaptive immune system (Andérica-Romero, González-Herrera, 
Santamaría, & Pedraza-Chaverri, 2013; Pintard, Willems, & Peter, 2004; Singer, Gurian-
West, Clurman, & Roberts, 1999).  It is possible that the loss in methylation in women 
with GBS alters antigen presentation and how the body responds to GBS (e.g. allowing 
colonization or clearing the bacteria). The GAP43 gene has been associated with 
inflammatory disease processes including contact dermatitis (El-Nour et al., 2006) and 
cutaneous malignant melanoma (Reed, Finnerty, & Albino, 1999). Since the gene is 
hypomethylated in women with GBS, it is possible there is increased cutaneous 
inflammation which is damaging to normal flora and creates a niche for GBS to colonize. 
Additional research investigating expression levels, protein products, and associated 
clinical outcomes, could be beneficial for the genes in this functional cluster.     
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There were two additional functional clusters with enrichment scores above the 
1.3 threshold for biological significance: cellular metabolic and biosynthetic processes 
(1.46, p= 0.03) associated with genes that were hypermethylation and regulation of 
apoptosis (1.34, p = 0.05) associated with genes that were hypomethylated.  Upon 
searching in GeneCards and PubMed, there does not appear to be any literature directly 
associating the genes examined in this study to with immune variations related to 
infections in either of the aforementioned pathways. There are 1,166 publications 
associating the genes identified with various cancers and neurological ailments, but none 
of the studies directly pertaining to infectious disease processes. Therefore, it seems 
unlikely that the genes in this cluster will offer any mechanistic insight unless there are 
indirect linkages to inflammatory processes. However, genes identified in this cluster 
may still be useful as clinical biomarkers in the future for identifying carriers, or women 
at risk for colonization in early pregnancy to prevent preterm labor or other poor health 
outcomes if the results are replicated in a larger cohort.  
Two of the genes (CUL3 and PRCKA) in the apoptosis cluster are the same as in 
the cell morphogenesis cluster. The remaining genes in the apoptosis functional cluster 
do not appear to have any direct linkages to immune processes related to infection. There 
were 1,462 publications identified for the three genes that did not overlap with the 
morphogenesis cluster that were associated primarily with tumors, cancers, and muscular 
dystrophies. Similar to the metabolic and biosynthetic cluster, it seems unlikely that this 
cluster will offer any significant mechanistic understanding to GBS colonization. 
However, these genes may also be useful clinical biomarkers in the future after additional 
analysis is conducted for identifying GBS carriers or individuals susceptible to GBS 
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colonization. Further evaluation in a larger cohort and gene expression data may assist in 
determining if these genes are useful as clinical biomarkers for GBS colonization. Future 
studies investigating the relationship between PRKCA, CUL3, and GAP43 genes and 
GBS colonization may offer mechanistic insight and provide targets for future GBS 
treatment or to develop colonization prevention strategies.   
Nursing Implications 
 Advances in epigenomic research are beginning to contribute significantly to 
scientific understanding of how environmental factors may contribute to various disease 
processes. This study is the first to assess laboratory values that are increasingly being 
used for nursing research (cytokines, vitamin D and DNA methylation) related to GBS 
colonization status in pregnant women. Existing gene-environment interaction models 
(Figure 1) were adapted (Figure 2) in order to guide the approach for this nursing 
research study to investigate if quantitative variations in cytokines or DNA methylation 
levels identified in in pregnant women’s could be used to identify women at risk for GBS 
colonization. Although this study did not identify any significant differences between 
women colonized with GBS and women without GBS colonization, this study adds a 
novel model and approach method that can be used in future nursing research that can be 
modified as research methodology continues to evolve. Expanding on existing research 
models to bridge the gap for nurses to conduct translational research to improve 
outcomes will have implications for nursing research, practice, education and policy.   
Nursing Research Implications 
 Nurses are uniquely poised to accelerate the translational arm of epigenomic 
research to better assist clinical populations of interest to attain and maintain optimal 
health functioning. Conducting research that critically examines environmental exposures 
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and unique epigenomic signatures will allow for the discovery of new treatment targets 
and the ability to create new disease prevention strategies ranging from diet modification 
to driving forward policy chance to protect public health and well-being. This is the first 
study investigating cytokines, vitamin D, or DNA methylation levels in peripheral blood 
to identify potential associations with GBS colonization susceptibility. Historically, much 
of the epigenomic literature is dominated by cancer studies. However, studies 
investigating the relationship between epigenomic alterations and complex diseases, other 
than cancer, have been increasing in recent years. It is important to note that identifying 
aberrant DNA methylation patterns alone will not explain why or how it was altered, how 
to intervene, or help the patients avoid acquiring abnormal patterns.  
Nursing Practice Implications 
 A holistic approach for investigating the impact of epigenomic alterations on 
health status is a necessity if science intends on using epigenomic information to improve 
health. Other lifestyle patterns (diet, lifestyle, stress) and exposures must be assessed to 
identify interactions that may be causing the altered DNA methylation pattern. Nursing 
clinical assessments can help illuminate human-environment interactions, the endogenous 
and exogenous factors in the model developed to guide this study (Figure 2), that may be 
altering DNA methylation patterns that cannot be identified by studies using cell or 
animal models. Studies involving actual clinical populations are needed, specifically for 
disease processes that are inflammatory in nature because the immune response in murine 
models does not correlate with the human inflammatory response (Seok et al., 2013). 
Although it is near impossible to select populations to eliminate all confounding 
variables, perhaps it is time to embrace studies that acknowledge and address 
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confounding variables.  The environment has an undeniable impact on health and disease 
states, therefore to completely eliminate all confounding variables from bench studies 
may explain some of the barriers encountered when translating research from bench to 
bedside. Humans do not live in a well-controlled, isolated environment; and their 
environment will alter how they respond to treatment and environmental exposures. Most 
complex diseases are the results of a culmination of genetic and environmental factors 
unique to an individual. Each person’s DNA and environmental exposures are unique and 
assessing both (Figure 2), as well as the interaction of the two, will result in more 
personalized healthcare. Because nurses are educated on how to assess patients and the 
environment holistically; nurses are well poised to drive translational research and 
include information obtained from these assessments to investigating the interaction of 
environment and epigenomic signatures.  Strong communication between bedside nurses 
and nurse scientists are needed to reconcile the gap between bench studies and what 
nurses find applicable and useful in the clinical setting. 
Nursing Policy Implications 
 Investigation of clinical values that may be directly altered by environmental 
exposures has implications for nursing policy as well as general public health policies. 
Person, health, environment, and nursing are the metaparadigm concepts that remain the 
pillars of the nursing discipline. Perception of these concepts constantly evolves to 
incorporate new knowledge gained through practice, research, education, and exposure to 
other disciplines. Since most human disease processes are multifactorial in nature and 
nurses interact with individuals throughout the illness-wellness continuum, it is 
imperative nurses become involved with policy development to protect public health 
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based on research findings that are evident in clinical populations.  For example, if the 
results from this study had indicated that women without GBS colonization had 
significantly higher serum vitamin D levels additional studies would be needed to 
validate that the findings were accurate and then to determine if vitamin D 
supplementation could be protective. After further studies, a significant effort would be 
required to incite policy change incorporating vitamin D supplementation to prevent GBS 
colonization into practice. As the state of the science continues to rapidly evolve, it is 
important to being considering how public health and nursing policies can be addressed 
and updated to reflect current methodologies and research findings. 
Nursing Education Implications 
 Incorporating research models, like the one developed for this study, could have 
implications for nursing education. Students are usually required to complete basic 
science courses prior to acceptance and entry into a nursing program (nutrition, 
chemistry, anatomy, physiology). The base knowledge is required in order to understand 
how biological phenomena can be utilized, manipulated, and applied to nursing practice. 
Since the sequencing of the human genome was completed, striking advances in genetics 
and genomics have occurred and nurses at all levels will be expected to be able to 
communicate these findings to patients and be able to identify how the gene-environment 
interactions affect health and illness (Consensus Panel on Genetic/Genomic Nursing 
Competencies, 2009). Per the recommendations from the Consensus Panel on 
Genetic/Genomic Nursing Competencies, all programs of nursing should be 
incorporating education on genetics and genomics for entry level nurses. Essential 
content that should be taught includes: incorporating genetic and genomic knowledge 
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into nursing assessment and care, what to do with the information obtained or where to 
refer patients, understanding how personal opinions of genetic and genomic testing and 
interventions may affect practice. Translation of genetics into treatment is already 
occurring and very prevalent in certain areas of nursing, such as maternal-child health 
and oncology and will become more pronounce in other areas as the state of the science 
continues to evolves (Kirk, Calzone, Arimori, & Tonkin, 2011). It is imperative that 
nurses incorporate this knowledge into practice to properly care for patients. Further, 
“there is a growing abundance of genomic resources already available in a range of 
formats that cover most teaching environments and learning approaches. For many topic 
areas, particularly bioscience, there is no need to reinvent the wheel and develop new 
resources” (Tonkin, Calzone, Jenkins, Lea, & Prows, 2011, p. 336).  Content on the 
epigenetics and appropriate models for analysis should be incorporated into the genomics 
content due to the increasing number of research studies investigating epigenetic 
mechanisms contributions to alter health status. 
Limitations 
 Many of the limitations of this study are a direct result of being a secondary data 
analysis. Therefore, it is difficult to eliminate the possibility of misclassification bias. The 
first major limitation of the study is the small sample size. The intent of this exploratory 
study was to identify significant group differences and determine effect size so that 
sample size could be determined in future investigations. There have been no previous 
studies evaluating DNA methylation patterns, serum cytokine levels or vitamin D 
(25[OH]D) status in pregnant women with and without GBS colonization. Given the high 
cost of conducting these types of laboratory analyses, conducting a study with a small 
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sample size to determine feasibility and potential clinical utility is the most economically 
sound option. Additionally, the intent of using the DAVID database was to identify 
additional clinically relevant findings that could be utilized as pilot data for a subsequent 
grant proposal. As outlined in the methods section in the approach for analyzing DNA 
methylation, both gain and loss of methylation was determined and evaluated. The 
functional significance varied depending on the direction of change in methylation. We 
did find significant pathways for methylation gains and losses. However, future studies 
focusing on genes identified in the methylation loss pathways may prove to have some 
clinical utility. As discussed previously, the genes involved in the cell morphogenesis and 
regulation of apoptosis pathways make clinical sense and could potentially be epigenetic 
factors that contribute to GBS colonization susceptibility.  
 Another limitation of the study is that only peripheral blood samples were 
available for analysis and all other information had been previously extracted from the 
medical record. For example, it would have been more ideal to run the genome-wide 
DNA methylation analysis on epithelial cells taken from the recto-vaginal swabs at the 
time of GBS screening because that is when colonization status is determined and that is 
the reservoir site for neonatal infection. However, we had no access to the swabs or 
peripheral blood samples at the exact same time point. Since we had maternal DNA 
samples from the first trimester in pregnancy, any differences associated with GBS 
colonization could be a clinical indicator for susceptibility. It may also allow for a more 
targeted screening approach for preventing poor pregnancy outcomes associated with 
GBS colonization that are currently not prevented or screened. Additionally, a breakdown 
of the composition of cell types in the peripheral blood samples was not available. 
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Statistical corrections can be completed to correct for the heterogeneity of cell types 
found in peripheral blood (Houseman et al., 2012). However, Houseman et al., (2012) 
states that current statistical correction strategies are “a computationally difficult task that 
would have extreme vulnerability to model mis-specification.” (p. 10). Given the 
exploratory nature, small sample size, difficulty in establishing model fit, and the fact that 
the variable cell types that may have an impact on results only make up 2-3% of the cell 
population, corrections for cell type were not incorporated into the analysis. However, in 
future studies with a larger sample size consideration will be given to separate cell types 
prior to analysis of DNA methylation to avoid this type of confounding in the analysis.  
Conclusions 
 As the state of the science continues to evolve, it is imperative for nurses to 
incorporate advances in science into their program of research. Nurses are trained to 
translate information to people and populations with all levels of understanding. It is a 
natural fit for nurse scientists to step into a translational role and design studies to assess 
how the environment interacts with the individual in order to improve health outcomes. 
Investigation of epigenomic and genomic alterations related to complex disease processes 
has the potential to identify biologic mechanisms that contribute to the development of 
disease. Overall, gene-environment interaction models are useful for guiding nursing 
research investigating DNA methylation patterns because it allows for a holistic approach 
that clinical assessment data can be incorporated into. Additionally, DNA methylation 
patterns are readily measurable and offer insight into how environmental interaction can 
impact health by causing changes in gene expression. A number of standard laboratory 
protocols and bioinformatics tools can be utilized to complete exploratory studies. Since 
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DNA methylation patterns can now be identified by laboratory techniques, clinicians and 
research scientists must learn to decipher what the patterns mean and what the 
implications are for health. As health care progresses to incorporate more patient centered 
approaches, identification of altered DNA methylation patterns will improve nurses’ 
ability to provide optimal care for patients. With an understanding of the impact of DNA 
methylation patterns, personalized, individual interventions can be developed to improve 
health based on research findings. Ultimately, this will improve care at the level of the 
individual. 
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CpG Site DNA Sequence Data for Primer Design 
 
RHPN1>hg19_dna range=chr8:144457427-144457927 5'pad=250 3'pad=250 strand=+ 
repeatMasking=none 
CTGGCTTCTGGTGTCCTTGGCAGGTGCCAGCCTCCCCCGCTGACCCCCATCAC
GAGTCAGCAGCTTACCCCACCGACCACGTCCTTCTGCATTGACTGCCTCCTGT
CCTGCTCTGGCCAGGCCTGTGTTCACACTAGTTCTGTCCAGCCCCTCCCTGTG
AGGCCAGCTCCAGCCCCAGCGCATGGTGACCATCCCGTTACCCATGGGCAGG
ATGCACTCCTCTCAGTGGCTGGCGAGGCGCAGCCTGGTGCGGGCGCCACGGG
GTCGGGCTGTGATCGCCTGTGGCCTCCCTGCAGGGCTGTGACTCCCTGACGCA
GATCCAGTGCGGCCAGCTGCAGAGCCGCAGGGCCCAGATTCACCAGCAGATT
GACAAGGAGCTGCAGATGCGGACGGGCGCTGAGAACCTCTACAGGTCAGTG
CTTGAGACTGCCCGGCCCCGGGAGCAGGGCCCACCTGGGTGAGGGGGGCAG
GACAGCCACGCAGGCAGATGTCTGCCCCATG 
 
HLA-DRB6>hg19_dna range=chr6:32522622-32523122 5'pad=250 3'pad=250 strand=+ 
repeatMasking=none 
TCCTGACCATTCTGGAACCACCTGACTTTAATGCTGCCTGGATAGAAACCACT
CACAGAGCCGACCAGGGGGTTGCGGTGATGCAGGGGCTGGGTCTTTGCAGGA
TACACAGTCACCTTAGGATGGACTAGGAGAAAAAAAGGTAGAGAGAATGAA
TCAGGAAGTTAGAGTCTCGTTGTTCAGCTGTTTGTATGCTTCTCTGTAAACCC
AGGCTCTGGCCTCGACCAGGCCTCCAGCACAGCTGGCCATACGCCCTCACAG
TGTCATCGGCCTGGAATTTAATCGTGATAGTGTGGACCTATCAGATTTGAGAG
ATGTTATAAAAAATTTTATTTGTTTCTTCATAGCTTGAAATTGTCACGCATTGT
TGAAGTGTTTACAAATCTCTGAAAGTACAGTGTGTATTAATTAAAACTGATAC
CTGAGCCAGGTTGCCTGGTTCAAATCCAAGGTCTGCCTTTTACTGGTTGATCC
TGGAAGAGTTTTTTGATTCTTTTGTGT 
 
 
ANXA2>hg19_dna range=chr15:60643907-60644407 5'pad=250 3'pad=250 strand=+ 
repeatMasking=none 
GGCCACATTCACTTACCCAGGTTCAGGAAAGCATTTTCCAGGTCTCCTTTAAC
CTCTTTCCTGATGCTTTCCAACATGTCATAAGGGCTGTAACTCTTGTACCTATC
AAATACTGAGGAAAAACAACAAAGAGTTATCAGATCCGAGCCACTAGTCAA
AGCTGTCAACGATCACCCACCTAGTTTTATGCACCATAATTTTTTTAAAAATT
GAGGATGATCACAGCATCCTAGGAGCTTAGAGGTTACCACGGTGACCAGAGC
CAACATTGGCCAAGTTTGTCGTGGAACAGCCATACCACCTGTCCTGAATGGC
ACTGCCCAGGCCACATATTTGGACCATCTCTATCTCCCCTGAGTGGAACCCAT
TCCATCCGAAAACCATAGGAAACAGTACAGAGCATGCACCAAAGTCCACTAC
TTCAACAAATAATGGCAAGACCAAATGATCATCAAACAAGAAGGAGCTGCA
GAATAAAGCACCAAATGCAGAAACTATTTG 
 
 
 
MRI1>hg19_dna range=chr19:13874611-13875611 5'pad=500 3'pad=500 strand=+ 
repeatMasking=none 
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CCTCAGCCTCCCGAGCAGCTGGGACTACGGGTGTGCGCCACCACGCCCAGCT
AATTTTTTGTATTTTTAGTAGAGACTGGGTTTCACCATGTTGGCCAGGCTGGT
CTCGAACTCCTGACCTCAAGTGATCTGCCCGACTCGGCCTCCCAAAATGCTGG
GATTCCAGGCGTGAGCCACAGCGCCTGTCCTGCATGTTACTTTTGAATGAAAC
CGAGCAGAAAATGGCCCAGAAACAGCCTTGCATCCATCAAGGGGCACACGA
CCCCCCACTACCTCCCCCTCAACCTTGGAAGATCATTTAACAAATTCTTTGGT
TTGAACACTTGATGTTACCTTGCCACTGGGGATACATCCCTAACTCTAGACAG
CAGGTTGTTAAACACGGGGCCTGGTATCCACTAGGCGTCCCATAAATGCTGC
CACTTTTGTGGTTCCGAGGAGGCGGCTCACTCCGTTCGGGCTTGGCAGGAGTC
GTGGAGTGGGTTCGGCCACGTGGAATCCGCGTCCTGGGAACCCGTGGAATCC
GCGTCCTGGGAACCCGTGGAATCCGCCTCCTGGGAACCCGTGGAATCCGCCT
CCTGGGAACCCGTGGAATCCGCCTCCTGGGAACCCGTGGAATCCGCCTCCTG
GGAACCCGTGGAATCCGCCTCCTGGGAACCCGTGGAATCGGGTTGGATGCGC
ATGTGCGTGTCTCTTTTTCCGGGGGAGGCTCCGCCCACGGCCCCGCCCCGCTC
CCAAGTGCGCGCGGACCCCTAGCTCCCTCTGAGTTGCGCTGGGCTTGGCTGCT
GCACCATGACCCTGGAGGCGATCCGCTACTCGCGGGGCTCCCTGCAGATCCT
AGACCAGCTGCTGCTGCCCAAGCAGAGCCGCTACGAGGCGGTGGGCTCGGTG
CACCAGGCCTGGGAGGCCATCCGCGCCATGAAGGTGCAGCGGGGCGGCGGG
GCGGCGGGGCGGCGGGGCGGCGGGGCGGCGGGGCGGCGGGGCGGCGGGGC
GGCGGGGCG 
 
GAP43>hg19_dna range=chr3:115376099-115376599 5'pad=250 3'pad=250 strand=+ 
repeatMasking=none 
AGTGTAGGAGAGGTGAGTTGCTTAGGTCTAAGGAGAAAGACTGCTTAGGTGT
GTGTTCACCCCCAGGACGAAGAAAGGAACACTGGGTGAGATTTTGTTCAACT
ACCCATAGTTACCACCAGATGGTGAAACTGATCCCGGGCCTCTTGGGTATTG
ATCAGTTTATGGGGAGATGGGGAGAAGACTATCTTTCACTTGTTAATTCATTA
ATTTCTTTCGCAAATATTTTTTCAGTACCTGCTAAGTCCCACGGACTATGCTA
GGAGCTGCTGTTAAAATGACAAACCAGATAAGGTCACTGCCCTTAATCAACT
TACAGTTGGGTGAGAAGCTATCAGGTACAAGTATGGCCCTAGAACAAATTAG
TCTTTTCTAGTTAATAATCTTATGTGATGAGATTTGGCCTTGCTCCTTTGGTGA
CTTGCCTCAAGGAGCCCCAGGCAAAACCAATGTAACATATATTAATAATATA
TGAAATAATATATTTTGTAGACACAATTG 
 
CUL3>hg19_dna range=chr2:225441582-225442082 5'pad=250 3'pad=250 strand=+ 
repeatMasking=none 
ATCATATATGAACTTCTGTTTTTGAAGCCACCCCTCAAGAGCCAACAGGATTC
TTTAAGTATCCCAGTGGTACTAAACCCATATCCTTTGAGAATGCTTTCTTAGA
ACGATTCACAAACTGGCTCTGCAGGCTTTTCAAAACTTAAGTTCTAGAAGTTG
TACAATAAAATGACAGGATCGCTAAAATAAGTGTATGGCATTCGATGTAACT
GCTTGCAAAAACAACATCCAATTTTAATATTGGCCTAATCGTGGCTAAATATT
GGTATAATAATAGTTAACTATCTGCTAAGTTCTATTTTAAAGCTTTATTTTATT
TATCACACAACAAACCTGTAAGGTGGGTCTCATTAGCAGTCTCATTTTACACA
GGGGAAAACTGAGGCTACAAGAAGTAACTTGTTAAAGGTTATGCAGCTAGAG
GCCGGGCGCGGTGGCTCACGCCTGTAATCCCAGCACTGTAGGAGGATGAGGC
AGACGGATCACGAGGTCAGGAGATCG 
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RHPN1 
CGAGGCGCAGCCTGGTGCGGGCGCCACGGGGTCGGGCTGTGATCGCCTGTGG
CCTCCCTGCAGGGCTGTGACTCCCTGACGCAGATCCAGTGCGGCCAGCTGCA
GAGCCGCAGGGCCCAGATTCACCAGCAGATTGACAAGGAGCTGCAGATGCG
GACGGGCGCTGAGAACCTCTACAGGTCAGTGCTTGAGACTGCCCGGCCCCGG 
excluded: RHPN16216FWD-RHPN1FWD Sequence identity: 89.2% 
excluded: RHPN16216REV-RHPN1REV Sequence identity: 89.2% 
excluded: RHPN16217FWD-RHPN1REV Sequence identity: 87.2% 
excluded: RHPN16228FWD-RHPN1FWD Sequence identity: 87.7% 
excluded: RHPN16228REV-RHPN1REV Sequence identity: 89.5% 
excluded: RHPN16235FWD-RHPN1FWD Sequence identity: 88.6% 
excluded: RHPN16235REV-RHPN1REV Sequence identity: 15.4% 
excluded: RHPN16252FWD-RHPN1FWD Sequence identity: 88.2% 
excluded: RHPN16259FWD-RHPN1FWD Sequence identity: 76.6% 
excluded: RHPN16259REV-RHPN1REV Sequence identity: 86.3% 
excluded: RHPN16217FWD-RHPN1FWD Sequence identity: 90.2%; Conversion rate: 
100.0%; N-sites at non CpG cytosines positions: 5.9%; N-sites at CpG positions: 28.6%; 
Gaps: 1.4% 
 
1 out of 12 uploaded sequencing results pass the quality criteria when compared to the 
reference sequence. At the next step all sequences are compared against all others to 
detect clonal amplifications as described in the manual. 
Sequence Alignment of the sequences included: 
RHPN16252REV-RHPN1RE 
 
ANXA 
CCGAGCCACTAGTCAAAGCTGTCAACGATCACCCACCTAGTTTTATGCACCAT
AATTTTTTTAAAAATTGAGGATGATCACAGCATCCTAGGAGCTTAGAGGTTAC
CACGGTGACCAGAGCCAACATTGGCCAAGTTTGTCGTGGAACAGCCATACCA
C 
excluded: ANXA26216FWD-ANXA2FWD Sequence identity: 65.0% 
excluded: ANXA26216FWD-ANXA2FWD_R Sequence identity: 71.5% 
excluded: ANXA26216REV-ANXA2REV Sequence identity: 80.9% 
excluded: ANXA26216REV-ANXA2REV_R Sequence identity: 64.6% 
excluded: ANXA26217FWD-ANXA2FWD Sequence identity: 68.8% 
excluded: ANXA26217FWD-ANXA2REV Sequence identity: 79.7% 
excluded: ANXA26228FWD-ANXA2FWD Sequence identity: 67.1% 
excluded: ANXA26228REV-ANXA2REV Sequence identity: 69.7% 
excluded: ANXA26235FWD-ANXA2FWD Sequence identity: 78.5% 
excluded: ANXA26235REV-ANXA2REV Sequence identity: 67.7% 
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excluded: ANXA26252FWD-ANXA2FWD Sequence identity: 65.6% 
excluded: ANXA26252REV-ANXA2REV Sequence identity: 79.6% 
excluded: ANXA26259FWD-ANXA2FWD Sequence identity: 57.0% 
excluded: ANXA26259REV-ANXA2REV Sequence identity: 51.3% 
No sequence passed the chosen sequence identity threshold of 90% 
 
HLA-DRB6 
AAGGTAGAGAGAATGAATCAGGAAGTTAGAGTCTCGTTGTCAGCTGTTTGTA
TGCTTCTCTGTAAACCCAGGCTCTGGCCTCGACCAGGCCTCCAGCACAGCTGG
CCATACGCCCTCACAGTGTCATCGGCCTGGAATTTAATCGTGATAGTGTGGAC
CTATCAGATTTGAGAGATGTTATAAAAAATTTTATTTGTTTCTTCATAGCTTG
AAATTGTCAC 
excluded: HLADBR66216FWD-HLADBR6FWD Sequence identity: 36.5% 
excluded: HLADBR66216REV-HLADBR6REV Sequence identity: 23.4% 
excluded: HLADBR66217FWD-HLADBR6FWD Sequence identity: 18.3% 
excluded: HLADBR66217REV-HLADBR6REV Sequence identity: 18.0% 
excluded: HLADBR66228FWD-HLADBR6FWD Sequence identity: 13.6% 
excluded: HLADBR66228REV-HLADBR6REV Sequence identity: 26.3% 
excluded: HLADBR66235FWD-HLADBR6FWD Sequence identity: 17.2% 
excluded: HLADBR66235REV-HLADBR6REV Sequence identity: 13.2% 
excluded: HLADBR66252FWD-HLADBR6FWD Sequence identity: 44.2% 
excluded: HLADBR66252REV-HLADBR6REV Sequence identity: 33.3% 
excluded: HLADBR66259FWD-HLADBR6FWD Sequence identity: 33.3% 
excluded: HLADBR66259REV-HLADBR6REV Sequence identity: 27.2% 
No sequence passed the chosen sequence identity threshold of 90% 
MRI1 
CGACTCGGCCTCCCAAAATGCTGGGATTCCAGGCGTGAGCCACAGCGCCTGT
CCTGCATGTTACTTTTGAATGAAACC 
excluded: MRI16216FWD-MRI1FWD Sequence identity: 37.8% 
excluded: MRI16216FWD-MRI1FWD_R Sequence identity: 40.3% 
excluded: MRI16216REV-MRI1REV Sequence identity: 37.7% 
excluded: MRI16216REV-MRI1REV_R Sequence identity: 55.8% 
excluded: MRI16217FWD-MRI1FWD Sequence identity: 33.8% 
excluded: MRI16217REV-MRI1REV Sequence identity: 44.2% 
excluded: MRI16228FWD-MRI1FWD Sequence identity: 51.9% 
excluded: MRI16228REV-MRI1REV Sequence identity: 64.4% 
excluded: MRI16235FWD-MRI1FWD Sequence identity: 50.6% 
excluded: MRI16235REV-MRI1REV Sequence identity: 35.1% 
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excluded: MRI16252FWD-MRI1FWD Sequence identity: 30.6% 
excluded: MRI16252REV-MRI1REV Sequence identity: 36.0% 
excluded: MRI16259FWD-MRI1FWD Sequence identity: 44.6% 
excluded: MRI16259REV-MRI1REV Sequence identity: 68.4% 
No sequence passed the chosen sequence identity threshold of 90% 
GAP43 
CGAAGAAAGGAACACTGGGTGAGATTTTGTTCAACTACCCATAGTTACCACC
AGATGGTGAAACTGATCCCGGGCCTCTTGGGTATTGATCAGTTTATGGGGAG
ATGGGGAGAAGACTATCTTTCACTTGTTAATTCATTAATTTCTTTCGCAAATA
TTTTTTCAGTACCTGCTAAGTCCCACGGACTATGCTAGGAGCT 
excluded: GAP436216FWD-GAP43FWD Sequence identity: 54.8% 
excluded: GAP436216REV-GAP43REV Sequence identity: 44.3% 
excluded: GAP436217FWD-GAP43FWD Sequence identity: 70.1% 
excluded: GAP436217REV-GAP43REV Sequence identity: 31.2% 
excluded: GAP436228FWD-GAP43FWD Sequence identity: 37.8% 
excluded: GAP436228REV-GAP43REV Sequence identity: 74.6% 
excluded: GAP436235FWD-GAP43FWD Sequence identity: 76.6% 
excluded: GAP436235REV-GAP43REV Sequence identity: 36.0% 
excluded: GAP436252FWD-GAP43FWD Sequence identity: 80.3% 
excluded: GAP436252REV-GAP43REV Sequence identity: 48.9% 
excluded: GAP436259FWD-GAP43FWD Sequence identity: 60.7% 
excluded: GAP436259REV-GAP43REV Sequence identity: 67.9% 
No sequence passed the chosen sequence identity threshold of 90% 
CUL3 
TAACTTGTTAAAGGTTATGCAGCTAGAGGCCGGGCGCGGTGGCTCAC 
excluded: CUL36216FWD-CUL3FWD Sequence identity: 45.7% 
excluded: CUL36216REV-CUL3REV Sequence identity: 60.9% 
excluded: CUL36217FWD-CUL3FWD Sequence identity: 56.5% 
excluded: CUL36217REV-CUL3REV Sequence identity: 54.3% 
excluded: CUL36228FWD-CUL3FWD Sequence identity: 50.0% 
excluded: CUL36228REV-CUL3REV Sequence identity: 60.9% 
excluded: CUL36235FWD-CUL3FWD Sequence identity: 45.7% 
excluded: CUL36235REV-CUL3REV Sequence identity: 52.2% 
excluded: CUL36252FWD-CUL3FWD Sequence identity: 54.3% 
excluded: CUL36252REV-CUL3REV Sequence identity: 47.8% 
excluded: CUL36259FWD-CUL3FWD Sequence identity: 54.3% 
excluded: CUL36259REV-CUL3REV Sequence identity: 58.7% 
No sequence passed the chosen sequence identity threshold of 90% 
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library(BiocInstaller) 
biocValid() 
source("http://bioconductor.org/biocLite.R") 
biocLite("limma") 
biocLite("illuminaio") 
biocLite("minfi") 
biocLite("minfiData") 
biocLite() ##installs every package on bioconductor 
biocLite("IlluminaHumanMethylation450kmanifest") 
require("minfi") 
require("minfiData") 
 
##generate a Red Green data set 
baseDir<-("C:\\Users\\Michelle\\Dropbox\\dissertation\\iDat_all") 
targets <- read.450k.sheet(baseDir) 
RGset<-read.450k.exp(base=baseDir, targets=targets) 
pd<-pData(RGset) 
qcReport(RGset, sampNames = pd$Sample_ID,sampGroups=pd$GBS,pdf = 
"qcReport.pdf") 
densityPlot(RGset, sampGroups = pd$GBS,main = "Beta", xlab = "Beta")##shows 
density plot in R workspace 
par(oma=c(2,10,1,1)) 
densityBeanPlot(RGset, sampGroups = pd$GBS,sampNames = pd$Sample_ID) 
##Methylation sets 
MSet.raw <- preprocessRaw(RGset) 
MSet.norm <- preprocessIllumina(RGset, bg.correct = TRUE, normalize = "controls", 
reference = 2) ##normalizes methylation data 
controlStripPlot(RGset, controls="BISULFITE CONVERSION II",sampNames = 
pd$Sample_ID)##control bisulfite conversion II 
annot<-read.csv("http://supportres.illumina.com/documents/myillumina/b78d361a-def5-
4adb-ab38-e8990625f053/humanmethylation450_15017482_v1-2.csv", 
skip=7,head=TRUE) 
getMeth(MSet.raw)[1:4,1:3]##returns raw methylation values use 
getUnmeth(MSet.raw)[1:4,1:3]##returns raw unmethylated values 
getBeta(MSet.raw, type = "Illumina")[1:4,1:3] ##returns raw beta values 
MSet.raw<-preprocessRaw(RGset) 
Beta.raw<-getBeta(MSet.raw) 
rownames(Beta.raw)[1:5] 
annot$IlmnID[1:5] 
annot<-annot[match(rownames(Beta.raw),annot$IlmnID),,drop=FALSE] ##annotates 
betafile with illumina IDs 
class(rownames(Beta.raw)) 
class(annot$IlmnID) 
all.equal(as.character(annot$IlmnID),rownames(Beta.raw)) 
names(annot) 
head(annot) 
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table(annot$Probe_SNPs) 
##first removed CpG sites that were known to be associated with SNP 
any.SNPs<-ifelse(annot$Probe_SNPs!="",1,0) 
raw.wo<-Beta.raw[any.SNPs!=1,] 
dim(raw.wo) 
annot.wo<-annot[any.SNPs!=1,] 
dim(annot.wo) 
all.equal(as.character(annot.wo$IlmnID),rownames(raw.wo)) 
sum(raw.wo==1,na.rm=TRUE) 
sum(raw.wo==0,na.rm=TRUE) 
## To avoid errors when applying the logit transformation that would occur if beta=0 or 
beta=1,  
## we imputed 0.999 when beta=1 and 0.001 when beta=0 
raw.wo[raw.wo==1]<-0.999 
raw.wo[raw.wo==0]<-0.001 
sum(raw.wo==1,na.rm=TRUE) 
sum(raw.wo==0,na.rm=TRUE) 
#After imputation, the logit transformation was applied to the beta values 
logit<-log(raw.wo/(1-raw.wo)) ## Logit transformed beta values 
hist(logit[1,]) 
hist(raw.wo[1,]) 
Peak.correction<- 
function(exprs,annot) { 
         for (i in 1:dim(exprs)[2]) { 
 
        dens.I<-density(exprs[annot$Infinium_Design_Type=="I", i],na.rm=T) 
         dens.II<-density(exprs[annot$Infinium_Design_Type=="II", i],na.rm=T) 
         sigma.uII<- -dens.II$x[dens.II$x<0][which.max(dens.II$y[dens.II$x<0])] 
         sigma.mII<-dens.II$x[dens.II$x>0][which.max(dens.II$y[dens.II$x>0])] 
         sigma.uI<- -dens.I$x[dens.I$x<0][which.max(dens.I$y[dens.I$x<0])] 
         sigma.mI<-dens.I$x[dens.I$x>0][which.max(dens.I$y[dens.I$x>0])] 
         exprs[,i]<- ifelse(annot$Infinium_Design_Type=="II" & exprs[,i]<0,  
            exprs[,i]/sigma.uII*sigma.uI, 
 
            ifelse(annot$Infinium_Design_Type=="II" & exprs[,i]>0,  
                     exprs[,i]/sigma.mII*sigma.mI, exprs[,i])) 
 } 
 
         exprs 
 
        } 
all.equal(as.character(annot.wo$IlmnID),rownames(logit) 
##The logit transformed beta values were then peak corrected to ensure the peaks of the 
Infinium II 
##design beadtype were comparable to the peak locations of the Infinum I beadtype 
correct.methyl<-Peak.correction(logit,annot.wo) 
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pData(MSet.raw) 
plot(density(logit[annot.wo$Infinium_Design_Type=="I",1]), col="black", xlab="M-
values",main="Sample 1", ylim=c(0,0.3)) 
lines(density(logit[annot.wo$Infinium_Design_Type=="II",1]), col="red") 
lines(density(logit[annot.wo$Infinium_Design_Type=="II",1],na.rm=TRUE), col="red") 
plot(density(correct.methyl[annot.wo$Infinium_Design_Type=="I",1]), col="black", 
xlab="M-values",main="Peak-corrected Sample 1", ylim=c(0,0.3)) 
lines(density(correct.methyl[annot.wo$Infinium_Design_Type=="II",1],na.rm=TRUE), 
col="red") 
plot(density(logit[annot.wo$Infinium_Design_Type=="I",4]), col="black", xlab="M-
values",main="Sample 4", ylim=c(0,0.3)) 
lines(density(logit[annot.wo$Infinium_Design_Type=="II",4],na.rm=TRUE), col="red") 
plot(density(correct.methyl[annot.wo$Infinium_Design_Type=="I",4]), col="black", 
xlab="M-values",main="Peak-corrected Sample 4", ylim=c(0,0.3)) 
lines(density(correct.methyl[annot.wo$Infinium_Design_Type=="II",4],na.rm=TRUE), 
col="red") 
plot(density(logit[annot.wo$Infinium_Design_Type=="I",7]), col="black", xlab="M-
values",main="Sample Unmethy", ylim=c(0,0.3)) 
lines(density(logit[annot.wo$Infinium_Design_Type=="II",7],na.rm=TRUE), col="red") 
plot(density(correct.methyl[annot.wo$Infinium_Design_Type=="I",7]), col="black", 
xlab="M-values",main="Peak-corrected Sample unmeth", ylim=c(0,0.3)) 
lines(density(correct.methyl[annot.wo$Infinium_Design_Type=="II",7],na.rm=TRUE), 
col="red") 
##this is unnecessary because GBS is either positive or negative so a subset does not 
need to be created; 
##however other data sets may need subsets created to carry out analysis and here for 
your reference 
Msubset<-correct.methyl[,pData(MSet.raw)$GBS=="Negative"| 
   pData(MSet.raw)$GBS=="Positive"] 
##Notice results for GBS will be the same as the above using 
Msubset2<-correct.methyl 
all.equal(Msubset,Msubset2) 
dim(Msubset) 
class(Msubset) 
 
##if you need a group vector, this is how it should be formatted 
group<-pData(MSet.raw)[pData(MSet.raw)$GBS=="Negative"| 
    pData(MSet.raw)$GBS=="Positive","GBS"] 
##However, I don't need to use one because of how my data is structured; 
##instead I could use group<-pData(MSet.raw)$GBS as the vector in design 
pData(MSet.raw) 
library(limma) 
design<-model.matrix(~as.factor(group)-1) 
design 
colnames(design)<-c("Negative","Positive") 
design 
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fit<-lmFit(Msubset, design) ##least squares fitting off linear model for each gene 
fit 
contr.matrix<-makeContrasts(GBS.status=Positive-Negative, levels=design) 
contr.matrix 
fit2<-contrasts.fit(fit, contr.matrix) #makes contras to compare by GBS status 
fit3<-eBayes(fit2) ##use of array weights increases the significance of top genes 
results<-topTable(fit3, coef="GBS.status",  number=dim(Msubset)[1], 
   sort.by="none", adjust="BH") 
### Warning, the sort.by="none" and number=dim()[1] parameters are important to 
ensure your results are aligned with the annotation data 
head(results) 
results<-data.frame(ID=rownames(results),results) 
head(results) 
head(Msubset) 
dim(results) 
dim(Msubset) 
all.equal(results$ID, rownames(Msubset$ID)) 
class(results$ID) 
class(Msubset) 
class(Msubset[,1]) 
all.equal(comp[,1],comp[,2]) 
all.equal(results$ID,Msubset[,1]) 
### Note that without specifying sort.by="none" the annotation information is misaligned 
##correct.beta is the back-transformed peak corrected logitvalues 
correct.beta<-exp(Msubset)/(1+exp(Msubset)) 
dim(correct.beta) 
head(correct.beta) 
sum(results$adj.P.Val<0.05) 
 
mu.Negative<-apply(correct.beta[,group=="Negative"], 1, mean) 
mu.Positive<-apply(correct.beta[,group=="Positive"], 1, mean) 
delta.beta<-mu.Positive-mu.Negative 
mu.Negative[1:10] 
mu.Positive[1:10] 
delta.beta[1:10] 
all.equal(results$ID,as.character(annot.wo$IlmnID)) 
 
class(results$ID) 
class(annot.wo$IlmnID) 
all.equal(comp[,1],comp[,2]) 
all.equal(results$ID,annot.wo$IlmnID) 
class(results$ID)==class(annot.wo$llmnID)  
head(annot.wo) 
head(results) 
results<-data.frame(ID=rownames(results),results) 
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### Note that final.results and annot.wo are matched so we can append annot.wo to final 
results; 
 
## using generally accepted FDR cut off standards 
final.FDR.001results<-data.frame(Probe=rownames(results), 
beta.Negative=mu.Negative, beta.Positive=mu.Positive, delta.beta=delta.beta, 
p.value=results$P.Value, FDR=results$adj.P.Val, annot.wo) 
sign.results<-final.results[final.results$FDR<0.001 & abs(final.results$delta.beta)>0.2,] 
dim(sign.FDR.001results) # yields 0 rows = zero significantly different CpG sites 
final.FDR.05results<-data.frame(Probe=rownames(results), beta.Negative=mu.Negative, 
beta.Positive=mu.Positive, delta.beta=delta.beta, p.value=results$P.Value, 
FDR=results$adj.P.Val, annot.wo) 
sign.results<-final.results[final.results$FDR<0.05 & abs(final.results$delta.beta)>0.2,] 
dim(sign.FDR.05results) # yields 0 rows = zerp significantly differnt CpG sites 
final.FDR.01results<-data.frame(Probe=rownames(results), beta.Negative=mu.Negative, 
beta.Positive=mu.Positive, delta.beta=delta.beta, p.value=results$P.Value, 
FDR=results$adj.P.Val, annot.wo) 
sign.results<-final.results[final.results$FDR<0.01 & abs(final.results$delta.beta)>0.2,] 
dim(sign.results) # yields 0 rows = zero significantly differnt CpG sites  
 
##Volcano plot, showing no significant differences. Signifincat CpG sites would be blue 
install.packages("ggplot2") 
require(ggplot2) 
##Highlight CpGs that have an absolute fold change > 2 and a FDR < 0.05 
FDRcut = as.factor(abs(results$logFC) > 2 & results$adj.P.Val < 0.05) 
sum(abs(results$logFC) > 2 & results$adj.P.Val < 0.05) 
##Construct the plot object 
g = ggplot(data=results, aes(x=logFC, y=-log10(P.Value), colour= FDRcut)) + 
  geom_point(alpha=0.4, size=1.75) + 
  theme(legend.position = "none") + 
  xlim(c(-4, 4)) + ylim(c(0, 6)) + 
  xlab("log2 fold change") + ylab("-log10 p-value") ##returns no blue (significant) dots, 
all pink CpGs 
 
 
### using generic p-value 0.05 cutoff that Joyce uses 
final.results<-data.frame(Probe=results$ID, beta.Negative=mu.Negative, 
beta.Positive=mu.Positive, delta.beta=delta.beta, p.value=results$P.Value, 
FDR=results$adj.P.Val, annot.wo) 
sign.results<-final.results[final.results$p.value<.05& abs(final.results$delta.beta)>0.2,] 
dim 
### To output in order to email your findings to an investigator, use write.table 
write.table(sign.results,"significantRrun.csv",sep=",",row.names=FALSE) 
### You could also remove some of the annotation fields using -c() in square bracket 
notation; investigators may not be interested in all fields. 
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### bisulfitesequencing validation code 
 
getBeta(MSet.raw)["cg11164659",] ##RHPN1 raw uncorrected beta value 
getBeta(MSet.raw)["cg09785377",] ##ANXA2 raw uncorrected beta value 
 
cpgsD<-c("cg09785377","cg11164659") 
cpgsD 
plotCpg(Msubset, cpg=cpgsD[1], pheno=pData(Msubset)$GBS) #ANXA2 plot of raw 
beta values by GBS status for each participant 
plotCpg(Msubset, cpg=cpgsD[2], pheno=pData(Msubset)$GBS) ##RHPN1 plot of raw 
beta values by GBS status for each participant 
 
(correct.beta)["cg11164659",] ##RHPN1 normalized beta value 
(correct.beta)["cg09785377",] ##ANXA2 normalized beta value 
 
##raw and corrected beats for CpG site only significant using R platform compared to 
genome studio significant values 
getBeta(MSet.raw)["cg23947138",] ##RASA3 raw beta value 
 
(correct.beta)["cg23947138",] ##RASA3 normalized beta value 
 
getBeta(MSet.raw)["cg00540295",] ##FAM69B raw beta value 
 
(correct.beta)["cg00540295",] ##FAM69B - snp 
 
getBeta(MSet.raw)["cg01270299",] ##ZNF137 - snp 
(correct.beta)["cg01270299",] 
 
getBeta(MSet.raw)["cg25909532",] ##VIPR2 - snp 
(correct.beta)["cg25909532",] 
 
getBeta(MSet.raw)["cg06688803",] ##CLPTM1 - snp 
(correct.beta)["cg06688803",] 
getBeta(MSet.raw)["cg07304760",] ##SND1 - reads 
(correct.beta)["cg07304760",] 
getBeta(MSet.raw)["cg15290312",] ##TIMP2 - snp 
(correct.beta)["cg15290312",] 
getBeta(MSet.raw)["cg10058204",] ##FLJ37201 - reads 
(correct.beta)["cg10058204",] 
getBeta(MSet.raw)["cg05331763",] ##FOxK2 - reads 
(correct.beta)["cg05331763",] 
getBeta(MSet.raw)["cg12434901",] ##KCNH6 - reads 
(correct.beta)["cg12434901",] 
getBeta(MSet.raw)["cg24634471",] ##JRK - reads 
(correct.beta)["cg24634471",] 
getBeta(MSet.raw)["cg01421902",] ##ZNF665 - reads 
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(correct.beta)["cg01421902",] 
getBeta(MSet.raw)["cg04388792",] ##ZNF490 - reads 
(correct.beta)["cg04388792",] 
getBeta(MSet.raw)["cg13506281",] ##MTUS2 - snp 
(correct.beta)["cg04388792",] 
getBeta(MSet.raw)["cg07703391",] ##BMP8B/PPIE -reads 
(correct.beta)["cg07703391",] 
getBeta(MSet.raw)["cg10632770",] ##KIAA1199 -snp 
(correct.beta)["cg10632770",] 
getBeta(MSet.raw)["cg20479209",] ##FLJ43860 -reads 
(correct.beta)["cg20479209",] 
getBeta(MSet.raw)["cg13066461",] ##MRGPRX2-reads 
(correct.beta)["cg13066461",] 
getBeta(MSet.raw)["cg21130926",] ##SULF2 -reads 
(correct.beta)["cg21130926",] 
getBeta(MSet.raw)["cg04922606",] ##FAM120B -SNP 
(correct.beta)["cg04922606",] 
getBeta(MSet.raw)["cg03292225",] ##TNNT3 -reads 
(correct.beta)["cg03292225",] 
getBeta(MSet.raw)["cg10890644",] ##TUBAL3- snp 
(correct.beta)["cg10890644",]                  
getBeta(MSet.raw)["cg17671604",] ##SPTBN4- snp 
(correct.beta)["cg17671604",]                  
getBeta(MSet.raw)["cg09307883",] ##ANAPC2- reads 
(correct.beta)["cg09307883",] 
getBeta(MSet.raw)["cg10528424",] ##SYT8 - reads 
(correct.beta)["cg10528424",] 
getBeta(MSet.raw)["cg07480176",] ##CASD1 - snp 
(correct.beta)["cg07480176",] 
getBeta(MSet.raw)["cg14252149",] ##LGALS8 -snp 
(correct.beta)["cg14252149",] 
getBeta(MSet.raw)["cg12155450",] ##NAT14/ZNF628 -reads 
(correct.beta)["cg12155450",] 
getBeta(MSet.raw)["cg20976286",] ##OCA2 - reads 
(correct.beta)["cg20976286",] 
getBeta(MSet.raw)["cg10995422",] ##HLA-DRB6 - snp 
(correct.beta)["cg10995422",] 
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